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Abstract 
 Skeletal muscle differentiation requires synergy between tissue-specific 
transcription factors, chromatin remodeling enzymes and the general transcription 
machinery.  Here we demonstrate that two distinct protein arginine methyltransferases are 
required to complete the differentiation program.  Prmt5 is a type II methyltransferase, 
symmetrically dimethylates histones H3 and H4 and has been shown to play a role in 
transcriptional repression.  An additional member of the Prmt family, Carm1 is a type I 
methyltransferase, and asymmetrically methylates histone H3 and its substrate proteins.  
MyoD regulates the activation of the early class of skeletal muscle genes, which includes 
myogenin.  Prmt5 was bound to and dimethylates H3R8 at the myogenin promoter in a 
differentiation-dependent fashion.  When proteins levels of Prmt5 were reduced by 
antisense, disappearance of H3R8 dimethylation and Prmt5 binding was observed.  
Furthermore, binding of Brg1 to regulatory sequences of the myogenin promoter was 
abolished.  All subsequent events relying on Brg1 function, such as chromatin 
remodeling and stable binding by muscle specific transcription factors such as MyoD, 
were eliminated.  Robust association of Prmt5 and dimethylation of H3R8 at myogenin 
promoter sequences was observed in mouse satellite cells, the precursors of mature 
myofibers.  Prmt5 binding and histone modification were observed to a lesser degree in 
mature myofibers.  Therefore, these results indicate that Prmt5 is required for 
dimethylating histone at the myogenin locus during skeletal muscle differentiation in 
order to facilitate the binding of Brg1, the ATPase subunit of the chromatin remodeling 
complex SWI/SNF. 
 vii 
 Further exploration of the role of Prmt5 during the activation of the late class of 
muscle genes revealed that though Prmt5 is associated with and dimethylates histones at 
the regulatory elements of late muscle genes in tissue and in culture, it was dispensable 
for late gene activation.  Previous reports had indicated that Carm1 was involved during 
late gene activation.  We observed that Carm1 was bound to and responsible for 
dimethylating histones at late muscle gene promoters in tissue and in culture.  In contrast 
to Prmt5, a complete knockout of Carm1 resulted in abrogation of late muscle gene 
activation.  Furthermore, loss of Carm1 binding and dimethylated histones resulted in a 
disappearance of Brg1 binding and chromatin remodeling at late muscle gene loci.  Time 
course chromatin immunoprecipitations revealed that Carm1 binding and histone 
dimethylation occurred concurrently with the onset of late gene activation.  In vitro 
binding assays revealed that an interaction between Carm1, myogenin and Mef2D exists.  
These results demonstrate that Carm1 is recruited to the regulatory sequences of late 
muscle genes via its interaction with either myogenin or Mef2D and is responsible for 
dimethylates histones in order to facilitate the binding of Brg1.  Therefore, these results 
indicate that during skeletal muscle differentiation, distinct roles exist for these Prmts 
such that Prmt5 is required for activation of early genes while Carm1 is essential for late 
gene induction.   
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CHAPTER I 
 
INTRODUCTION 
 
 Cellular differentiation events require the exquisite temporal regulation of specific 
subsets of genes.  This is accomplished through the seamless interplay between 
transcription factors, coactivators, chromatin remodelers and transcriptional machinery.   
The expression of specific muscle regulatory factors (MRFs) initiates specification of 
cells to the myogenic lineage while expression of other MRFs permit the activation of 
structural genes required for terminal differentiation.  This process requires the combined 
efforts of the MyoD family of transcription factors, tissue specific co-factors such as 
Myocyte Enhancer Factor 2 (MEF2), ATP-dependent chromatin remodelers and histone 
modifying enzymes such as histone acetyltransferases (HATs) and histone 
methyltransferases (HMTs).   
 
 During early embryonic development, gastrulation generates the formation of the 
mesodermal layer, which lies between the ectoderm and endodermal layer.  Mesoderm 
forms the blood, vasculature, bones, cartilage, connective tissue and muscles of the body 
trunk (27, 40).  The mesoderm is divided into the axial mesoderm (notochord), 
intermediate mesoderm, paraxial mesoderm, and the lateral plate mesoderm.  In the 
developing embryo, skeletal muscle progenitors arise from the paraxial mesoderm.  The 
paraxial mesoderm is comprised of bilateral strips of mesodermal tissue that run parallel 
to the notochord and the neural tube and are delimited by the lateral plate and 
Skeletal muscle development 
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intermediate mesoderm (27, 40).  Following gastrulation, somite maturation is initiated 
when the paraxial mesoderm begins to segment into pairs in a rostral to caudal fashion, or 
head to toe (175, 176, 210, 212).  These newly formed somites then assemble to form the 
dorsal epithelial dermomyotome and ventral mesenchymal sclerotome.  Cells of the 
ventral somites undergo an epithelial to mesenchymal transition, which comprise the 
sclerotome and eventually form the vertebrae and ribs.  The dermomyotome is further 
partitioned into the epaxial and hypaxial dermomyotome, which are the sources of lateral 
trunk & deep back, and intercostal, & abdominal musculature, respectively (175, 176, 
210, 212).  The ventral sclerotome goes on to form the cartilage and bone of the vertebral 
column and ribs.  Cells from the dorsal medial lip and ventral lateral lip migrate 
underneath the dermomyotome to form the epaxial and hypaxial myotome (175, 176, 210, 
212).  Myogenic precursors that originate from the hypaxial dermomyotome express 
homeodomain proteins Pax3 and Pax7 as well as low levels of the muscle regulatory 
factor Myf5 (83, 96, 105, 109).  However, signaling from the lateral plate mesoderm 
maintains these cells in a proliferative but undifferentiated state (5).  Cells from the 
ventral lateral lip also undergo an epithelial to mesenchymal transition, delaminate and 
ultimately migrate to sites of limb bud, ventral body wall, diaphragm, tongue and other 
areas of muscle development (40, 161). 
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Figure 1-1. 
(Buckingham, M et al.  The formation of skeletal muscle: from somite to limb.  J. Anat. 
202;59-68.  2003) 
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Figure 1-1. 
Mature somites originate from the paraxial mesoderm, a bilateral strip of tissue that is 
localized adjacent and parallel to the notochord and neural tube.  It is delimited by the 
intermediate mesoderm and lateral plate.  Upon maturation, the paraxial mesoderm 
segments into pairs that are further partitioned into the dorsal epithelial dermomyotome 
and ventral mesenchymal sclerotome.  The dermomyotome is divided into a hypaxial and 
epaxial dermomyotome.  Cells delaminating from the dermomyotome migrate underneath 
to form the epaxial and hypaxial myotome.  Cells originating from the hypaxial 
dermomyotome delaminate to sites of limb bud development or other areas destined to 
become skeletal muscle such as tongue, diaphragm or the ventral body wall.   
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 Delamination and migration of skeletal muscle precursors are dependent on the 
tyrosine kinase receptor c-met and its ligand, spatter factor (HGF), which is produced by 
non-somitic mesodermal cells that mark the route these delaminating cells must travel 
(58).  The paired-box homeodomain-containing transcription factor Pax3 
transcriptionally regulates c-met (68).  Pax3 expressing cells could be visualized using a 
lacZ reporter introduced into a Pax3 allele.  Pax3 was integral for this process since in 
Pax3 mutant mice, cells failed to delaminate from the hypaxial dermomyotome and as a 
result, never migrated to sites of skeletal muscle development (77, 213, 214) (Figure 1-2).  
 Another homeodomain-containing protein, Lbx1, has been implicated in 
migration (197).  In Lbx1 mutant mice, skeletal muscle progenitors were able to 
delaminate from the hypaxial dermomyotome, but did not migrate to sites of skeletal 
muscle development such as limb buds, and therefore these cells adopt different fates 
(197).  It was postulated that Lbx1 functions as a transcription factor, though its targets 
have not been identified in muscle progenitor cells (99).  Msx1, which was present in 
migrating muscle precursor cells at the level of the forelimb, maintains muscle 
precursor/progenitor cells (mpcs) in a proliferative state (99).  Additionally Msx1 has 
been shown to contribute to repression of muscle-specific genes as it is able to interact 
with endogenous H1b but not with Histone H3 and Pol II in C2C12 myoblasts (124).  
Msx1 also associates with the core enhancer region (CER) of the MyoD promoter.  The 
N-terminus of Msx1 (105-138) is required for the interaction with H1b but the 
homeodomain is required for DNA binding.  Msx1 increases the amount of H1b 
associated with the CER of MyoD, which renders the chromatin at this locus in an 
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inaccessible and therefore repressed state (124).  In fact, overexpression of Msx1 in 
terminally differentiated c2c12 myotubes resulted in reduction of myogenic transcripts 
and reversion of cells to a proliferative state (156) indicating that a mechanism of 
repression must be in place to coordinate the proper temporal activation of muscle-
specific genes since muscle precursors migrating from the hypaxial dermomyotome do 
not yet express muscle determination factors until they arrive at the limb bud or other 
sites of skeletal muscle development.   
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Figure 1-2. 
 
(Buckingham, M et al.  The formation of skeletal muscle: from somite to limb.  J. Anat. 
202;59-68.  2003) 
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Figure 1-2. 
Mouse embryos at embryonic day (E) E10.5 with one (A-C) or two (D-F) alleles of Pax3 
targeted with an nlacZ reporter sequence.  Black arrows denote the location of forelimb 
bud while blue arrows indicate hindlimb bud.  ß-galactosidase (Pax3)-positive cells can 
be observed in the forelimb while ß-galactosidase (Pax3)-positive cells can be seen 
delaminating from somites and migrating.  In homozygous null animals, spinal bifidia 
and exencephaly are apparent in addition to reduced dermomyotome formation.  No 
labeled Pax3-positive cells were observed in the forelimb or hindlimb, nor is there any 
indication of migrating cells.  
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 Quiescent satellite cells do not express MRFs, though in response to muscle 
damage or heavy exercise, they become activated, commit to the myogenic lineage, and 
Adult Skeletal Muscle 
 Pax3 is expressed in pre-somitic mesoderm and early epithelial somites (83).  
Pax7, a paralogue of Pax3, is not expressed in the pre-somitic mesoderm but is induced 
during somite formation (105).  Pax7 is dispensable for embryonic myogenesis (202), but 
limb and diaphragm muscles are not formed due to defective lateral migration and 
reduced proliferation of the dermomyotome in Pax3 mutant mice (23, 47, 219).  Ectopic 
expression of Pax3 in embryonic tissues activates MyoD, Myf5 and Myogenin expression 
(17, 135).   
 Pax7 expressing cells derived from the central dermomyotome give rise to most if 
not all satellite cells (202).  Satellite cells arise during the late stages of embryogenesis in 
chick and mouse.  This subpopulation of cells provides most of the myonuclei to adult 
muscles during postnatal muscle growth.  In adult muscle, satellite cells exist in a 
quiescent state and are located between the basal lamina and the sarcolemma of 
myofibers.  Pax3, Pax7, M-Cadherin and c-Met are identifying markers of satellite cells 
(93).  It has been proposed that these cells are of somitic origin, but recent studies have 
shown that satellite cells may derive from cells associated with the embryonic vasculature, 
specifically the dorsal aorta (201).  Somitic angioblasts derived from the paraxial 
mesoderm colonize the dorsal aorta.  Other groups have found considerable heterogeneity 
in satellite cell populations, which could reflect a more varied developmental origin than 
previously demonstrated (13, 244).   
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express Myf5 or MyoD, during which time the cells undergo a proliferative phase (22, 
84).  Coexpression of Myf5 and MyoD in satellite cell derived progenitors defines 
myogenic precursors that proliferate in response to growth factors and cytokines (93, 
201).    Activation of downstream MRFs such as myogenin or MRF4 is a hallmark of 
terminal differentiation and fusion of myogenic precursor cells to new or existing fibers.  
 The capacity of satellite cells to renew is essential to perpetuate muscle 
regeneration or repair over the life span of the organism.  Without this ability to self 
renew, the number of satellite cells would decline after repetitive injury and in the course 
of normal tissue turnover.  Two possible mechanisms have been proposed to describe 
satellite cell renewal (reviewed in (97, 121, 122, 148, 204).  During asymmetric division, 
two daughter cells are formed, of which one remains quiescent and the other undergoes 
myogenic activation and ultimately terminal differentiation.  In contrast, during 
symmetric division, both daughter cells are proliferative and activated.  The majority of 
daughter cells down-regulate Pax7 and differentiate into myofibers, while a sub-
population retain Pax7 expression and returns to a quiescent state, earmarked for 
replenishing the satellite cell pool (reviewed in (97, 121, 122, 148, 204).    
 During the regulation of adult myogenesis, an essential role exists for MyoD (42, 
193, 238).  In mice that lack MyoD (MyoD-/-), there are increased numbers of satellite 
cells and deficient regenerative process in skeletal muscle (42, 193, 238).  Similar 
phenotypic signatures were found in MyoD and Dystrophin null (MyoD-/-,Dmd-/-) mice 
indicating that MyoD deficient satellite cells have increased potential for renewal rather 
than differentiation (144).  Alternatively, others have shown that MyoD-deficient mice 
 
 
11 
have defects in differentiation which is accompanied by increases in Myf5 expression, 
consistent with generated mouse knockout models (42, 193, 238).  In the absence of 
Myf5, Lacz-expressing epaxial myogenic progenitors were reduced, indicating that Myf5 
may regulate myoblast proliferation (211).  Adult myoblasts that are deficient for MyoD 
but express high levels of Myf5 proliferate rapidly but differentiate poorly, whereas 
Myf5-/- myoblasts from newborn mice have reduced proliferative potential (42, 147, 193, 
238).  Transcription profile analysis using MyoD-/-, Myf5-/- myoblasts expressing 
oestradiol inducible MyoD demonstrate that MyoD regulates several gene clusters, which 
orchestrate differentiation events.   
 Approximately 20 years ago, subtractive hybridization led to the identification of 
a factor that was able to direct conversion of 10T1/2 fibroblast to the myogenic lineage 
(82).  This transcript was aptly termed MyoD and was capable of orchestrating the 
myogenic conversion of many cell types including fibroblasts, chondrocytes, and neurons.  
Identification of MyoD, which belongs to a class of DNA binding proteins that contain a 
basic helix-loop-helix (bHLH) domain, was closely followed by the identification of 
other member of this bHLH family; Myf5, Myogenin, and MRF4.  These transcription 
factors bind to a consensus sequence (CANNTG) called an E-box that is present in the 
regulatory regions of muscle-specific genes.  MRFs interact with Myocyte Enhancer 
Factor 2 (MEF2) proteins, which bind A/T rich sequences in regulatory regions of 
muscle-specific genes to synergistically activate downstream muscle gene expression.  
MEF2 was originally identified as a muscle-specific DNA binding protein that was 
induced when myoblasts differentiated into myotubes (82).  The 4 genes of the MEF2 
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family have 85% homology within the 56 amino acid MADS (MCM1, Agamous, 
Deficiens, SRF) domain, which has been shown to regulate serum-inducible and muscle 
gene expression (205).   
 MEF2 binding sites CTA(A/T)4 
 As many MAPKs phosphorylate similar motifs, the question of specificity can be 
resolved with an additional determinant.  Members of the MAPK family interact with 
their target substrates via a docking domain for efficient phosphorylation and maximal 
TG have been identified in the promoter 
sequences of muscle-specific genes and were shown to be important for skeletal muscle 
and cardiac muscle gene expression (65, 160).  The MEF2 binding site within the 
myogenin promoter has been shown to be essential for transcription activation in cultured 
mouse cells and converted mouse fibroblasts (38, 64, 243).  Transfection of MEF2 family 
members into fibroblasts failed to induce myogenic conversion unless coexpressed with 
myogenic bHLH proteins.  This transcriptional cooperativity required interactions 
between the DNA-binding domain (DBD) of MEF2 and bHLH of MRFs.    
 In mammalian cells, the MAPK p38 was initially identified with a member of the 
MEF2 family, MEF2C (87).  Induction of the host immune system defense cascade can 
be triggered by lipopolysaccaride, the endotoxin secreted by Gram (-) bacteria, and is 
mediated by MAPKs.  Phosphorylation of this protein potentiates its trancriptional 
activity.  It was further established that p38 substrates include another member of the 
MEF2 family; MEF2A but not MEF2B or MEF2D (249).  Phosphorylation of threonine 
residues within the transcriptional activation domain of MEF2A results in enhanced 
MEF2-dependent gene expression (249).   
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activation (242).  MEF2A and MEF2C were preferentially phosphorylated by p38•  and 
p38ß and the phosphorylation and resulting transactivation were dependent on a kinase 
docking domain (242).   
 Additional members of the MAPK are essential during muscle differentiation.  
Expression of a dominant negative version of PI3K or growth of myoblasts in the PI3K 
inhibitors, LY294002, inhibits the transcriptional activity of MEF2 but its DNA binding 
activity is intact (215).  Phosphorylation of MEF2 proteins during muscle differentiation 
is prevented if PI3K is non-functional.  Interestingly, the activity of p38 is not affected by 
PI3K in muscle cells and can substitute for PI3K during the induction of MEF2 and 
muscle gene activation, indicating that these kinases function in distinct but parallel 
pathways to transactivate myogenic targets (215).   
 Regulatory sequences within the myogenin proximal promoter include the E-box, 
MEF2 and MEF3 sites.  MyoD, MEF2s and Six proteins are bound to these sites and 
function in parallel but nonredundant pathways to control myogenin expression.  
Inhibition of any of these pathways results in reduced activation of myogenin (235).  The 
association of MEF2 with various cis-elements was examined in primary human skeletal 
muscle and isolated rat muscle following various stimuli (2).  Exposure to insulin, 
hydrogen peroxide, osmotic stress or AICAR led to robust increases in MEF2 DNA 
binding.  Preincubation of human skeletal muscle cells with inhibitors of p38 MAPK, 
MEK1, PKC, PI3K or AMPK.  Cells failed to differentiate when treated with MAPK 
inhibitors and were partially blocked in response to inhibition of PKC, PI3K and AMPK 
(2).   
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 During differentiation, activation of p38 MAPK facilitates the binding of MyoD 
and MEF2 at a subset of late gene promoters (166).  Mef2D binding is able to recruit the 
active phosphorylated and elongating form of RNA Pol II.  Precocious activation of p38 
and coexpression of Mef2D are able to shift the activate the expression of late myogenic 
genes to earlier stages of differentiation (166).  Extracellular factors initiate signal 
cascades within the cell.  Activity of MAPK p38 is induced during terminal 
differentiation of rat L8 cells (245).  The addition of the p38 inhibitors SB 203580 to 
myoblasts prevented them from accomplishing fusion into multinucleated myotubes and 
inhibited expression of MyoD and MEF2 family members as well as terminal 
differentiation markers such as myosin light chain 2 (MLC2) (245).    
       During developmental myogenesis, MEF2A and p38 expression is concurrent with 
Myf5 protein expression in the somite at E9.5.  Inhibition of p38 signaling using SB 
203580 resulted in the failure of MEF2 activation as well as blockage of myogenic 
differentiation in somite culture and embryos (51).  Malignant cells such as 
rhabdomyosarcomas (RMS), a tumor that arises from muscle precursors, are 
characterized by a block in the differentiation program and deregulated proliferation 
despite MyoD expression.  Ectopic overexpression of p38 by activated MKK6, restores 
MyoD function and augments MEF2 activity in RMS, resulting growth arrest and 
terminal differentiation (179).  GRIP1, a cofactor of MEF2 is expressed in proliferating 
myoblasts, but upon differentiation its localization becomes punctuate and is observed in 
nuclear bodies (36).  MEF2 and GRIP are coexpressed in the nucleus of differentiated 
myotubes.  In RMS cells derived from human tumors, GRIP1 expression is weak and 
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MEF2-dependent activation of transgenes is defective in ARMS cells.  Aberrant 
localization of GRIP1 and its cofactor MEF2 contribute to RMS phenotype (36).  
Collectively, these findings indicate that an integral exists for MEF2 proteins during 
skeletal myogenesis and their enzymatic function is required for potentiate the activity of 
tissue specific transcription factors such as MyoD but also to facilitate the recruitment of 
chromatin remodeling enzymes and general transcription machinery.     
 
 Genetic disruption of the MyoD locus was used to generate MyoD null mice 
(191).  These mice were viable and had no gross abnormalities in the musculature.  
Interestingly Myf5 mRNA was elevated in the postnatal skeletal muscle of these mice, 
suggesting that Myf5 is regulated by MyoD and that Myf5 possibly compensates for 
MyoD (191).  Null mutations of the Myf5 locus resulted in mice that were unable to 
breathe and died immediately after birth due to the absence of a major portion of distal 
ribs (26).  Though the mice were not viable, no gross morphological defects were 
observed in skeletal muscle.  Of note, the appearance of myotomal cells in somite was 
delayed by several days and complete ossification of the sternum occurred (26).  As no 
muscle-specific phenotype was noted in either MyoD or Myf5 null mice, these factors 
were postulated to behave redundantly and to compensate for each other.  To address this 
assertion, MyoD/Myf5 double knockout mice were generated.  These mice were born, 
but were immobile and died shortly after birth.  These mice were characterized by a 
complete absence of skeletal muscle, when analyzed using histology (192).  Gene 
Transgenic and Knockout  mice 
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expression analysis indicated no detectable skeletal muscle specific mRNAs and 
examination by immunocytochemistry showed absence of desmin-expressing myoblast-
like cells.  Studies conducted using the double knockout (DKO) MyoD/Myf5 null  mice 
indicate that MyoD or Myf5 are essential for the determination of skeletal myoblasts and 
are also required for propagation and specification of myoblasts during development 
(192).   
 Myogenin null mice were generated by disrupting the myogenin locus (92, 152).  
These mice were able to survive fetal development but died shortly after due to a severe 
reduction in mature skeletal muscle fiber, though the population of proliferating 
myoblasts was unperturbed.  These studies indicated that myogenin was dispensable for 
specification to the myogenic lineage but was necessary for terminal differentiation of 
myofibers (92, 152).  To examine the relationship between MyoD and/or Myf5 with other 
MRFs, DKO Myog/Myf5 null mice were generated (183).  These mice were not viable 
and died within first few minutes of birth due to absence of functional skeletal muscle 
and ribs, respectively.  Since MyoD/Myf5 null mice were nonviable this suggests that 
two viable copies of Myf5 are required for survival in the absence of MyoD.  When 
examined by by hematoxylin and eosin histology, the phenotype of the Myog/Myf5 DKO 
was indistinguishable from Myog null mice; severe reduction in myofibers in a 
background of mononucleate myoblasts.  Immunostaining of total MHC was reduced and 
highly disorganized as was also seen in myogenin null cells, though the additional 
disruption of the Myf5 gene did not exacerbate the phenotype, indicating that MyoD or 
Myf5 do not share overlapping functions with myogenin.  Gene expression analysis via 
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RT PCR showed no upregulation of MyoD, indicating that MyoD did not compensate for 
the lack of myogenin.  Additionally, a failure to activate MRF4 and MCK was observed, 
implying that these genes are activated by myogenin.  MyoD/Myog DKO mice were 
generated to further probe the relationship between these MRFs.  When stained with 
hematoxylin and eosin, the phenotype of these mice was indistinguishable from 
myogenin null mice.  Similarities included a severe reduction in myofibers, accompanied 
by an unperturbed population of mononucleate myoblasts.  As seen in Myog/Myf5 DKO 
mice, MHC staining was reduced and highly disorganized.  Interestingly, RT PCR 
showed upregulation of Myf5 twofold in response to the null mutation of MyoD.  
Myog/MyoD double mutant also failed to activate MRF4 and MCK (183).    
 The Mrf4 locus was disrupted to generate Mrf4 null mice (25).  Interestingly 
perturbation of the Mrf4 locus also resulted in pronounced down-regulation of Myf5, 
rendering this mouse model essentially Mrf4/Myf5 knockout.  Mrf4 mutants resembled 
the phenotype observed in Myf5 null mice, with aberrant and delayed early myotome 
formation with lack of distal rib structure and a reduction in size of axial muscles in the 
back.  Existing myofibers appeared fairly normal, implying that Mrf4 has no major role 
in maturation of myotubes (25).  In contrast, others have revealed that a Myf5/MyoD 
DKO mouse bears no muscle phenotype when Mrf4 is intact, asserting that Mrf4 too, is 
able to modulate specification of cell fate to the myogenic lineage (107).  Mrf4/MyoD 
double null embryos did not survive beyond birth due to an inability to breathe.  These 
mice presented with lordokyphosis, absence of skeletal muscle and an accumulation of 
fat at the neck.  Gross examination indicated a similar phenotype to the myogenin null 
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mouse.  Residual myofibers were found surrounded by mononucleated cells.  Intriguingly, 
the residual myofibers had centrally located nuclei, indicating they were newly fused.  
Gene expression analysis indicated that expression of MCK, MHC and alpha-skeletal 
actin was severely affected in double Mrf4/MyoD null mice.  These studies indicate that 
Myogenin and MRF4 are involved in the differentiation of skeletal muscle but are not 
functionally redundant and do not compensate for each other.   
 
Chromatin Organization 
 A paradox exists in eukaryotic cells since over a meter of DNA must be 
condensed into the limited volume of the nucleus and yet still be accessible for processes 
such as transcription, replication and DNA repair.  The simplest unit of chromatin is the 
nucleosome, which is comprised of 146 bp of DNA and 8 core histones; a tetramer of 
(H3-H4)2 and 2 dimers of H2A-H2B (44, 66, 114, 115, 170, 188).  The central 121 bp of 
DNA bind (H3-H4)2 while the peripherally localized H2A-H2B dimers bind DNA at the 
entrance and exit of the nucleosome, bringing the total length of DNA wound around the 
nucleosome to ~147 bp (67, 94, 129, 154).  The disc-shaped nucleosome is 
approximately 11nm in diameter x 5.7nm in height and has 1.7 turns of DNA associated 
with it (73, 187).  The histones interact with the phosphodiester backbone of DNA and 
these points of contact occur every 10 bp (132).  As such the minor groove of the DNA is 
turned inside, facing the nucleosome.  DNA bases do not interact with histones, therefore 
DNA interactions are not sequence dependent, though it is noteworthy that some DNA 
sequences favor the positioning and formation of nucleosomes (132). 
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 Each histone has two domains; the histone fold motif which is necessary for 
histone-histone and histone-DNA interactions, and the histone tail motifs in the N and C-
termini, which contain residues for post-translational modification that affect the 
organization of chromatin into a transcriptionally permissive or non-permissive state  (89, 
95).  Limited proteolysis was used to create tailless core histones.  Nucleosome arrays 
without N-terminal domains (NTDs) were unable to form secondary or tertiary chromatin 
structures (3, 75, 80, 200, 221, 230).  Therefore, the 14-38 amino acids from the NTD 
extend outside the disc-shaped complex and are required for formation of condensed 
higher order chromatin structures.  The NTD of core histones is required for linker DNA 
and internucleosomal interactions (3, 75, 80, 200, 221, 230). 
 Linker histones are another integral component of chromatin structure.  Linker 
histones are not structurally related to core histones, but do exist in practically 
stoichiometrical association with nucleosomes, indicating they are involved in the 
assembly and formation of higher order chromatin structures and dynamics (9, 228, 229).  
The linker histones is composed of a short unstructured NTD, a central globular winged 
helix domain and a long C-terminal domain (CTD) consisting of approximately 100 
amino acid residues  (9, 228, 229).  The association of linker histones with core histones 
and linker DNA protects an additional 20 bp of DNA from nuclease digestion, stemming 
from a proposed “stem-loop” structure which forms upon binding of H1 linker histone.  
Linker histones are also required for stabilization of the 30nm fiber and oligomeric 
tertiary chromatin structures (16, 33).     
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 The chromatin fiber is defined as an assembly of linker histone and non-histone 
proteins associated with nucleosomal arrays forming compacted chromatin structures in 
vivo.  Repeating nucleosomal units exist as “beads on a string” in low salt conditions.  
This 10nm fiber exists in equilibrium with highly compacted chromatin structures and 
can be condensed into the 30nm fiber in a solution containing the ionic conditions 1-
2mM divalent cation (8, 241).  Self-association of these condensed fiber structures is 
accomplished through the NTDs of the core histones.  In fact, the NTD of H4 is critical 
for full fiber folding (61, 200, 221).  In eukaryotic cells during mitosis, further 
compaction of the 30nm chromatin solenoid into a 60-300nm fiber is observed, though 
this process is far from elucidated.  Linker histones are thought to aid in the condensation 
of chromatin structure either by continuing the coiling or assembling into a zig-zag 
formation  (230).  Formation of higher order chromatin structures may occur through 
further compaction of these 30nm fibers or through side-by-side arrangement of the fibers 
(45, 72, 131, 231, 232).    
 Packaging of promoter elements into nucleosomes in vitro inhibits the initiation 
of transcription by bacterial and eukaryotic RNA polymerases (112, 130).  Further, the 
genetic abrogation of histone synthesis in yeast results in loss of nucleosome formation 
and consequently, precocious activation of previously inactive genes (88).  Thus, the 
chromatin structure at specific gene loci are non-permissive and must be manipulated in a 
fashion to render DNA sequences accessible to the transcriptional machinery.  Alteration 
of chromatin structure can be achieved through the modification of N-terminal histone 
tails by acetylation, deacetylation, methylation, phosphorylation, ubiquitination, or 
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sumoylation.  ATP-dependent chromatin remodelers are able to affect nucleosomal 
structure by “sliding” or changing the path of DNA around the histone octamer.  The 
interplay between ATP-dependent remodelers and histone methyltransferases during the 
temporal regulation of skeletal muscle target genes will be emphasized in this 
introduction. 
 
ATP- dependent chromatin remodelers 
 ATP-dependent remodeling enzyme are divided into four major subfamilies, 
characterized by the identity of the central catalytic subunit Brg1 (or hBrm), ISWI, Mi-2 
and Ino80, which belong to SWI/SNF, ISWI, NuRD and INO80 complexes, respectively 
(reviewed in (63, 206).  These enzymes use energy derived from ATP hydrolysis to 
actively alter nucleosomal structure, which is an essential step for transcriptional 
regulation of many eukaryotic genes (28, 103, 106, 108, 169, 181, 185).  Specific 
temporal regulation of gene activation must occur during skeletal muscle differentiation.  
The chromatin structure of inactive genes precludes access of transcription factors, 
coactivators and the transcriptional machinery to the DNA.  In order for muscle specific 
gene expression to proceed, MyoD must form heterodimers with ubiquitous E proteins 
via helix-loop-helix (HLH) domains (120, 151).  The basic regions of MyoD act as a 
sequence specific DNA binding domain that recognizes a consensus sequence CANNTG 
termed the E-box.  MyoD-E protein heterodimers recognize E-boxes commonly found in 
the regulatory regions of skeletal muscle genes in order to regulate transcription (81).   
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 In addition to interctions between MyoD and cofactors with requisite cis-elements, 
post-translation modifications of MyoD are essential for determining its functional status.  
MyoD contains two putative PKC phosphorylation sites (Thr 115 and Ser 200), which are 
analogous to Thr85 within the highly conserved basic domain of myogenin (128).  
Phosphorylation of these residues results in reduced transactivation of myogenin.  Thr 
115-Ala was mutated to determine if this site would also attenuate MyoD function.  
CH310T1/2 fibroblasts expressing wt or mutant MyoD were able to induce terminal 
differentiation and fuse into multinucleated myotubes.  Mutant MyoD was able to bind a 
consensus E-box sequence when subjected to EMSA (128).  However, when cells were 
differentiated and maintained in high mitogen conditions, only mutant MyoD was able to 
induce cell cycle arrest, late gene activation and E-box oligonucleotide binding.  Cells 
maintained in high mitogen conditions contained phosphorylated MyoD and significant 
levels of phosphorylated threonine.  In RMS cells, MyoD was phosphorylated and its 
function attenuated (128).    
 Using nuclease accessibility studies, it was determined that the gene loci regulated 
by MyoD exist in a heterochromatic state prior to MyoD expression in the cell (81).  
MyoD expression was accompanied by induction of chromatin remodeling at these loci.  
The functional status of MyoD is an essential event during the induction of skeletal 
muscle transcripts and therefore, modulation of MyoD activity is essential for the 
initiation of gene expression.  
 To determine the requirement for chromatin remodeling enzymes in cellular 
differentiation events, fibroblasts inducibly expressing dominant negative versions of 
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human Brahma-related gene 1 (BRG1), and Brahma (Brm), the ATPase subunits of 
distinct SWI/SNF enzymes (30, 153, 167, 206, 209, 227), were used to examine MyoD-
induced skeletal muscle differentiation.  Induction of myogenin and myosin heavy chain 
(MHC) transcripts and protein was abrogated in cells expressing dominant negative 
enzymes (53).  Extracts from mock or MyoD-differentiated cells were incubated with a 
oligonucleotide probe encompassing the MyoD binding site at the muscle creatine kinase 
(MCK) enhancer, and the bound complex was specifically super-shifted by MyoD 
antibody.  These results demonstrated that a MyoD-associated complex was able to bind 
the MCK enhancer and this interaction was unaffected by dominant negative BRG1.  
Compromised muscle-specific gene activation correlated with ablation of nuclease 
accessibility at the myogenin promoter indicating that ATP-dependent SWI/SNF-
mediated chromatin remodeling is required for activation of muscle-specific targets(53).  
 Though the transcriptional activation of muscle regulatory factors and structural 
genes was inhibited by dominant negative SWI/SNF, activation of cell cycle regulators 
was unperturbed.  Fluorescence activated cell sorting (FACS) indicated that cells arrested 
normally in the presence of dominant negative proteins (56).  Further, transcript and 
protein synthesis of cell cycle genes were unaffected in cells expressing mutant SWI/SNF, 
indicating that ATP-dependent chromatin remodelers are required for muscle-specific 
 genes but not cell cycle targets (56).  Since ATP-dependent chromatin remodeling is 
required for MyoD-mediated muscle differentiation, the interplay between SWI/SNF and 
the other muscle regulatory factors (MRFs), Myf5, myogenin and MRF4 was examined 
(190).  Induction of muscle-specific genes by Myf5 and MRF4 was inhibited by 
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dominant-negative BRG1, but myogenin was unable to activate any myogenic transcripts.  
In contrast, all four MRFs were able to induce cell cycle regulatory transcripts and 
proteins even in the presence of mutant SWI/SNF  proteins, indicating that MRFs have a 
similar requirement for the activity of SWI/SNF during the activation of myogenic targets 
but not cell cycle genes (190).   
 Microarray analysis determined that approximately 30% of MyoD-regulated 
genes required the activity of SWI/SNF (19, 54).  To finely dissect the interplay between 
MyoD and SWI/SNF, chromatin immunoprecipitations (ChIPs) were performed on the 
myogenin promoter, revealing that hyperacetylated histone H4 was enriched in a MyoD-
dependent manner prior to the binding of Brg1.  As chromatin remodeling enzymes 
require the function of a transcription factor to recognize and bind regulatory sequences, 
a two-step mechanism of MyoD-mediated gene activation was revealed.  Though stably 
bound MyoD does not appear at the myogenin promoter until ~8 hours post-
differentiation, at the time of myogenin activation, MyoD interacts with the constitutively 
bound Pbx/Meis homeodomain protein complex, which permits targeting of chromatin 
remodelers such as HATs and SWI/SNF (19, 54).  SWI/SNF family members contain a 
bromodomain motif that allows recognition and binding to acetylated lysine residues 
within histone N-terminal tails in vitro.  Indeed, co-immunoprecipitation studies 
demonstrate that Pbx1 and BRG1 are able to associate prior to the appearance of stable 
MyoD binding and well before the onset of myogenin gene activation (19, 54).  These 
findings revealed a two-step mechanism of gene activation, in which MyoD associates 
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with the constitutively bound heterodimer Pbx/Meis at the myogenin promoter in order to 
target HAT and SWI/SNF activity to histones.  (Figure 1-3) 
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Figure 1-3. 
(de la Serna, IL et al.  2005.  MCB) 
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Figure 1-3. 
The heterodimer containing homeodomain proteins Pbx1 and Meis is constitutively 
bound to the myogenin promoter.  MyoD associates with this heterodimer in order to 
target HATs and mediate acetylation of histones at the myogenin promoter.  
Hyperacetylated histones allow binding of Brg1 to target sequences in the myogenin 
promoter and subsequent chromatin remodeling allowing binding of sequence-specific 
binding of transcription factors such as MyoD and Mef2, which initiate transcription 
activation. 
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Additional regulatory mechanisms are in place to modulate the activity of early 
muscle specific gene transcription.  The p38 pathway, which is activated by extracellular 
signaling upon differentiation, causes targeting of p38 kinase to the chromatin of muscle-
specific regulatory sequences and facilitates the binding of SWI/SNF to myogenic loci 
(207).  Inhibition of p38 binding resulted in a loss of SWI/SNF complex binding at these 
elements but did not affect other factor binding.  Forced activation of p38 in myoblasts 
elicited precocious recruitment of SWI/SNF to the myogenin promoter (207).  
Inflammation induced MKK6-p38 and insulin growth factor 1 (IGF1) signaling induced 
PI3K/AKT function in concert to target transcriptional components to the chromatin of 
muscle specific genes (203).  p38 kinases recruit SWI/SNF while PI3K/AKT promote the 
association of MyoD with p300 and pCAF by direct phosphorylation of p300.  
Perturbation of either pathway leads to disassembly of chromatin bound complexes.  
PI3K,AKT permitted recruitment of MEF2-SWI/SNF complexes that were defective for 
chromatin remodeling activity in the absence of MyoD and HAT activity (203).  In the 
context of malignant cells, the combination of MyoD and myogenin is not sufficient to 
induce terminal differentiation (126).  Treatment of cells with tetradecanoylphorbol-13-
acetate (TPA), resulted in recruitment of PCAF and BRG1 to the myogenin promoter.  
Recruitment of chromatin modifying enzymes was dependent on p38 MAPK activity 
(126).  These findings demonstrate that transcriptional regulation of early myogenic gene 
expression is governed by a complex array of factors that can translate cellular signaling 
events into chromatin changes at muscle specific loci.   
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As the functional relationship between SWI/SNF and MRFs has been well 
described at the promoter regions of early myogenic markers, analysis of molecular 
events at late muscle-specific loci remained.  In embryonic tissue and transdifferentiated 
cell culture, MyoD is bound concomitantly with HDAC2 at the promoter regions of late 
myogenic targets upon the onset of differentiation but prior to late gene activation (157).  
Upon induction of muscle-specific transcripts, a transition in which MyoD is replaced 
with myogenin, occurs concurrently with the loss of HDAC2, association of the Mef2d 
coactivator, and binding of the BRG1 remodeling enzyme at these regulatory regions.  
Expression of dominant-negative BRG1 results in abrogation of late myogenic gene 
activation and diminished nuclease accessibility at these loci, indicating that SWI/SNF 
activity is required for the transcription activation of these genes.  Indeed, co-
immunoprecipitation and ChIPs demonstrate that BRG1, Mef2d1b, and myogenin 
associate with each other and are present at the promoter regions of these loci 
concomitantly.  From these studies it is apparent that myogenin and Mef2d1b are 
sufficient to induce activation of late myogenic target genes in the absence of MyoD in a 
BRG1-dependent manner.  Therefore, myogenin cooperates with Mef2d to facilitate 
recruitment of SWI/SNF to the regulatory sequences of late myogenic loci to activate 
gene transcription (157).   
 
 20 years ago studies done in chicken myoblasts indicated that histone 
acetyltransferase activity increased robustly for 24 hours and declined after several days 
Histone Acetyltransferases 
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in culture (127).  Since the levels of HAT transcript and protein were temporally 
regulated during differentiation, it is likely that HAT activity is required for the 
transcription of myogenic genes (127).  FLAG-tagged MyoD was able to 
coimmunoprecipitate with p300/CBP-associated factor (PCAF).  Acetylation of lysine 
residues in the N-terminus of MyoD was mediated by PCAF, which enabled MyoD to 
bind its target DNA with greater affinity (196).  Mutation of these residues from lysine to 
arginine abrogated the activity of MyoD to transactivate reporter DNA in c2c12 
myoblasts, though dimerization with E12 and binding of DNA were still intact.  When 
these arginine mutants were exogenously expressed in 10T1/2 cells, myogenic 
differentiation failed to occur as immunohistochemical analysis revealed few MyoD and 
MCK double positive cells (196).   
 Other groups indicated that MyoD is modified by additional HATs such as 
CBP/p300 (171).  Anti-acetyl lysine antibody was able to coimmunoprecipitate MyoD in 
c2c12 myoblasts and reciprocal pulldowns using MyoD antibody also precipitate acetyl-
lysine.  Recombinant MyoD could be acetylated by p300 in vitro though lysine to 
arginine mutations in the N-terminus precluded p300-mediated acetylation (171).  To 
further examine the interaction between these two coactivators, coimmunoprecipitations 
were performed and demonstrated that acetylated MyoD interacts with the bromodomain 
of p300/CBP .  Deletion of the bromodomain rendered p300 unable to associate with 
MyoD.  K-R mutants, or the non-acetylatable forms of MyoD were unable to associate 
with p300/CBP, though the acetylated form of MyoD exhibits enhanced affinity for CBP.  
Additionally, acetylated MyoD which interacts with p300/CBP, was also proficient at 
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transactivating an MCK-Luciferase promoter.  Association of p300/CBP with myogenic 
promoters corresponded to specific increases in acetylated histone H4, implying that the 
activity of histone acetyltransferases was needed for potentiation of transcription factor 
activity but also for histone modification (172-174). 
 Cooperation between MRFs and E proteins is required for optimal activation of 
muscle-specific genes.  To determine if coactivators such as p300/CBP were also 
required for full-fledged induction, transactivation studies were performed using FLAG-
tagged MyoD, and FLAG-tagged E47 in concert with PCAF, and p300/CBP (59).  
Maximal activation of a luciferase reporter containing 4 tandem E-boxes required the 
synergistic activity of both p300/CBP and PCAF.  Addition of p300/CBP or PCAF alone 
did not achieve robust transactivation.  Temporal analysis indicated that p300/CBP is 
required to acetylate histones while PCAF was needed for MyoD acetylation, and this 
order of modifications was required for maximal transactivation (59).   
 The MEF2 family of coactivators interacts with MyoD to potently activate 
myogenic gene targets (133).  To describe the interplay between HATs and this 
coactivator, coimmunoprecipitations were performed, demonstrating that acetylated 
MEF2C was able to associate with p300/CBP.  Transfection of MEF2C and p300 into 
293T cells indicated that p300/CBP specifically acetylates MEF2C as si-RNA-mediated 
knockdown of p300 resulted in compromised MEF2C acetylation (133).  Truncation 
mutants without the MADS and MEF2 domain were unable to bind p300/CBP and were 
consequently, hypoacetylated.  Mutations in acetylated lysines of MEF2C resulted in 
diminished transactivation of a luciferase reporter containing 3 tandem MEF2 sites.  
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Failure to transactivate was likely due to inability of unacetylated MEF2C to bind DNA, 
as EMSA analysis indicates that lysine to arginine mutants that cannot be acetylated, 
have reduced ability to bind DNA.  Transfection of these mutants concurrently with 
myogenin in 10T1/2 cells results in failed myogenic conversion and down-regulation of 
MHC, and myogenin at early time points of differentiation (133).     
 
 The activity of HDACs must be carefully manipulated to coincide with temporal 
gene regulation.  Post-translational modification, specifically phosphorylation, of 
HDAC1 at residues in the extreme C-terminus is mediated by the serine/threonine kinase 
Histone Deacetylases 
 Histone deacetylases are divided into three classes based on their homology to 
yeast homologues Rpd3, Hda1, and Sir2.  Class I and II HDACs are expressed in 
proliferating undifferentiated myoblasts where they are thought to repress gene activation 
(143).  The muscle regulatory factor MyoD associates with HDAC1, a class I HDAC, and 
prevents precocious activation of myogenic genes (11, 134).  MyoD is released from 
HDAC1, which then associates with hypophosphorylated Rb upon differentiation, 
allowing the activation of skeletal muscle targets (18, 119, 177).  Rb and HDAC1 
stimulate myogenic differentiation by complexing with the transcription factor E2F and 
repressing downstream gene targets that promote cell proliferation.  Forced ectopic 
expression of HDAC1 appears to block activation of late myogenic genes, therefore the 
reciprocal interactions between MyoD, HDAC1, and Rb serve to regulate expression of 
transcripts from late but not early stages during differentiation (18, 119, 177).   
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Casein kinase II (CKII) (29, 78, 79, 168).  Alanine substitution of these residues reduces 
the deacetylase activity of HDAC1 even though these residues are not part of the catalytic 
domain (49).  The phosphorylation of residues at this site inhibits an interaction between 
repressors and/or cofactors like Rb, p38, and Sin3A, that stimulate HDAC1 activity and 
ultimately affect specific gene induction.  Intriguingly, HDAC1 is also sumoylated on 
lysine residues in the C-terminus.  SUMO is a small ubiquitin-like moiety which is 
attached by an E3 ubiquitin ligase as a monomer, but does not target the protein for 
degradation.  Sumoylation increases protein stability, and/or alters the sub-cellular 
localization of a protein.  It has been observed that sumoylated proteins have altered 
enzymatic properties and protein interactions with cofactors are disrupted.  In the case of 
HDAC1, sumoylation enhances its ability to promote gene repression.  C-terminus lysine 
to arginine mutants cannot be efficiently sumoylated and have reduced repressive 
capacity (49).   
 Inhibitors of HDAC activity include trichostatin A (TSA), valproic acid, and 
sodium butyrate (21, 74, 104, 208).  These compounds were capable of stimulating or 
inhibiting muscle differentiation depending on the time and duration they were added to 
differentiation media.  HDAC inhibitors added at the onset of differentiation, 
concurrently with serum withdrawal in culture, resulted in the failure of myoblasts to 
differentiate (101).  Differentiation media supplemented with inhibitors prior to 
differentiation, or prior to serum withdrawal exhibited enhanced muscle differentiation 
(101).  MEF2 interactions with class II HDACs also regulated skeletal muscle gene 
activation (140, 142).  Lysine 9 on histone H3 N-terminal tails located near a MEF2 
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binding site were hypermethylated in a proliferating undifferentiated myoblast (247).  
However, upon differentiation, expression of myogenin was upregulated and H3 lysine 9 
became hyperacetylated.  HDACs formed a complex with heterochromatin protein 1 
(HP1), which targeted the activity of lysine methyltransferases to the site, generating 
methylated hypo-acetylated chromatin (247).  HDAC and HP1 interactions could be 
disrupted by calcium calmodulin kinases (CaMKs) without phosphorylation of 14-3-3 
binding sites.  Myogenic signals overcome the MEF2-HDAC interactions by stimulating 
nuclear export.  CaMK I-IV could phosphorylate HDACs 4, 5, 7, and 9 at two conserved 
serine residues.  These phosphor-serine residues could be bound by 14-3-3, which led to a 
disruption between MEF2 and HDAC and exposure of a nuclear export sequence in 
HDACs 4, 5, 7, and 9 (62, 86, 139, 141, 224).  CaMK-independent regulation of class II 
HDAC phosphorylation also has been identified (246, 247).  This putative kinase, 
mediating CaMK-independent regulation was capable of phosphorylating 14-3-3 binding 
site residues on HDACs 4, 5, 7, and 9 but is resistant to CaMK inhibitors, and 
pharmacologic antagonists of PKC, PKA, PKG, & various MAPKs.  Interestingly, this 
unidentified kinase was sensitive to broad-spectrum antagonists.  The identity of this 
kinase is incredibly important as it regulates transcriptional control of skeletal muscle, 
cardiac muscle, and neuronal gene expression (246, 247).     
 
Histone Methyltransferases 
Lysine Methylation 
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 A conserved feature found in a few chromatin-associated proteins was termed the 
Su(var), Enhancer of zeste, Trithorax (SET) domain (102, 220) (184, 189, 225).  The 
homology of the SET domain to the plant protein Rubisco, which was characterized as a 
methyltransferase, led to the identification of several proteins identified as histone lysine 
methyltransferases (184, 189, 225).  The methyltransferase Ezh2 is present in 
proliferating myoblasts and in embryos at E9.5.  Ezh2 overexpression inhibits muscle 
gene activation while a SET-deficient mutant allows gene transcription (32).  Analysis by 
ChIP indicates that Ezh2 is present at the MHC II and MCK, but not the myogenin 
promoters in myoblasts.  Coimmunoprecipitation demonstrates that Ezh2 associates with 
HDAC1 and the transcriptional repressor YY1 and these proteins are present at the MCK 
and MHC II promoters exclusively in myoblasts but not in myotubes, while SRF was 
present at MCK and MHC II promoters in myotubes.  Ezh2 association with the 
regulatory regions of MCK and MHC II resulted in increased histone H3 K27 tri-
methylation.  Si-RNA-mediated knockdown of YY1 resulted in loss of Ezh2 binding, and 
also H3 K27 tri-methylation at the MCK and MHC II promoters, indicating that Ezh2 
binds YY1 to access the DNA.  The proposed model postulates that DNA-bound YY1 
interact with Ezh2 and HDAC1 prior to gene activation, but are replaced with SRF, 
which causes hypomethylation at H3K27 and loading of MyoD and other chromatin 
remodelers and transcription factors (32).   
 
 Protein arginine methyltransferases are evolutionarily conserved from yeast to 
humans and are classified based on their inclusion in class I, II, or III methyltransferases 
Arginine Methylation 
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(reviewed in (163) and references therein).  Type I PRMTs mono- or asymmetrically 
dimethylate their substrates and type II PRMTs mono- or symmetrically dimethylate their 
substrates, while type III PRMTs simply mono-methylate their substrates.  To date, 
eleven members of the PRMT family have been identified.  With the exception of 
PRMTs 2, 10, and 11 all others have been experimentally shown to catalyze arginine 
methylation.  PRMTs 1, 4, 5, 7, 8 and 9 are capable of methylating arginines on histone 
substrates (reviewed in (163) and references therein). 
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Figure 1-4. 
(Pal, S et al.  2007.  J Cell Phys) 
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Figure 1-4. 
The PRMT family is comprised of 11 members to date.  The conserved catalytic domains 
and specific motifs of the PRMT are shown.  Prmt7 and Prmt10 are unique as they 
contain two copies of the catalytic domain.  Histone substrates of each member are listed 
though the histone substrates of PRMT2, PRMT9 isoforms 1-3, PRMT10 and 11 are 
currently unknown.    
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 Prmt4, which is also known as coactivator arginine methyltransferase 1 (Carm1) 
was identified in a yeast two hybrid screen designed to identify proteins that interact with 
the AD2 region of p160 coactivators (199).  Carm1 has also been shown to interact with 
and methylate transcriptional coactivators such as p300 and GRIP1.  Arginine residues in 
the N- and C-terminus of histone H3 are methylated by Carm1, specifically Arg 2, 17 and 
26 in the N-terminus and Arg 128, 129, 131, and 134 in the C-terminus.  Cell lines 
expressing FLAG-tagged Carm1 were used to purify a multi-subunit complex termed 
NUMAC, which was found to contain subunits of the Brg1-based SWI/SNF complex.  
These findings suggest interplay exists between Carm1 and Brg1 (237).  Carm1-mediated 
methylation of H3 is associated with enhanced GRIP-1 and Estrogen-Receptor •  (ER• ) 
transcriptional activation (12, 34).  Analysis of mice with a genetic disruption of Carm1 
reveals that Carm1 is an essential gene since knockout mice undergo normal development 
but are perinatal lethal (240).  At embryonic day E12.5, homozygous null embryos appear 
normal though at E18.5-19.5, 60% of embryos are smaller when compared to wild type 
embryos.  Mouse embryo fibroblasts (MEFs) isolated from homozygous null animals at 
E12.5 are deficient for methylation of Carm1 substrates such as Poly-A binding protein 
(PABP1), p300, and H3R17 (240).   
 Glutathione-agarose-immobilized GST and GST-Carm1 incubated with 35-S 
Methionine radiolabel led GRIP-1, MEF2C, MyoD or Myogenin revealed that an 
interaction exists between Carm1 and Mef2C (35).  Though the MADS box of MEF2C 
was not required for interaction with Carm1, it was required for association with GRIP1.  
The C-terminal domain of MEF2C is essential for its interaction with Carm1.  GST-
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MEF2C chimeras containing functional domains of MEF2C were created to determine 
the specificity of this interaction.  Deletion of MADS box or MEF2 domain did not 
compromise the association between MEF2C and Carm1.  However, perturbation of the 
C-terminal transactivation domain (TAD) ablated any interaction between MEF2C and 
Carm1 (35).   
 To further characterize the relationship between these coactivators and their 
contribution to transcriptional regulation, mammalian two-hybrid was performed.  Robust 
transactivation of a luciferase reporter was achieved when MEF2C, GRIP1, and Carm1 
interacted, indicating these cofactors cooperate synergistically during transcription 
activation of muscle-specific genes (35).  A luciferase reporter containing 3 tandem 
MEF2 sites was transfected into 10T1/2 fibroblasts.  Robust transactivation of the 
reporter was accomplished in 10T1/2 fibroblasts when MEF2C, GRIP1, and Carm1 were 
expressed concurrently, indicating that Carm1 coactivates MEF2C-dependent 
transcription.  To determine the interaction of these cofactors in vivo, ChIPs were 
performed demonstrating that Carm1 and Mef2 were present at the muscle creatine 
kinase promoter in differentiated myotubes but not proliferating myoblasts.  These 
findings are consistent with the findings that Carm1 protein and transcripts are expressed 
in both proliferating myoblasts and differentiated myotubes though its activity was 
required for the activation of myogenic marker genes in differentiated cells (35).  
Immunohistochemical analysis indicated that Carm1 is localized to both the cytoplasm 
and nucleus in proliferating myoblasts but becomes nuclear during differentiation.  
Treatment of c2c12 myoblasts with the methyltransferase inhibitor adenosine dialdehyde 
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(AdOX) inhibited differentiation.  Analysis of gene expression indicates that activation of 
early and late myogenic targets was compromised when cells were treated with AdOX.  
Antisense-mediated knockdown of Carm1 in c2c12 myoblasts results in compromised 
gene activation of myogenin, corroborating the assertion that Carm1 is essential for 
myogenic gene activation (35).   
 Prmt5 was first identified in a yeast two hybrid screen to identify proteins 
interacting with JAK2.  Biochemical characterization revealed that Prmt5 is a type II 
arginine methyltransferase that mono- and symmetrically di-methylates Arg 8 and Arg 3 
in the N-terminal tails of histone H3 and H4, respectively (6, 24, 123, 164, 165, 216).  
Other cellular proteins that are substrates of Prmt5 include, MBD2, SmD1, and SmD3 (6, 
24, 123, 164, 165, 216).  Prmt5 is associated with multiple complexes where it directs 
various processes such as RNA processing, transcriptional regulation, germ line and 
skeletal muscle differentiation (6, 69, 123, 164, 165).  Prmt5 has been purified in 
association with chromatin remodeling complexes hSWI/SNF and NuRD.  These 
interactions have also been shown to be important for transcriptional repression of cell 
cycle regulator and tumor suppressor genes (6, 69, 123, 164, 165), indicating that Prmt5 
is involved in the transcriptional regulation of a diverse array of genes. 
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Thesis Aims 
 Skeletal muscle differentiation is a complex process and has been demonstrated 
by many groups, to require the combined action of transcription factors, HDACs, HATs 
and HMTs.  However, the role of protein arginine methyltransferases and their 
relationship with muscle regulatory factors and other chromatin remodeling enzymes is 
poorly understood.  Exquisite temporal regulation of gene transactivation is a hallmark of 
development and differentiation events, though the mechanisms which govern this 
process are not well understood.  The objective of this thesis was to analyse the 
mechanism of protein arginine methyltransferase function during myogenic gene 
transcription.   
 In Chapter I, we began by utilizing a cell line containing antisense-mediated 
knockdown against Prmt5 in order to determine whether muscle-specific gene expression 
was perturbed.   
• When Prmt5 protein levels were reduced, activation of myogenic transcripts was 
diminished.   
• Further analysis by ChIP revealed that Prmt5 directly targets the promoter 
sequences of myogenin, a gene required for terminal differentiation of skeletal 
muscle.   
• Enrichment of di-methylated histone H3 arginine 8 (diMeH3R8) at this locus was 
mediated by Prmt5.   
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A time course of ChIPs demonstrated that Prmt5 association with the myogenin 
promoter occurred at early time points, and did not require the activity of ATP-dependent 
chromatin remodeling in order to target the DNA.   
• Co-IPs indicated that Prmt5 interacts with MyoD, in order to access the regulatory 
regions of the myogenin locus.   
 Though many groups have catalogued the dependence of one type of histone 
modification on another, few reports exist detailing the requirement for histone 
modifications prior to nucleosome remodeling.  In this thesis we uncover that a 
requirement exists for Prmt5 and its enzymatic activity during myogenesis, specifically to 
facilitate the recruitment of the ATP-dependent chromatin remodeling enzymes 
SWI/SNF.  In order to determine the dependence of Brg1 binding on Prmt5 binding and 
activity, we performed ChIPs in cells where Prmt5 recruitment to gene sequences of 
myogenin was lost.   
• Failure of Prmt5 to bind the regulatory regions of myogenin resulted in loss of 
Brg1 interaction with the promoter and consequently, ablation of nucleosome 
remodeling, which precluded sequence specific transcription factors such as 
MyoD from associating with the promoter and intiating transcription.   
• ChIPs performed using muscle satellite cells and mature myotubes revealed that 
Prmt5 associated with and regulated H3R8 dimethylation at myogenin promoter 
sequences in activated but not quiescent satellite cells in vivo. 
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 In order to further examine the role of Prmt5 during myogenic differentiation, we 
wished to explore the possibility that Prmt5 was associated with and required for the 
activation of late stage muscle genes.   
• ChIPs performed using mouse skeletal muscle tissue samples revealed that Prmt5 
was also bound to late myogenic promoters such as desmin and muscle creatine 
kinase (MCK).   
• Time course ChIPs indicated that Prmt5 was bound to late muscle promoter 
sequences at early times prior to the onset of late gene activation, or 
differentiation.   
To further examine the role of Prmt5 during the transcription activation of late 
muscle-specific target genes we induced late genes using a combination of exogenously 
expressed myogenin and Mef2d1b.  Cells were also induced using ectopically expressed 
MyoD.  In cells containing intact levels of Prmt5, binding was enriched in late muscle 
gene loci in cells differentiated using MyoD, but interestingly, Prmt5 was absent on late 
gene promoters when cells were differentiated with myogenin and Mef2d1b.  Using cells 
in which Prmt5 was knocked down, we examined late myogenic gene expression and 
observed that when late genes were induced using myogenin and Mef2d1b, no defect in 
activation was seen.  However, in cells where differentiation was accomplished using 
MyoD alone, late gene activation was significantly reduced.  This observation was in 
agreement with our initial findings, that Prmt5 and dimethylation of H3R8 were 
necessary for activation of myogenin, a gene required for the induction of late muscle-
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specific transcripts.  Thus, Prmt5 did not directly influence transcription of late myogenic 
targets, but was necessary for myogenin activation.   
 To further our analysis of PRMT involvement during myogenic gene transcription 
we performed ChIPs in muscle tissue and discovered that  
• Carm1 was present at the regulatory sequences of late muscle-specific genes in 
vivo.   
• ChIP time course analysis revealed that Carm1 binding occurred concurrently 
with the onset of late myogenic gene activation.   
Using Carm1 -/- null and +/+ wild type MEFs, we observed that Carm1 was 
associated with the promoter regions of late gene loci in MyoD- or myogenin/Mef2d1b-
differentiated wild type samples.   
• Loss of Carm1 binding in null MEFs resulted in a loss of Brg1 binding, which 
consequently led to abrogation of nucleosome remodeling at these loci.   
Regardless of MyoD-mediated or myogenin/Mef2d1b-mediated myogenic conversion, 
null MEFs failed to robustly activate late myogenic targets but were still able to activate 
myogenin.  Thus, Carm1 is directly required for the activation of late muscle-specific 
transcripts as it facilitates the targeting of SWI/SNF. 
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 The protein arginine methyltransferases (PRMTs) are an additional class of 
enzymes that can be linked to histone modification and gene regulation during skeletal 
muscle differentiation.  This family has 9 members (Prmt 1-9), six of which have been 
shown to generate asymmetric (type I) or symmetric (type II) dimethylarginine and to 
CHAPTER II 
Prmt5 facilitates ATP-dependent chromatin remodeling and is required 
during myogenesis 
Introduction 
 Gene expression is a highly regulated process that frequently requires coordinated 
function between transcription factors and chromatin remodeling enzymes.  These 
enzymes are divided into two classes; ATP-dependent remodelers that hydrolyze ATP 
and alter nucleosome structure, and histone modifiers that covalently modify specific 
histone residues post-translationally.  The activation of skeletal muscle differentiation is 
regulated by members of the basic helix-loop-helix (bHLH) family of tissue specific 
transcription factors, including MyoD, Myf5, Mrf4, and myogenin, as well as by 
members of the Mef2 family of transcriptional regulators, which act cooperatively with 
bHLH proteins (20, 140, 178).  Numerous chromatin remodeling enzymes have been 
shown to both positively and negatively affect myogenic gene expression.  These include 
histone acetyl transferases, types I, II and III histone deacetylases, histone lysine 
methyltransferases, and members of the SWI/SNF family of ATP-dependent remodeling 
enzymes (55, 195, 217).  The relationships between the different classes of chromatin 
remodeling enzymes during myogenesis have been largely unexplored. 
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affect a range of cellular processes through arginine methylation of substrate proteins (15, 
217).  Of particular note, the Prmt4 enzyme, also called Carm1, has been linked to 
skeletal muscle differentiation and to control of estrogen mediated gene activation via 
methylation of histones H3 and H4 (12, 35, 48, 237).  Prmt4 functions at estrogen 
induced promoters as part of a multi-protein complex that also contains the Brg1 ATPase 
of SWI/SNF chromatin remodeling complexes (237).  Another family member, Prmt5, 
has also been isolated as part of an enzymatic complex containing Brg1, though in this 
case the complex is associated with transcriptional repression of genes involved in 
growth control and tumor suppression (164, 165).  Other studies indicated that Prmt5 acts 
as a repressor of cyclin E (69, 186).  Prmt5 was also shown to associate with and 
methylate the elongation factor Spt5, which decreased this protein’s affinity for RNA 
polymerase II and impeded transcriptional elongation (117).  Thus Prmt5 negatively 
affects gene expression via symmetric arginine methylation of both histones and 
components of the transcriptional machinery.  Prompted by association between Prmt5 
and Brg1 as well as by the fact that Prmt4 is involved in the transcriptional regulation of 
myogenic genes, we sought to determine whether Prmt5 contributes to skeletal muscle 
differentiation. 
 Previous work described NIH3T3 based cell lines that constitutively express a 
Prmt5 antisense vector and thereby cause a significant reduction in Prmt5 mRNA and 
protein levels (164).  Ectopic expression of MyoD in fibroblast cells induces the 
myogenic differentiation program (50); this system has been extensively utilized to 
examine the mechanisms of skeletal muscle gene regulation for nearly twenty years (217).  
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Using this system, we determined that cells containing reduced levels of Prmt5 failed to 
activate myogenic gene expression upon introduction of MyoD.  Detailed examination of 
the events leading to activation of the myogenin locus, the production of which is 
necessary for the activation of myogenic late genes that encode structural and functional 
skeletal muscle proteins, determined that Prmt5 dependent dimethylation of histone 3 
arginine 8 (H3R8) was required for the interaction of the SWI/SNF ATPase Brg1, for 
chromatin remodeling of the locus, and for all subsequent events leading to gene 
activation.  We also present evidence that Prmt5 interacts with the myogenin promoter in 
activated satellite cells isolated from adult skeletal muscle tissue, which further supports 
the conclusion that Prmt5 functions in myogenic gene activation and is necessary for the 
induction of skeletal muscle differentiation.  Thus we have determined that a histone 
methyltransferase is necessary for the function of an ATP-dependent chromatin 
remodeling enzyme during tissue differentiation. 
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Results 
 RT-PCR was performed to determine if the reduction of Prmt5 had an effect on 
the transcription of myogenic target genes.  As shown in Fig. 1B, expression of MyoD 
mRNA was comparable in each cell line, indicating that each cell line was infected by the 
retrovirus and expressed equivalent levels of MyoD.  As expected, both the early muscle 
marker myogenin and the late genes desmin and skeletal alpha actin were induced upon 
Transcription of skeletal muscle genes is significantly impaired in cells with reduced 
levels of Prmt5 
 Cooperation between myogenic transcription factors and chromatin remodeling 
enzymes is needed to properly regulate the transcription of muscle specific genes.  To 
address the function of the Prmt5 arginine methyltransferase in skeletal muscle 
differentiation, we utilized two independently derived NIH3T3 cell lines that express a 
Prmt5 antisense vector.  These cell lines were previously shown to have significantly 
decreased levels of this protein and its corresponding mRNA (164).   
 In vitro skeletal muscle differentiation was initiated by infection of both the 
control and antisense lines (c15, c12) with a retrovirus encoding MyoD (53, 155) for 30 
hours.  After infection, low-serum differentiation media was added to the cells and the 
cells were allowed to undergo differentiation for 36 hours.  Control samples that were 
mock infected were also placed in differentiation media, and are referred to as mock-
differentiated.  Westerns were performed to demonstrate that the antisense vector present 
in these two clones reduced the amount of Prmt5 in both mock and MyoD-differentiated 
c15 and c12 cells (Fig. 1A).   
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differentiation with MyoD in the control cells.  In contrast, in MyoD-differentiated Prmt5 
antisense lines, the expression of all three marker genes was significantly reduced.  
Quantitative real time PCR was used to more precisely measure the differences in 
transcript levels (Fig. 1C).  Impaired gene activation of early and late muscle-specific 
transcripts suggests a role for Prmt5 in the activation of myogenic transcription during 
the differentiation process.   
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Figure 2-1 
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Figure 2-1:  Prmt5 is required for skeletal muscle differentiation.  NIH3T3 cells and two 
independently derived NIH3T3 lines expressing an antisense vector against Prmt5 (c15, 
c12) were mock differentiated or differentiated by ectopic expression of MyoD.  (A) 
Western blots show that protein levels of Prmt5 were significantly reduced in 
differentiated and mock differentiated antisense lines compared to levels in the parental 
NIH3T3 cells.  Cells were differentiated as described in the methods section for 36 hours 
prior to sample collection.   (B) Expression of myogenic target genes myogenin, desmin, 
skeletal α-actin and ectopic expression of MyoD were monitored by RT-PCR in mock- 
and MyoD-differentiation cells collected 36 hours post-differentiation.   (C)  
Quantification of muscle specific gene expression by quantitative real-time PCR confirms 
that early and late differentiation markers are significantly decreased in cells containing 
reduced levels of Prmt5.   
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 In order to initiate the process of skeletal muscle differentiation, MyoD promotes 
cell cycle arrest, which involves the induction of cdk inhibitors such as p21 and cell cycle 
regulators like Rb (136, 248).  As a consequence, the activity of cyclins and cyclin 
dependent kinases is down-regulated and cell cycle arrest is achieved.  To eliminate the 
possibility that defects seen in myogenic gene expression upon reduction of Prmt5 levels 
stem from aberrant cell cycle arrest, we performed fluorescence activated cell sorting 
(FACS) analysis following propidium iodide incorporation to determine whether the cells 
were arresting properly (Table 1).  The percentage of cells in S phase did not differ 
between the control and antisense cell lines under any of the conditions evaluated.  
Cycling cell populations contained approximately 30% of cells in S phase.  In mock or 
MyoD-differentiated cells, the percentage of cells in S phase was 12-14% (Table 1), 
which is consistent with the level of cell cycle withdrawal that can be achieved with 
immortalized fibroblasts under these conditions (56, 190).  These data indicate that the 
control and both Prmt5 antisense lines withdrew from the cell cycle upon differentiation.  
RT-PCR analysis indicated that p21 and Rb mRNAs were upregulated equivalently in 
each of the cell lines upon differentiation with MyoD (data not shown), further 
corroborating these findings.  Thus, the reduction in myogenic gene expression observed 
upon reduction of Prmt5 levels was not due to a failure of the cells to undergo cell cycle 
arrest.  Further, the data indicate that Prmt5 is not needed for cell cycle arrest under the 
conditions utilized for these experiments.  
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 The requirement for Prmt5 during MyoD induced differentiation suggests that 
Prmt5 may physically associate with MyoD and other regulators of differentiation.  Co-
immunoprecipitation experiments revealed that endogenous Prmt5 was associated with 
MyoD in differentiating cells (Fig. 2).  As expected, no interactions were observed in 
mock-differentiated cells.  Additional experiments showed that endogenous Prmt5 was 
associated with endogenous Brg1 (Fig. 2).  This association was not dependent upon 
differentiation, consistent with previous reports demonstrating that a subset of Brg1 
containing SWI/SNF chromatin remodeling enzymes are associated with Prmt5 in tumor 
derived cell lines (164, 165). 
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Figure 2-2. 
 
 
57 
 
 
 
 
 
 
Figure 2-2:  Prmt5 co-immunoprecipitates with Brg1 and MyoD.  Mock differentiated or 
cells differentiated for 0h, at which point the MyoD infected cells were exposed to 
differentiation conditions, or for 36h were harvested and used to perform co-
immunoprecipitation experiments with the indicated antibodies.  
(A) In 10% of input samples, indicated proteins were detected by western blot.  (B) 
Whole cell extracts from mock and differentiated samples were co-immunoprecipitated 
with Prmt5 antibody (#611538 – BD Biosciences) or purified IgG.  Immunoprecipitated 
material was run on SDS-PAGE, transferred to a membrane and probed for the presence 
of Brg1, MyoD and Prmt5.   (C) Co-immunoprecipitations were performed using Brg1 
antisera and probed for Prmt5 and Brg1.   (D) Co-immunoprecipitations were performed 
using MyoD antisera and probed for the presence of Prmt5 and MyoD.     
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Prmt5 binding and H3R8 dimethylation at the myogenin promoter are required for 
binding of Brg1 and MyoD
 To further investigate the interaction of Prmt5 with the myogenin promoter, 
ChIPs were performed over a time course of differentiation.  Both Prmt5 and 
dimethylated H3R8 were detected at the time when differentiation media was first added 
(t = 0) and the interaction of these proteins was observed throughout the time course (Fig. 
3C).  These interactions precede the activation of myogenin expression (54), suggesting 
that the Prmt5 methyltransferase contributes to the initial promoter reorganization that 
  
 We wished to determine if Prmt5 was directly influencing the expression of the 
myogenin gene by directly interacting with its regulatory regions.  We examined the 
myogenin promoter because transcriptional activation at this locus is necessary for the 
subsequent expression of late marker genes, such as desmin and skeletal alpha-actin, and 
for terminal differentiation.  Chromatin immunoprecipitation (ChIP) for Prmt5 was 
performed in mock and MyoD-differentiated NIH3T3 and Prmt5 antisense lines (Figs. 
3A-B).  In the NIH3T3 cells, binding of Prmt5 to the myogenin promoter required 
MyoD-induced differentiation.  Arginine 8 of histone H3 (H3R8) is a known substrate for 
Prmt5 (164, 165).  Dimethylation of H3R8 at the myogenin promoter was enriched upon 
differentiation.  As expected, Prmt5 binding was significantly reduced in the antisense 
lines and was comparable to binding seen in mock-differentiated cells.  Similarly, in the 
antisense lines, dimethylation of H3R8 was reduced to the level observed in mock-
differentiated samples, indicating that dimethylation of H3R8 at the myogenin promoter 
required Prmt5.   
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promotes myogenin expression.  Curiously, though the levels of dimethylated H3R8 at 
the myogenin promoter were relatively constant during the differentiation protocol, a 
reproducible increase in amount of Prmt5 present at the promoter was observed between 
0 and 12 hours post-differentiation (Fig. 3C).  The significance of this observation, if any, 
is not known.        
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Figure 2-3. 
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Figure 2-3:  Prmt5 binds to the myogenin promoter and dimethylates H3R8.  Chromatin 
immunoprecipitations (ChIPs) were performed using antibodies against Prmt5 and 
dimethylated H3R8 in mock and MyoD differentiated NIH3T3 and Prmt5 antisense cell 
lines. (A) ChIPs demonstrate that binding of Prmt5 and dimethylated H3R8 at the 
myogenin promoter in differentiated cells is significantly reduced in the antisense lines.  
Amplification of the coding region of elongation factor EF1-alpha was performed as a 
negative control.  (B) Quantification of Prmt5 binding and H3R8 dimethylation at the 
myogenin promoter was performed by Q-PCR.  (C)  Time course of Prmt5 and 
dimethylated H3R8 association with the myogenin promoter.  Q-PCR analysis of binding 
in differentiated cells at the indicated times is shown.  Values are expressed relative to the 
values obtained at time 0, which was set at 1. 
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 Prior work showed that induction of myogenin transcription required the binding 
and activity of Brg1, an ATPase that is the catalytic subunit of some of SWI/SNF 
chromatin remodeling enzymes (53).  To ascertain whether a reduction in Prmt5 affected 
Brg1 binding to the myogenin promoter, additional ChIPs were performed.  These 
experiments showed that in cells with reduced levels of Prmt5, recruitment of Brg1 at the 
myogenin promoter was diminished to the level of binding seen in mock-differentiated 
cells (Figs. 4A-B).  Control westerns showed that the lack of Brg1 binding to the 
myogenin locus was not due to changes in Brg1 levels in the Prmt5 antisense cells (Fig. 
4C).  Thus Prmt5 binding and dimethylation of H3R8 are prerequisites for Brg1 binding.  
The lack of Brg1 at the myogenin promoter implies a lack of chromatin remodeling at 
this locus.  A restriction enzyme accessibility assay (REAA) allowed us to detect 
accessibility changes in the chromatin at the myogenin locus in response to induction of 
differentiation by MyoD in the presence of normal and reduced levels of Prmt5.  When 
mock-differentiated, none of the cell lines displayed significant enzyme accessibility at 
the myogenin locus (Fig. 4D).  Upon differentiation there was an expected increase in 
accessibility in the NIH3T3 cells, but little or no accessibility was observed in the Prmt5 
antisense lines.  These findings reiterate the requirement for Brg1 to alter myogenin 
promoter structure in a manner that permits restriction enzyme accessibility and indicate 
that the presence of Prmt5 and dimethylated H3R8 is insufficient to cause such structural 
changes at the myogenin locus.  
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Figure 2-4. 
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Figure 2-4:  Brg1 and MyoD binding at the myogenin promoter require Prmt5.  (A)  
ChIPs were performed using antibodies against Brg1 and MyoD in mock and MyoD 
differentiated cell lines harvested 36 h post-differentiation, and the myogenin promoter 
and EF1α coding region (input control) were PCR amplified.  Data from Figs 3A and 4A 
were from the same experiment, thus the input control bands are the same for both panels.  
(B) Brg1 and MyoD binding were quantified by Q-PCR.  (C)  Western blot showing that 
Brg1 and MyoD protein levels were unaffected by the reduction in Prmt5 protein levels.  
(D)  A restriction enzyme accessibility assay (REAA) was performed to evaluate the 
accessibility of a Pvu II site at -320 relative to the myogenin mRNA start site.  Chromatin 
accessibility was dependent upon Prmt5 expression.   
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 Previous work has implicated the Pbx/Meis homeodomain factors as playing an 
important role during the induction of myogenin transcription by providing a mechanism 
to initially target MyoD to the locus (19, 113).  Further studies showed that Brg1-
mediated chromatin remodeling at the myogenin promoter subsequently permits stable 
binding of MyoD to its consensus binding sites upstream and downstream of the 
Pbx/Meis site (54).  Since Brg1 did not bind to or remodel chromatin at the myogenin 
promoter in Prmt5 antisense cell lines, we would predict that stable binding of MyoD 
would also not be observed in these cells.  As expected, an additional consequence of 
decreased Brg1 interactions in the antisense lines was that binding of MyoD was reduced 
to background levels (Figs. 4A-B).   In summary, the reduction in Prmt5 levels resulted in 
a failure to activate myogenin expression because neither Prmt5 nor Brg1 interacted with 
the promoter.  Thus, subsequent events such as histone methylation, ATP dependent 
chromatin remodeling, and MyoD binding did not occur.   
To further probe the molecular events occurring at the myogenin locus, we 
assessed whether binding of Prmt5 and dimethylation of H3R8 required functional Brg1.  
We previously described and characterized tetracycline suppressible cell lines that in the 
absence of tetracycline (tet) express a flag-tagged, ATPase deficient, dominant negative 
Brg1 protein (52, 53) and showed that expression of dominant negative Brg1 blocks 
activation of myogenic early and late genes because chromatin remodeling at each 
inducible locus is blocked (53, 54, 157).  Upon differentiation with MyoD, Prmt5 was 
able to bind to the myogenin promoter in cells expressing functional Brg1 (+ Tet) as well 
as in cells expressing the dominant negative version of Brg1 (- Tet; Fig. 5A).  
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Dimethylation of H3R8 was also enriched at the promoter, regardless of the functional 
status of Brg1 (Fig. 5A).  Control westerns demonstrated that Prmt5 protein levels were 
unaffected by the expression of dominant negative Brg1, and, as previously documented, 
expression of dominant negative Brg1 did not alter the overall levels of Brg1 in the cells 
(Fig. 5B; (54)).  Additional mRNA analyses indicated that MyoD was equivalently 
expressed in cells expressing or lacking dominant negative Brg1 and that the expression 
of dominant negative Brg1 inhibited subsequent myogenic gene expression (Fig. 5C and 
data not shown).  We conclude that chromatin remodeling by Brg1 is not required to 
facilitate the binding of Prmt5 at the myogenin promoter.  Thus, Prmt5 binding is 
required for the binding of Brg1, but Brg1 function is not needed for the binding of Prmt5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
 
 
 
 
 
 
Figure. 2-5. 
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Figure 2-5:  Prmt5 is able to bind to and dimethylate H3R8 at the myogenin promoter in 
the absence of functional Brg1.  ChIPs were performed 36 h post-differentiation in a cell 
line containing a Tet-suppressible vector expressing a FLAG-tagged, ATPase deficient, 
dominant negative Brg1.  (A) Q-PCR shows binding of Prmt5 and dimethylated H3R8 at 
the myogenin promoter in the presence (+ tet) and absence (- tet) of functional Brg1.   (B) 
Protein levels of Brg1, Prmt5 and the FLAG-tagged dominant negative mutant Brg1 were 
evaluated by Western blot.  Expression of FLAG in (-) Tet samples indicates expression 
of dominant negative Brg1.  (C) Q-PCR evaluation of MyoD mRNA, to demonstrate that 
differentiated cells expressed MyoD, and myogenin, to demonstrate that MyoD 
dependent gene expression was inhibited by dominant negative Brg1.  
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The separation protocol utilized results in a satellite cell pool that contains both 
quiescent and activated cells.  To evaluate whether the purification scheme adequately 
separated satellite cells from myofibers, quantitative PCR was performed to examine the 
expression of satellite cell and myofiber marker genes.  Pax3 is a transcription factor that 
is a member of the paired box/homeodomain family and that is expressed in satellite cells 
(41).  Pax3 is highly expressed in satellite cells compared to mature myofibers or the 
negative control liver tissue, indicating that this fraction is enriched for satellite cells 
while the myofiber preparation contains few if any satellite cells (Fig. 6A).  Since the 
satellite cell fraction contains both quiescent and activated satellite cells, both satellite 
cell and myofiber fractions displayed expression of MyoD and myogenin, as expected.  
Expression of the late skeletal muscle marker dystrophin was seen only in the myofiber 
Prmt5 and dimethylated H3R8 are present at the myogenin locus of satellite cells in 
vivo 
 To determine whether Prmt5 binds to the myogenin promoter in vivo, we isolated 
hind limb muscle from 4-5 week old BL6 mice and separated satellite cells and myofibers 
(see materials and methods).  Satellite cells are quiescent muscle progenitor cells located 
in the basal lamina of mature muscle fibers (138, 198).  Upon activation, they express 
myogenic regulatory factors and initiate the differentiation program by proliferating and 
fusing with existing myofibers or fusing to form new myofibers (reviewed in (57, 97)).  
Investigation of the molecular roles of transcriptional regulators and chromatin 
remodeling enzymes during myogenic gene activation in these cells has been limited by 
the difficulties associated with isolation and analysis of these cell populations.   
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fraction, establishing that the satellite cell fraction was not contaminated with myofibers 
(Fig. 6A).   
We then isolated nuclei from these separated tissue samples and performed ChIP 
experiments to assess factor interactions at the myogenin locus.  Prmt5 was highly 
enriched at the myogenin promoter in satellite cells but this enrichment was significantly 
reduced in the myofibers (Fig. 6B).  H3R8 dimethylation also was highly enriched at the 
myogenin promoter in satellite cells while enhanced to a much lesser extent at the 
myogenin promoter in myofibers, which is consistent with the reduced binding of Prmt5 
that was observed.  Comparable levels of Prmt5 were expressed in both tissue samples 
(Fig. 6C). 
Since the satellite cell population contains both quiescent and activated cells, we 
could not definitively conclude that Prmt5 association with the myogenin promoter was 
related to the activation of gene expression in these cells.  To better address this question, 
we asked whether Prmt5 and MyoD could be co-localized to the myogenin promoter.  
Since only activated satellite cells express MyoD , the simultaneous presence of MyoD 
and Prmt5 would indicate that Prmt5 was present at the myogenin locus in cells that were 
actively expressing myogenin.  Re-ChIP experiments were preformed in which chromatin 
from satellite cell nuclei immunoprecipitated with Prmt5 antibodies was subsequently 
immunoprecipitated with MyoD antibodies.  The results show that Prmt5 and MyoD are 
present together at the myogenin locus in activated satellite cells (Fig. 6D).  
Collectively, these results indicate that the Prmt5 arginine methyltransferase is 
required for MyoD-mediated differentiation.  Examination of one of the early myogenic 
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target genes shows that Prmt5 binds to the myogenin promoter and dimethylates H3R8.  
Prmt5 binding was required for association of the Brg1 chromatin remodeling enzyme 
with the promoter and for all subsequent events that occur during the activation of 
myogenin expression.  Thus cells containing reduced levels of Prmt5 failed to activate 
myogenin and, due to the absence of myogenin, failed to activate myogenic late genes, 
leading to the observed block in differentiation.  The co-recruitment of Prmt5 and MyoD 
to the myogenin locus in primary satellite cells corroborates a role for Prmt5 in myogenic 
differentiation in vivo.  The findings presented here provide evidence for an important 
physiological role for Prmt5 during the induction of skeletal muscle differentiation 
because it facilitates ATP dependent chromatin remodeling at myogenic loci, which then 
leads to gene expression. 
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Figure 2-6. 
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Figure 2-6:
 
  Prmt5 binds to and dimethylates H3R8 at the myogenin promoter in muscle 
satellite cells.  (A) The separation and purification of satellite cells and myofibers were 
monitored by Q-PCR of marker gene mRNAs.  (B) ChIP analysis using nuclei obtained 
from muscle satellite cells and myofibers indicates that Prmt5 binding and dimethylated 
H3R8 were present at the myogenin promoter in satellite cells and at reduced levels in 
myofibers.  (C) Transcript levels of Prmt5 in both cell types were quantified by Q-PCR.  
(D) Re-ChIP analysis quantified by Q-PCR.  Material immunoprecipitated with Prmt5 
antibodies were subsequently immunoprecipitated with MyoD antibodies. Q-PCR data 
are the average +/- standard deviation of 3 independent experiments. 
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Discussion 
There are two previous reports suggesting Prmt5 promotes reporter gene 
activation; all other studies suggest that Prmt5 functions in transcriptional repression.  In 
one study, dose dependent reduction of Prmt5 by RNAi methods resulted in 
Prmt5 is necessary for the activation of myogenin expression and myogenesis 
 The results indicate that the protein methyltransferase Prmt5 is required for 
MyoD-mediated skeletal muscle differentiation.  Prmt5 localizes to the myogenin 
promoter, a MyoD inducible gene whose expression mediates terminal differentiation (92, 
111, 152) .  In both cell culture and satellite cells isolated from muscle tissue, the 
presence of Prmt5 at the myogenin promoter is coincident with the presence of 
dimethylated H3R8, a known substrate for Prmt5 (164).  Manipulated cells expressing 
low levels of Prmt5 were unable to activate the expression of myogenin or other 
myogenic genes, and the lack of activation correlated with the lack of Prmt5 and 
dimethylated H3R8 at the myogenin locus.  Moreover, both Prmt5 and dimethylated 
H3R8 were present at the myogenin locus prior to, at the onset of, and following 
myogenin expression.  Finally, re-ChIP experiments from satellite cell nuclei indicate the 
presence of both MyoD and Prmt5 at the myogenin promoter in primary tissue.  The 
satellite cell pool contains both quiescent cells as well as activated cells that have 
initiated differentiation.  Since only the activated cells express MyoD, the re-ChIP 
experiment places Prmt5 on the myogenin promoter in primary cells that are actively 
expressing myogenin and are in the process of differentiating.  The results support the 
conclusion that Prmt5 promotes gene activation during skeletal muscle differentiation.   
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corresponding decreases in NFAT and IL-2 driven promoter activity and in IL-2 secretion, 
suggesting that Prmt5 promotes IL-2 expression (186).  In a different report, Prmt5 was 
purified in a multi-protein complex with p44, an androgen receptor (AR) interacting 
protein that enhances AR-dependent transcription.  Prmt5 acted synergistically with p44 
to mediate AR-dependent reporter gene expression.  However, activation by Prmt5 in this 
system did not require its methyltransferase function, thus the mechanism by which 
Prmt5 activated transcription occurred was not clear (98).   In contrast, Prmt5 
involvement in gene repression is better understood.  Interestingly, multiple mechanisms 
appear to be involved.  Prmt5 can methylate the elongation factor, Spt5, which decreases 
its affinity for pol II and impedes transcription elongation (117).  In contrast, Prmt5 
directly binds to regulatory sequences controlling expression of cyclin E, the tumor 
suppressors NM23 and ST7, and the c-myc target gene, CAD, and methyltransferase 
function was required for repression where examined (69, 164, 165).  Microarray and 
confirmatory RT-PCR experiments identified additional Prmt5 target genes also involved 
in cell growth control (164).  Dimethylation of H3R8 at promoter sequences was 
associated with repression of the genes examined, and purification of Prmt5 as part of a 
multi-enzyme complex with HDAC2 and the SWI/SNF ATPase Brg1 (165) suggests 
mechanisms by which nucleosomes on gene regulatory sequences can be altered and/or 
repositioned and histones can be dimethylated and deacetylated in a manner that leads to 
transcriptional repression. 
 Prmt5 also functions in complexes with RNA polymerase II and the pol II-
associated phosphatase FCP1, and with several cytosolic proteins that together with 
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Prmt5 promote snRNP assembly (4, 10, 145).  Thus it is established that Prmt5 can 
function in multiple capacities in multiple complexes, likely through its protein methylase 
activity, to regulate disparate cellular processes.  Our results suggest that Prmt5 may also 
be a component of one or more additional complexes that function as coactivators of gene 
expression.  
 A number of studies have examined the factors involved in and the order of 
events that lead to activation of the myogenin locus (19, 54, 207).  Prior studies showed 
the homeodomain factor Pbx constitutively interacting with the myogenin promoter and 
providing a mechanism to initially target MyoD to the promoter.  This led to promoter 
specific histone acetylation, followed by binding of the Brg1 ATPase of SWI/SNF 
chromatin remodeling enzymes.  Subsequent steps, including increased chromatin 
accessibility, stable binding of MyoD and Mef2 to the promoter, and activation of 
Prmt5 function facilitates ATP dependent chromatin remodeling in the cascade of 
events leading to myogenin expression 
 The observation that Prmt5 is required for the binding and function of the Brg1 
ATP dependent chromatin remodeler indicates that the histone methyltransferase is 
required for ATP dependent chromatin remodeling to occur.  Though there are reports of 
specifically modified histones serving as recognition sites for the interaction of specific 
subunits of ATP dependent chromatin remodeling enzymes with chromatin (1, 90, 91, 
125, 234), we believe this is the first demonstration that a specific histone modification 
enzyme is required for an ATP dependent chromatin remodeling enzyme to modify 
chromatin structure and activate gene expression from an endogenous locus.   
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myogenin transcription, were absolutely dependent upon Brg1 function.  The kinetics of 
histone acetylation and Brg1 binding, coupled with protein:protein interactions between 
endogenous Brg1 and endogenous Pbx at the initiation of the differentiation process, 
supported the idea that chromatin modifying enzymes were targeted to the promoter via 
the MyoD/Pbx/Meis complex to permit histone modifications and ATP dependent 
chromatin remodeling, thereby enabling stable occupancy by transcription factors 
required for myogenin transcription.  The dependency of Brg1 binding on the presence of 
Prmt5 places Prmt5 function early in the activation process, coincident with or preceding 
Brg1 interaction with the promoter.  The timing of Prmt5 function and the observed 
physical associations between Prmt5, MyoD, and Brg1 suggest a similar mechanism of 
remodeling enzyme targeting to the myogenin promoter. 
 The observation that Prmt5 is required for the association of Brg1 with the 
myogenin promoter and its subsequent chromatin remodeling functions suggests that 
either the physical presence of Prmt5 at the myogenin promoter and/or the dimethylation 
of H3R8 at the promoter facilitate Brg1 binding. Histone acetylation also precedes Brg1 
interaction at the myogenin promoter (54), and both in vivo and in vitro data indicate that 
the bromodomain present in Brg1 interacts with acetylated histones and that SWI/SNF 
complex function can be facilitated by histone acetylation (1, 90, 91).  We speculate that 
Brg1 has a higher affinity for chromatin that contains H3R8 dimethylated by Prmt5 and 
that H3R8 dimethylation might combine with histone acetylation to create a more 
permissive substrate for Brg1 dependent chromatin remodeling.   
Functional interplay between different methyltransferases during myogenesis? 
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 A distinct protein methyltransferase, Prmt4/Carm1, was previously shown to 
contribute to myogenesis (35).  Prmt4, along with the Mef2C protein, were localized the 
muscle creatine kinase promoter in differentiating cell cultures by ChIP, and inhibition of 
Prmt4 expression blocked the expression of myogenic genes.  The fact that Prmt4 was 
found in a complex with Brg1 that promoted estrogen receptor stimulated gene 
expression (237), raises the possibility that both Prmts can cooperate with SWI/SNF 
chromatin remodeling enzymes during gene activation events.  However, the ATPase 
activity of Brg1 was required for Prmt4 histone methylation in vitro (237), whereas our 
data indicate that Prmt5 was necessary for Brg1 association with the myogenin promoter 
and subsequent changes in promoter chromatin accessibility.  Thus the mechanisms by 
which these two Prmts function may differ.  Furthermore, Prmt4 and Prmt5 do not share 
the same histone substrates, so far as is known.  Whether Prmt5 and Prmt4 can work 
synergistically to modify histones at the same myogenic loci remains to be determined.  
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Materials and Methods 
Cell Culture 
 Cells were maintained in DMEM supplemented with 10% calf serum and 2mM L-
glutamine.  Prmt5 antisense lines were maintained in the presence of 2.5ug/mL 
puromycin, since the antisense vector encodes a puromycin resistance gene (164).  Cells 
were differentiated as described (53, 56) except that the pBABE-MyoD retroviral 
construct was modified to contain a blasticidin resistance gene instead of one for 
puromycin.  Briefly, cycling cells were split so that they would be 75% confluent 24 
hours later.  At that time, retroviral infection with the MyoD encoding retrovirus was 
performed for 30 hours.  Subsequently, differentiation media (DMEM + 2% horse serum, 
2mM L-glutamine, 5ug/mL blasticidin, and 2ug/mL puromycin, and 10ug/mL insulin) 
was added to the cells and samples were collected at the indicated times.  Control 
samples from both 3T3s and antisense lines were mock-infected and subjected to the 
differentiation protocol and are designated “mock-differentiated.”   
B22 cells expressing a flag-tagged, dominant negative version of the SWI/SNF 
ATPase subunit BRG1 in the absence of tetracycline were described previously (52).  
Cycling cells were grown in the presence or absence of tetracycline for 3 days, were split 
to be 50-60% confluent 24 hours later, then were subjected to the differentiation protocol 
described above.     
 RNA was isolated from mock or MyoD-differentiated samples using Trizol 
(Invitrogen) and reverse transcribed as previously described (54).  The cDNA was 
mRNA analysis 
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amplified using the Qiagen HotStarTaq Master Mix kit (Qiagen) containing 0.1ug of 
specific primers and SYBR green.  RT-PCR and real time PCR were performed using 
procedures and primers previously described (222) (41, 157).  The dystrophin primer set 
was: 5’-AAG TTT GGA AAG CAA CAC ATA-3’ and 5’- GTT CAG GGC ATG AAC 
TCT TG -3’.  Prmt5 primers were 5’-GAT GGC GGC GAT GGC A-3’ and 5’-CTG TGT 
GTG TAG TCG G-3’.  All data sets are the average +/- standard deviation of 3 or more 
independent experiments. 
FACS 
 Cells were differentiated or mock-differentiated as stated above and fixed as 
previously described (116).  Propidium iodide incorporation was measured by flow 
cytometry to determine the percentage of cells in each phase of the cell cycle. 
Protein extracts, Western analysis, and antibodies 
 Whole cell extracts were generated as described (56, 60).  For Western analysis, 
100 ug of each extract were used for SDS-PAGE followed by transfer to nitrocellulose.  
Co-IP procedures were previously described (54, 157).  Antibodies used for ChIP 
included polyclonal rabbit antisera against Prmt5 and dimethylated H3R8 (164, 165), 
Brg1 (52), FLAG epitope, and MyoD (54).  Western analysis also made use of 
commercial antibodies against Prmt5/JBP1/Skb1Hs (#611538 - BD Biosciences) and 
MyoD (#554130 and #554099 - BD Biosciences).  
ChIPs were performed by modifying the Upstate protocol as described (194).  
Cultured cells or nuclei isolated from tissues (see below) were cross-linked in 1% 
Chromatin immunoprecipitation (ChIP) 
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formaldehyde and lysed in buffer containing 1% SDS, 10mM EDTA, 50mM Tris-Hcl, 
pH 8.1.  Samples were incubated on ice and the DNA was sheared by sonication to obtain 
an average length of 500 bp.  100ug of sonicated DNA was diluted 10-fold in IP buffer 
(0.01% SDS, 1.1% triton-X100, 1.2 mM EDTA, 16.7 mM Tris pH 8.1, 167 mM NaCl) 
containing protease  inhibitors (1 mM PMSF, 1 ug/ml aprotinin, 1 ug/ml pepstatin A) and 
precleared with a 50% slurry of protein A beads (Amersham) at 4°C for at least 1 hour.  
Cleared lysates were incubated with antibodies described above at 4°C for 4 hours or 
overnight.  Protein A beads were added to precipitate immune complexes from the cell 
lysates and incubated for 1 hour at 4°C.  Beads were collected by centrifugation then 
washed as described (194), and immune complexes were eluted from the beads using 1% 
SDS.  Crosslinks were reversed and DNA was purified by Qiaquick PCR purification kit 
(Qiagen).  Analysis of immunoprecipitated DNA was performed by PCR amplification 
(54) or by Q-PCR using a Quantitect SYBR Green PCR kit.  Primers were described (54, 
157).  Re-ChIP experiments were performed as described (146, 157).  Q-PCR data are the 
average +/- standard deviation of 3 independent experiments. 
Restriction Enzyme Accessibility Assay (REAA)  
 REAA and detection by a modified version of ligation-mediated PCR were 
described previously (54, 157).  Data are the average +/- standard deviation of 3 
independent experiments. 
 Skeletal muscle was dissected from the upper hindlimbs of 4-5 week old BL6 
mice and minced to approximately 1mm
Isolation of satellite cells and myofibers from mouse skeletal muscle 
3.  Tissues were then digested using 87.5 U/ml 
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collagenase type II (Invitrogen) in PBS supplemented with 1mM CaCl2 and incubated at 
37°C for 1 hour with agitation (7, 43).  Satellite cells were separated from mature 
myofibers by filtration with a cell strainer 70um (Becton Dickinson # 352350) (159).  
Flow through material was enriched for satellite cells while material that did not pass 
through the filter was enriched for myofibers.  Aliquots were taken for isolation of RNA 
as described above.  Satellite and myofiber preparations were kept on ice throughout the 
process.  The separated fractions were separately pelleted by centrifugation and 
resuspended in 7 volumes of lysis buffer (10mM HEPES-KOH (pH7.3), 10mM KCl, 
5mM MgCl2, 0.5mM DTT, 0.2mM PMSF, 3ug/mL cytochalasin B, 10ug/mL leupeptin).  
Samples were homogenized and dounced using pestle A to release nuclei, then samples 
were incubated on ice for 30 minutes.  Nuclei release and integrity was checked under a 
light microscope with Hoechst 33258 dye, and the samples were then centrifuged to 
remove cell debris.  Nuclei were resuspended in 2.5 volumes of 10 STM buffer (5mM 
MgCl2, 10mM triethanolamine pH 7.5, 5mM MgCl2, 10% Sucrose, 10ug/mL leupeptin) 
and subsequently 2 volumes of 2.0M Sucrose/10mM Tris-HCl/5mM MgCl2.  In an 
ultracentrifuge tube (Beckman #344057), 750uL of the 1.8M Sucrose/10mM Tris 
HCl/5mM MgCl2 was aliquoted and overlayed with the nuclei mixture described above.  
Samples were ultracentrifuged at 50,000 x g for 1 hour.  The supernatant was aspirated 
and discarded, and the pellet was resuspended in 500uL of lysis buffer + 0.1% NP-40.  
Following crosslinking with 2% formaldehyde at room temperature, nuclei were 
centrifugated at 13,500 x g, pellets were frozen in liquid nitrogen, and samples were 
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stored at -80°C or immediately thawed, resuspended in lysis buffer described above, and 
sonicated. 
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We and others have previously demonstrated that SWI/SNF chromatin 
remodeling enzymes containing the Brg1 ATPase are directly required for the induction 
of myogenesis because they remodel chromatin structure at the regulatory regions of both 
CHAPTER III 
Distinct protein arginine methyltransferases promote ATP-dependent 
chromatin remodeling function at different stages of skeletal muscle 
differentiation 
 
INTRODUCTION                                                                                                                                                      
 Skeletal muscle differentiation involves cooperation between myogenic basic 
helix-loop-helix transcription factors (MyoD, Myf5, myogenin, Mrf4), ubiquitous E 
proteins, Myocyte-enhancer factor 2 proteins (MEF2s), histone modifying enzymes and 
ATP-dependent chromatin remodeling enzymes.  The involvement and requirement for 
individual chromatin modifying and remodeling enzymes during skeletal muscle 
differentiation has been intensely investigated in recent years.   However, the 
interdependence of different enzymes affecting chromatin structure during myogenesis 
has not received as much attention.   In addition, regulation of myogenic gene expression 
is further complicated by the temporal regulation that exists and separates myogenic 
genes into different classes based on when they are activated relative to the onset of 
differentiation.  Whether chromatin altering enzymes specifically and differentially 
contribute to aspects of temporal regulation is largely unexplored.  
 
 
85 
early and late myogenic genes (53, 54, 157, 207).  Numerous histone modifying enzymes 
have also been implicated in the regulation of myogenic genes, including acetyl 
transferases, deacetylases, lysine methyl transferases, and arginine methyl transferases 
(reviewed in (55, 195, 217)).  Of particular interest to us are the arginine 
methyltransferases.  Type I arginine methyltransferases generate asymmetric dimethyl 
arginines on substrate proteins, while type II arginine methyltransferases catalyze the 
formation of symmetric dimethyl arginines (reviewed in (14, 15, 233)).  Both Prmt5, a 
type II arginine methyltransferase, and Carm1/Prmt4, a type I methyltransferase, have 
been shown to act as a co-regulator for numerous gene activation and repression events 
(reviewed in (15, 163, 233) and both have been independently purified in large protein 
complexes containing Brg1 (164, 165, 237).   The connections between Prmt5 and Brg1 
led us to investigate possible cooperativity between these different types of chromatin 
altering enzymes in cell differentiation systems shown to be Brg1 dependent. 
Our previous work demonstrated that the class II arginine methyltransferase, 
Prmt5 was required for myogenesis (46).  Prmt5 associated with the myogenin promoter 
and locally di-methylated H3R8.  Knockdown of Prmt5 protein levels resulted in a 
reduction of di-methylation of H3R8 at the myogenin promoter and importantly, a nearly 
total loss of Brg1 binding, which prevented chromatin remodeling of the promoter.  All 
subsequent transcription factor binding events and the initiation of myogenin expression 
were inhibited.   Thus the arginine methyltransferase was required for the function of the 
ATP-dependent chromatin remodeling enzyme. 
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To further probe the relationships between different classes of chromatin altering 
enzymes and to explore potential differences between the regulation of myogenin, a 
myogenic early gene, and genes expressed later in the differentiation process, we 
investigated the requirement for Prmt5 in the expression of myogenic late genes and also 
examined the involvement of Carm1/Prmt4, which had previously been linked to 
myogenesis via regulation of myogenin expression (35).  Our data demonstrate that both 
Prmt5 and Carm1/Prmt4 are associated with regulatory elements of representative late 
myogenic genes in vivo and in culture.  We also found a concomitant enrichment in di-
methylation of H3R8 and H3R17, substrates for Prmt5 and Carm1/Prmt4, respectively, at 
these loci.  Despite the presence of Prmt5 at late gene promoters, it is dispensable for 
transcriptional activation of late myogenic genes.  In contrast, Carm1/Prmt4 was 
absolutely required for activation of late myogenic targets.  In the absence of 
Carm1/Prmt4, Brg1 association with these promoter elements was lost, as were changes 
in nuclease accessibility that are concurrent with gene activation. These data support the 
assertion that a preferential requirement exists for Carm1/Prmt4 during the later stages of 
myogenic differentiation while Prmt5 governs the activation of early myogenic targets.  
The results indicate a differential requirement for two distinct protein arginine 
methyltransferases during the different stages of myogenic differentiation to facilitate 
loading and function of an ATP-dependent chromatin remodeling enzyme. This 
relationship between the different classes of enzymes may represent a paradigm for 
cooperation between PRMTs and ATP-dependent remodeling enzymes.  
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RESULTS 
 If specific arginine methyltransferases are functioning at myogenic late genes, the 
enzymes and histones modified by these enzymes should be localized at regulatory 
sequences controlling late gene expression.  To address physiological relevance, we first 
performed ChIPs using primary skeletal muscle tissue.  We isolated hind limb muscle 
from 4-6 week old BL6 mice and prepared mature myofibers for ChIP analysis, as we 
described previously (46, 158).  Liver was isolated as a negative control.  ChIP results 
were quantified by real-time PCR.  The data demonstrated that Prmt5 was bound to the 
regulatory regions of the muscle creatine kinase (MCK) locus in mature myofibers while 
no significant association was observed in the control liver tissue (Fig. 1A).  This 
induction of Prmt5 binding was accompanied by enrichment in the amount of di-
methylated H3R8 at the MCK locus in myofibers, thereby correlating the presence of 
Binding of Prmt5 and Carm1 to regulatory regions of late myogenic genes 
 Our previous studies showed that the protein arginine methyltransferase Prmt5 is 
required to facilitate the activation of myogenin, an essential gene that is induced during 
the early stages of skeletal muscle differentiation (46).  In that study, we also showed that 
genes expressed later during differentiation were not activated when levels of Prmt5 were 
reduced.  However, it was unclear if the lack of late gene expression was a direct 
consequence of Prmt5 reduction or was an indirect consequence resulting from the failure 
to induce myogenin, which is required for late gene activity and terminal differentiation 
(92, 152). 
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both Prmt5 and a histone modification known to result from Prmt5 activity (46, 69, 163, 
164).   
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Figure 3-1. 
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Figure 3-1.  Prmt5 and Carm1 both bind to the MCK regulatory sequences in vivo.  
Skeletal muscle was dissected from the hindlimb of 4-6 week old BL6 mice.  Nuclei were 
isolated from muscle tissue and liver.  ChIPs were performed using antibodies 
recognizing Prmt5, dimethylated (diMe) H3R8, Carm1, and dimethylated (diMe) H3R17.  
Specific binding of Prmt5 and Carm1/Prmt4 was seen at gene regulatory regions of 
muscle creatine kinase (MCK) in myofibers but not in liver.  Corresponding increases in 
dimethylated H3R8 and H3R17 were also observed specifically in myofibers.  Values for 
binding in liver samples were set at 1.  ChIPs with purified IgG generated background 
signals equivalent to the signals obtained with specific antibodies in liver samples.  Data 
represent the average +/- standard deviation of 4 independent experiments. 
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Previously, the Carm1/Prmt4 enzyme was shown to localize to the MCK locus in 
differentiating C2C12 myoblasts, though the functional significance of this event was not 
addressed (35).  Similarly, a considerable increase in the amount of Carm1/Prmt4 binding 
was seen at the MCK locus in myofibers, which correlated with an induction of 
dimethylated H3R17, a known epigenetic mark resulting from Carm1/Prmt4 activity 
(199).  These results are the first demonstration that distinct protein arginine 
methyltransferases and histone modifications caused by these enzymes are present at 
regulatory regions of a late myogenic gene in terminally differentiated, primary muscle 
tissue.    
We next turned to a well-established, manipulatable cell culture system for 
myogenic differentiation (50) to determine whether the association of arginine 
methyltransferases and specifically modified histones at late myogenic gene promoters 
was recapitulated.  Confluent, MyoD-expressing fibroblast cells were exposed to a low 
serum differentiation cocktail for varying times, and samples were evaluated by ChIP.  
Both Prmt5 and di-methylated H3R8 were already bound to regulatory regions of both 
the MCK gene and the desmin gene, which is expressed as a late gene in this and similar 
tissue culture systems (18, 157) at time 0, which is when the differentiation media was 
added to the cultures (Fig. 2A).  The presence of Prmt5 and dimethylated H3R8 were 
entirely dependent upon MyoD expression, since these proteins were absent from the loci 
in mock-differentiated cells (Fig. 2A).  In contrast, Carm1/Prmt4 and dimethylated 
H3R17 did not show significant binding at late gene loci until 8 hours post-differentiation 
(Fig. 2B), which in this culture system corresponds to the time when desmin and MCK 
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gene expression is induced (157).  As observed with Prmt5 and dimethylated H3R8, 
binding of Carm1 and dimethylated H3R17 did not occur in mock-differentiated cells and 
required MyoD expression.  Once bound, both arginine methyltransferases and modified 
histones remained present throughout the differentiation time course (Figs. 2A-B).  Thus 
Prmt5 and dimethylated H3R8 binding preceded early and late gene expression while 
Carm1/Prmt4 and dimethylated H3R17 binding correlated with the onset of late gene 
expression. 
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Figure 3-2. 
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Figure 3-2.  Prmt5 and Carm1 bind to and methylate histones at the regulatory regions of 
late myogenic target genes in cell culture.  A time course of MyoD-differentiated NIH 
3T3 cells were harvested for ChIP analysis, using antibodies recognizing Prmt5, 
dimethylated (diMe) H3R8, Carm1, and dimethylated (diMe) H3R17 to analyze the 
temporal binding of these PRMTs and the deposition of their corresponding histone 
modifications at late skeletal muscle target genes.  (A)  Kinetics of binding of Prmt5 and 
diMeH3R8 at the regulatory sequences controlling MCK and desmin in mock and MyoD 
–differentiated cells.  (B)  Kinetics of binding of Carm1 and diMeH3R17 at the 
regulatory sequences controlling MCK and desmin in mock and MyoD –differentiated 
cells.  All values are expressed relative to the values obtained for binding in mock-
differentiated NIH3T3 cells, which were set at 1.  Data represent the average +/- standard 
deviation of 4 independent experiments. 
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Prmt5 associates with promoter elements of late myogenic targets but is not required 
for gene activation 
To address the requirement for Prmt5 in the induction of myogenic late genes, we 
utilized cell lines (c12 and c15) that stably express an antisense construct to Prmt5 (164).  
Fig. 3A demonstrates that Prmt5 levels are significantly reduced under both mock and 
MyoD-induced differentiation conditions, in agreement with previous results (46).  We 
previously demonstrated that ectopic expression of myogenin and the muscle specific 
isoform of Mef2d (Mef2D1b) (137) in combination was sufficient to activate myogenic 
late genes and to drive myogenesis to completion in culture without inducing endogenous 
MyoD expression (157).  Thus, we can utilize ectopic expression of myogenin and 
Mef2D1b to address whether Prmt5 and Carm1/Prmt4 are directly required for late gene 
expression because this method (a) bypasses the requirement for MyoD to synthesize 
myogenin and (b) provides the muscle specific Mef2D1b isoform to cooperate with 
myogenin in the activation of late gene loci.  We would expect that if either arginine 
methyltransferase were indirectly required for late gene expression because of a 
requirement to synthesize early genes, lack of the arginine methyltransferase should not 
impact late gene expression when myogenin and Mef2D1b were ectopically expressed.  
In contrast, if there were a direct requirement for either arginine methyltransferase during 
late gene induction, simply providing myogenin and Mef2D1b should not be sufficient to 
induce late gene expression.  Before experimentally addressing these issues, we 
confirmed that the cell lines were still deficient for Prmt5 when differentiation was 
induced by myogenin and Mef2D1b (Fig. 3A). 
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We first examined whether Prmt5 and dimethylated H3R8 were present on late 
gene regulatory sequences in wildtype and Prmt5 antisense cell lines differentiated under 
the different conditions described.  Induced binding of Prmt5 at the MCK and desmin 
promoters was observed in MyoD-differentiated NIH3T3 cells (Fig. 3B).  As expected, 
Prmt5 antisense-expressing cell lines showed reduced levels of Prmt5 binding (Fig. 3B).  
Similarly, dimethylation of histone H3R8 was observed at the MCK and desmin 
promoters in the wildtype, MyoD differentiated cells and was significantly reduced in the 
MyoD differentiated, Prmt5 antisense-expressing lines (Fig. 3C).  Prmt5 and 
dimethylated H3R8 association with late myogenic gene sequences was specific to MyoD 
differentiated cells as no significant binding was seen in mock-differentiated samples or, 
interestingly, in myogenin/Mef2D1b differentiated cells (Fig. 3B-C).  These results 
support the assertion that Prmt5 is able to bind late gene promoter regions only in the 
presence of MyoD, which binds to these loci prior to gene activation (157) and is 
consistent with previous studies showing that Prmt5 and MyoD could be co-
immunoprecipitated from MyoD differentiated cell extracts (46).   
Analysis of gene expression in these cells was quantified by real-time PCR.  
Controls are presented in the first column of Fig. 3D.  MyoD was equivalently expressed 
in each of the cell lines where it was introduced; as previously reported, no MyoD was 
detected in mock or myogenin/Mef2D1b differentiated samples (55, 157).  Myogenin 
was equivalently expressed in lines that were myogenin/Mef2D1b differentiated.  We 
note that the levels of introduced myogenin were within 2-fold of the level normally 
induced by MyoD, thus introduced myogenin was not grossly overexpressed.  As 
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previously reported (46), in MyoD-differentiated cells, myogenin expression was 
compromised in both of the Prmt5 antisense lines.  Equivalent levels of Mef2D1b were 
present in the myogenin/Mef2D1b differentiated cells (Fig. 3D).  
We then examined late gene expression.  In wildtype MyoD differentiated cells, 
induction of MCK, desmin, and dystrophin, another late gene, was observed, while 
MyoD differentiated Prmt5 antisense-expressing cells failed to activate these late 
myogenic targets (Fig. 3D, right).  In cells differentiated with myogenin/Mef2D1b, all of 
the cell lines were able to induce each of the late genes equivalently (Fig. 3D, right).  
These results, coupled with the ChIP data in Fig. 3B-C, indicate that Prmt5 and 
dimethylation of H3R8 are not directly required for the activation of myogenic late genes.  
Instead, Prmt5 is required for the activation of myogenin (46) and Fig. 3D) and thus is 
indirectly required for late gene expression. 
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Figure 3-3.  Prmt5 binds to late myogenic target genes but is not required for gene 
activation. (A)  Western blot demonstrating the extent of Prmt5 expression in wildtype 
(3T3) and Prmt5 antisense  (c12, c15) cell lines that were mock differentiated or 
differentiated with MyoD or with myogenin + Mef2D1b (Myog/Mef2D1b) for 24 hours.  
Phosphoinositide 3-kinase (PI3K) levels are shown as a control.  (B, C)  ChIP 
experiments were performed using antibodies recognizing Prmt5 and diMeH3R8 and 
were analyzed by quantitative PCR (Q-PCR).  Values are expressed relative to the values 
obtained for binding in MyoD differentiated NIH3T3 cells, which were set at 1.  (D)  
mRNA expression analysis for the indicated genes was performed by reverse 
transcriptase PCR (RT-PCR) and quantified by Q-PCR.  Quantification of transcripts was 
normalized to total amount of EF1-α mRNA.  Values are expressed relative to the 
expression values obtained in MyoD differentiated NIH3T3 cells, which were set at 1, 
except for the evaluation for Mef2D1b expression, where the value obtained for 
myogenin/Mef2D1b differentiated cells was set at 1.  Data in panels B-D are the average 
+/- standard deviation of 4 independent experiments. 
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Carm1/Prmt4 associates with gene regulatory sequences of late myogenic targets and is 
required for transcriptional activation at these loci 
 Since Prmt5 is not directly required for the activation of late myogenic targets, 
this prompted us to examine if Carm1/Prmt4, the other arginine methyltransferase 
physically present on myogenic late gene regulatory sequences, could be co-activating 
late myogenic genes.  To address the requirement for Carm1/Prmt4 in late gene 
expression, we utilized immortalized MEFs derived from wildtype or Carm1/Prmt4 
deficient mice (240).  As expected, the cells were deficient for Carm1/Prmt4 under mock, 
MyoD-induced, and myogenin/Mef2D1b-induced differentiation conditions (Fig. 4A). 
 ChIP experiments were performed in mock, MyoD, or myogenin/Mef2D1b 
differentiated wild type (WT) and Carm1/Prmt4 knockout (KO) immortalized mouse 
embryo fibroblasts.  Carm1/Prmt4 binding to the MCK and desmin promoters was 
observed in MyoD-differentiatated as well as in myogenin/Mef2D differentiated WT 
MEFs (Fig. 4B).  A concomitant enrichment in the amount of dimethylated H3R17 was 
observed at both promoters (Fig. 4C).   As expected, no detectable Carm1/Prmt4 binding 
or enrichment in di-methylated H3R17 was observed in the mock differentiated cells 
(Figs. 4B-C).  In the KO MEFs, neither Carm1/Prmt4 nor dimethylated H3R17 was 
present, demonstrating that dimethylation of H3R17 at these loci is due to Carm1/Prmt4 
(Figs. 4B-C).  These findings demonstrate that Carm1/Prmt4 is able to directly bind late 
muscle promoter regions regardless of how gene activation is achieved; expression of 
either MyoD or myogenin/Mef2D1b is sufficient to promote binding and histone 
modification.   
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 The binding of Carm1/Prmt4 to late gene regulatory sequences at 8 hours post-
differentiation (Fig. 2) corresponds to the timing of binding of myogenin and Mef2 at 
these promoters, as well as the interaction of the Brg1 ATPase of SWI/SNF chromatin 
remodeling enzymes and concomitant increases in nuclease accessibility (157).  The 
simultaneous occurrence of these events suggests that Carm1/Prmt4 serves as a 
coactivator of myogenin and Mef2D1b.  We therefore performed re-ChIP analysis to 
determine whether myogenin and Carm1/Prmt4 were present together at late gene 
regulatory sequences.   We immunoprecipitated Carm1/Prmt4 from cross-linked 
chromatin isolated from MyoD-expressing cells prior to or after differentiation was 
induced and subsequently immunoprecipitated the Carm1/Prmt4 associated chromatin 
with antibodies against either myogenin or MyoD.  The results demonstrate that 
Carm1/Prmt4 and myogenin were co-localized on both MCK and desmin regulatory 
sequences in differentiated, but not undifferentiated cells (Fig. 4D).  No co-localization of 
Carm1/Prmt4 with MyoD was observed (Fig. 4D), in agreement with previous 
observations that MyoD binding to late gene regulatory sequences diminishes at the onset 
of late gene expression (157).  The data support the idea that Carm1/Prmt4 is 
simultaneously present with myogenin at myogenic late gene loci. 
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Figure 3-4. 
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Figure 3-4.  Carm1/Prmt4 and dimethylated H3R17 bind to late myogenic gene 
regulatory regions.  (A)  Western blot showing Carm1/Prmt4 protein levels in 
immortalized wildtype (WT) or Carm1/Prmt4 knockout (KO) mouse embryo fibroblasts 
(MEFs) that were mock differentiated or differentiated with MyoD or with myogenin + 
Mef2D1b (Myog/Mef2D1b) for 24 hours.  Phosphoinositide 3-kinase (PI3K) levels are 
shown as a control.  (B, C)  ChIP experiments were performed using antibodies 
recognizing Carm1/Prmt4 and diMeH3R17 and were analyzed by quantitative PCR (Q-
PCR).  Values are expressed relative to the values obtained for binding in mock-
differentiated WT MEFs, which were set at 1.   (D)  Re-ChIP experiments were 
performed and quantified by Q-PCR.  Material immunoprecipitated with Carm1/Prmt4 
antibodies were subsequently immunoprecipitated with either a MyoD or a myogenin 
antibody.  Data in panels B-C represent the average +/- standard deviation of 5 
independent experiments, while the data in panel D is the average +/- standard deviation 
of 4 independent experiments.  
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Gene expression analysis was then performed by real-time PCR to assess the 
functional significance of Carm1/Prmt4 binding.  MyoD was induced and equivalently 
expressed in MyoD-differentiated WT and KO MEFs but was not detectable in mock or 
myogenin/Mef2D1b-differentiated samples (Fig. 5 - left column).  Myogenin and 
Mef2D1b were equivalently expressed in myogenin/Mef2D1b-differentiated samples, 
and the levels of introduced myogenin were roughly equivalent to the levels normally 
induced by MyoD (Fig. 5 - left column).  Interestingly, in MyoD-differentiated samples, 
myogenin expression was robust and was not compromised in KO MEFs (Fig. 5 - left 
column), indicating that Carm1 was not required for the activation of the myogenin gene.  
 When late gene activation was examined, MCK, desmin, and dystrophin gene 
expression was induced in MyoD and myogenin/Mef2D1b-differentiated WT MEFs, but 
not in mock-differentiated WT MEFs (Fig. 5 - right column).  In contrast, induction of 
late myogenic genes was severely compromised in KO MEFs, regardless of whether the 
cells were differentiated with MyoD or with myogenin/Mef2D1b (Fig. 5 - right column).  
The lack of late gene expression in myogenin/Mef2D1b differentiated cells means that 
there is a direct requirement for Carm1/Prmt4 during late gene induction, because even 
when the myogenin and Mef2D1b regulators were provided to the cell, the lack of 
Carm1/Prmt4 prevented late gene expression.  In combination with the analysis of 
myogenin expression in MyoD differentiated cells (Fig. 4D - left column), the data 
indicate that Carm1/Prmt4 is required for late gene expression but not for expression of 
the early myogenin gene. 
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Figure 3-5. 
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Figure 3-5.  Carm1/Prmt4 is required for myogenic late gene expression   mRNA 
expression analysis of the indicated genes by Q-PCR in immortalized wildtype (WT) or 
Carm1/Prmt4 knockout (KO) mouse embryo fibroblasts (MEFs) that were mock 
differentiated or differentiated with MyoD or with myogenin + Mef2D1b 
(Myog/Mef2D1b) for 24 hours.  Transcript levels were normalized to the total amount of 
EF1-α mRNA.  Values are expressed relative to the expression values obtained in MyoD 
differentiated WT MEFs, which were set at 1, except for the evaluation for Mef2D1b 
expression, where the value obtained for myogenin/Mef2D1b differentiated WT cells was 
set at 1.  Data show the average +/- standard deviation of 5 independent experiments. 
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Carm1/Prmt4 binding to myogenic late gene regulatory sequences is independent of 
Prmt5 
The data indicate that Carm1/Prmt4 is required for the induction of late myogenic gene 
expression whereas Prmt5 is not.  This suggests that Carm1/Prmt4 binding should be 
independent of Prmt5 function.  To address this question we examined Carm1/Prmt4 
binding in the Prmt5 deficient cell lines using ChIP.  The data in Fig. 6A demonstrate that 
Carm1/Prmt4 bound equivalently well in the presence and absence of Prmt5, whether 
differentiation was induced by MyoD or by myogenin/Mef2D1b.  Although Prmt5 
binding to late myogenic regulatory sequences precedes Carm1/Prmt4 binding, we also 
performed the converse experiment to determine whether Prmt5 binding required 
Carm1/Prmt4.  Such an experiment would exclude the possibility that Prmt5 binding was 
dependent upon a Carm1/Prmt4 function that did not involve its ability to bind to 
myogenic late gene sequences.  Examination of Prmt5 binding in MyoD differentiated 
WT and Carm1/Prmt4 null MEF lines showed that Prmt5 binding did not require 
Carm1/Prmt4 (Fig. 6B).  Consistent with the data presented in Fig. 3B, Prmt5 did not 
bind to myogenic late gene regulatory sequences when differentiation was induced by 
myogenin/Mef2D1b due to the absence of MyoD (Fig. 6B).  Thus the binding of each of 
the two distinct Prmts to myogenic late gene loci is independent of the other. 
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Figure 3-6. 
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Figure 3-6.  Binding of Carm1/Prmt4 at the regulatory regions of late myogenic targets is 
not dependent on Prmt5, while binding of Prmt5 to these sequences does not require 
Carm1/Prmt4.   (A)  NIH3T3 cells or c12 and c15 cells that express antisense against 
Prmt5 were mock differentiated or differentiated with MyoD or with myogenin + 
Mef2D1b (Myog/D1b) for 24 hours and were used for ChIP analysis using an antibody 
recognizing Carm1.  (B)  Immortalized MEFs derived from Carm1 wild-type (WT) or 
knockout (KO) mice were mock differentiated or differentiated with MyoD or with 
myogenin + Mef2D1b (Myog/D1b) for 24 hours and used for ChIP analysis using an 
antibody recognizing Prmt5.  Values are expressed relative to the values obtained for 
binding in mock-differentiated cells, which were set at 1.  Data in panels A and B 
represent the average +/- standard deviation of 3 independent experiments.  
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In vitro interactions between myogenic regulatory factors and Prmt5 and Carm1/Prmt4 
We utilized GST fusions with Prmt5 and with Carm1/Prmt4 to investigate whether each 
Prmt was capable of directly interacting with the myogenic regulators implicated in 
controlling early and late myogenic gene expression.  GST-Prmt5, GST-Carm1/Prmt4, 
and GST were expressed in and purified from bacteria (Fig. 7C) and incubated with 35
In contrast, GST-Prmt5 interacted with IVT MyoD, myogenin, and Mef2D1b (Fig. 
7B).  The interaction between Prmt5 and MyoD is consistent with physical and functional 
data that demonstrated a requirement for Prmt5 in MyoD-mediated activation of the 
myogenin gene during myogenesis (46).  It is also consistent with the observation that 
Prmt5 is present on myogenic late gene regulatory sequences at early times of 
differentiation prior to the expression of the late genes (Fig. 2A), a time when MyoD and 
HDAC2 are also present (157).  Although interactions between Prmt5 and myogenin and 
S-
labeled, in vitro translated (IVT) MyoD, myogenin, or Mef2D1b.  GST alone did not 
interact with any of the tested myogenic regulators (Fig. 7A-B).  GST-Carm1/Prmt4 
could interact with both IVT myogenin and with IVT Mef2D1b but only weakly 
interacted with IVT MyoD (Fig. 7A).  These results are consistent with the re-ChIP data 
presented in Fig. 4D indicating that Carm1/Prmt4 and myogenin co-occupy myogenic 
late gene regulatory sequences and with the functional data presented in Fig. 5 showing 
that Carm1/Prmt4 was required for myogenin and Mef2D1b to activate myogenic late 
gene expression.  The weak interaction with IVT MyoD is consistent with the observation 
that Carm1/Prmt4 was not required for activation of the myogenin gene at early times 
(Fig. 5), which is a MyoD dependent event. 
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Mef2D1b were observed in vitro, differentiation mediated by myogenin/Mef2D 
expression did not involve recruitment of Prmt5 to the late gene loci (Fig. 3B).  This 
suggests that one or more of the proteins may be modified in vivo, or that the interactions 
that were revealed in vitro are occluded in the context of the factor binding at myogenic 
regulatory sequences in differentiating cells. 
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Figure 3-7. 
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Figure 3-7.  In vitro interactions exist between Prmt5 and Carm1/Prmt4 and muscle 
regulatory factors.  GST, GST-Prmt5 and GST-Carm1/Prmt4 were expressed and purified 
from BL21 cells by binding to glutathione beads.  (A)  Bead-bound GST and GST-Prmt5 
were incubated with in vitro translated, full-length, 35S-radiolabelled MyoD, myogenin, 
or Mef2D1b to determine if interactions exist between these factors.   Following 
extensive washing, pelleted beads and any bound proteins were electrophoresed on an 
SDS-polyacrylamide gel, and the gels was dried and exposed to film.  (B)  The 
experiment in (A) was repeated with GST and GST-Carm1/Prmt4. 
(C) Purified GST and GST fusion proteins were resolved on SDS-PAGE and visualized 
by Coomassie staining.   
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Our earlier work established that transcriptional activation of late myogenic genes 
requires the SWI/SNF chromatin remodeling enzymes, and, in particular, the activity of 
the Brg1 ATPase subunit (157).  The ChIP assays presented above revealed that 
Carm1/Prmt4 binds to the regulatory elements of late myogenic genes and is responsible 
for di-methylating H3R17, while gene expression analysis indicated that Carm1/Prmt4 
was required for late gene expression.  To probe the mechanism of the requirement for 
Carm1/Prmt4, we determined whether the loss of Carm1/Prmt4 affected Brg1 binding 
and function at late muscle genes.  In both MyoD and myogenin/Mef2D1b differentiated 
Carm1/Prmt4 KO cells, we observed that the binding of Brg1 at the regulatory sequences 
of late myogenic targets was severely diminished (Fig. 8A).  This reduction in Brg1 
binding was not due to a reduction in the levels of Brg1 protein as shown by Western blot 
(Fig. 8B).  Thus Carm1/Prmt4 is responsible for facilitating Brg1 binding.  The 
association of an ATP-dependent chromatin remodeling enzyme with a regulatory 
sequence implies a localized chromatin structural change.  To document any structural 
changes in chromatin at these loci in Carm1/Prmt4 WT and KO MEFs, a restriction 
enzyme accessibility assay (REAA) was performed.  Upon initiation of differentiation 
with MyoD or myogenin/Mef2D1b, but not in mock-differentiated cells, there was an 
induction of restriction enzyme accessibility at Pvu II sites present in the MCK and 
Carm1/Prmt4 binding at myogenic late gene regulatory sequences permits binding of 
the Brg1 ATPase of SWI/SNF chromatin remodeling enzymes and subsequent 
chromatin remodeling 
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desmin promoter regulatory regions in the WT MEFs (Fig. 8C).  We previously 
demonstrated that these changes in chromatin accessibility were Brg1 dependent (157). 
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Figure 3-8. 
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Figure 3-8.  Carm1/Prmt4 is required to facilitate the binding and function of the 
chromatin remodeling enzyme Brg1.  Immortalized MEFs derived from Carm1 wild-type 
(WT) and knockout (KO) mice were mock differentiated or differentiated with MyoD or 
with myogenin + Mef2D1b (Myog/Mef2D1b) for 24 hours and were used for (A) ChIP 
analysis using an antibody recognizing Brg1,  (B)  Western blot analysis to examine Brg1 
and PI3K protein levels in each sample, or (C) restriction enzyme accessibility assay 
(REAA) to assess the extent of chromatin accessibility at Pvu II restriction sites in the 
indicated gene regulatory regions.  Values presented in panels (A) and (C) are expressed 
relative to the values obtained for binding or accessibility in mock-differentiated WT 
MEFs, which were set at 1.   Data in panels A and C represent the average +/- standard 
deviation of 5 independent experiments. 
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However, in Carm1/Prmt4 KO MEFs, no increase in accessibility was observed 
(Fig. 8B), and the promoter chromatin structure at these loci remained in a more 
inaccessible state.  These results demonstrate that the Carm1/Prmt4 methyltransferase is 
required for myogenic late gene expression because it facilitates binding of the Brg1 
ATP-dependent chromatin remodeling enzyme and subsequent chromatin remodeling at 
these regulatory sequences.  Therefore the histone modifying enzyme is required for the 
activity of the ATP-dependent chromatin remodeling enzyme.  In conjunction with our 
earlier study, the results indicate a common molecular explanation for why different 
arginine methyltransferases are required for transcriptional activation at different stages 
of the skeletal muscle differentiation process .  
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DISCUSSION 
Our results contradict a conclusion of an earlier study where antisense constructs 
were used to reduce the levels of Carm1/Prmt4 (35).  These investigators observed that 
reduction of Carm1/Prmt4 inhibited differentiation but attributed the effect to a decrease 
Shared function by different Prmts at different stages of myogenesis 
Since both Prmt5 and Carm1/Prmt4 had been implicated in myogenesis (35, 46), 
we sought to determine whether these different arginine methyltransferases might 
cooperate in the activation of specific myogenic loci.  Although we demonstrated that 
both enzymes were physically located at regulatory sequences controlling the expression 
of myogenic late genes and that both enzymes modified histones at these loci, we also 
demonstrated that only Carm1/Prmt4 was necessary for late gene activation.  Thus while 
the contribution made by Prmt5 at myogenic late gene loci remains to be defined, it is 
clearly not a direct requirement for late gene expression. 
We also noted that the absence of Carm1/Prmt4 had no impact on the ability of 
MyoD to induce the expression of myogenin (Fig. 5), which contrasts the previous results 
obtained studying differentiation under conditions where Prmt5 levels were reduced (46).  
Thus, even though late gene expression was dependent upon Carm1/Prmt4, expression of 
the early gene, myogenin, was not.  Instead of cooperativity at specific loci, what we 
observed was a sequential requirement for Prmt5 and Carm1/Prmt4 that correlated with 
the temporal class of gene being activated.  To be specific, Prmt5 was required to 
facilitate activation of the early gene myogenin, whereas Carm1 was required for late 
myogenic gene induction.   
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in the induction of myogenin.  The reasons for the discrepancy between this report and 
our data are undetermined; our results clearly show that myogenin is robustly induced in 
the absence of Carm1/Prmt4 (Fig. 5). 
Having defined a series of protein:DNA interactions that occur at late gene 
regulatory sequences (157), we sought to determine which of these events might be 
compromised by the absence of Carm1/Prmt4 as a means to explain the lack of late gene 
expression observed in the absence of Carm1/Prmt4.  The results showed that interaction 
of Brg1, the ATPase of SWI/SNF chromatin remodeling enzymes previously 
demonstrated to be required for myogenesis, was compromised at late gene regulatory 
sequences (Fig. 6A).   The functional consequence of this loss was then demonstrated by 
the lack of chromatin remodeling at these loci (Fig. 6C).  We therefore conclude that 
Carm1/Prmt4 is required to promote Brg1 binding and chromatin remodeling at late 
myogenic genes.   
On a more general scale, the results indicate that an arginine methyltransferase is 
required for an ATP-dependent chromatin remodeling enzyme to function.  Our prior 
demonstration that Prmt5 facilitates Brg1 and SWI/SNF enzyme function at the 
myogenin promoter during gene activation (46) is extended by the observation that 
Carm1 is required at late myogenic gene regulatory regions for the same reason, 
suggesting this may be a general mechanism.  Combined, these studies indicate that 
Prmt5 and Carm1/Prmt4, two distinct arginine methyltransferases, promote the same step 
of gene activation, which is the recruitment of the SWI/SNF ATP-dependent chromatin 
remodeling enzyme.  Prmt5 and Carm1/Prmt4 are not known to methylate the same sites 
 
 
121 
on histones; Prmt5 dimethylates H3R8 and H4R3 (163, 164), while Carm1/Prmt4 
dimethylates H3R17 and H3R26 (199), however, both enzymes are capable of modifying 
non-histone substrates as well (39, 70, 110, 117, 123, 236).  Importantly, Prmt5 and 
Carm1/Prmt4 can methylate the same non-histone substrates, including CA150, SmB, 
PABP1, U1C and SF3b4 (37), although it is still not clear whether the same arginine 
residues are methylated in these common substrates (37).  The exact mechanism by 
which Prmt5 and Carm1/Prmt4 promote Brg1 interaction at different gene regulatory 
sequences during myogenesis remains to be determined, but one attractive hypothesis is 
that the dimethylation of different histone residues makes the chromatin a better substrate 
for the ATP-dependent remodeling enzyme.   
Another question that remains unclear is why different arginine 
methyltransferases would be required at different times of myogenesis to facilitate the 
same step in the activation process.  One possible explanation is that the combination of 
activators and cofactors present at early and late myogenic gene regulatory sequences are 
different (discussed further below) and that the specific arginine methylations mediated 
by each enzyme are specific for promoting gene activation by the different sets of 
regulatory proteins in ways that remain to be defined.  An additional possibility is that the 
arginine methyltransferases modify different transcriptional regulatory proteins in 
addition to modifying histone tails.  Finally, it must be noted that despite the presence of 
Carm1/Prmt4 and dimethylated H3R17 at late gene regulatory sequences both in tissue 
culture and in vivo, Carm1/Prmt4 deficient mice, which are perinatal lethal for 
undetermined reasons, show no gross defect in skeletal muscle appearance (240).  This 
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implies that there is either a functional defect in one or more muscles that contribute to 
breathing or feeding, or that there are undefined redundant mechanisms in vivo to 
compensate for the deficiency of Carm1/Prmt4.  Given the widespread redundancies 
between MyoD, Myf5, and Mrf4 during development (reviewed in (20, 176)), additional 
redundant mechanisms to ensure skeletal muscle formation and function are possible. 
 
 We previously determined that Prmt5 functioned directly in the induction of the 
myogenin gene (46).  It is well established that MyoD is critical in the activation of the 
myogenin promoter (reviewed in (20, 76, 195, 217)); demonstration by re-ChIP analysis 
that MyoD and Prmt5 are co-localized to myogenin promoters in primary cells that are 
actively transcribing the myogenin gene supports the idea that Prmt5 acts as a co-
activator for MyoD (46).  Additional experiments indicating that MyoD and Prmt5 can be 
co-immunoprecipitated from differentiated cells further support this conclusion (46).  
Here we report that Prmt5 can directly interact with MyoD in an in vitro interaction assay, 
providing further mechanistic explanation for the cooperativity exhibited by these factors.  
In addition, we show that Prmt5 is localized to myogenic late gene regulatory sequences 
at the onset of differentiation, prior to the initiation of late gene expression.  Previous 
work indicates that MyoD is also present at late gene loci before activation (157); it is 
accompanied by a class I HDAC, which has been shown to maintain MyoD in a 
transcriptionally inactive state in myoblast cultures (134, 177).  We propose that MyoD 
Mechanisms relating to Prmt5 and Carm1/Prmt4 function  
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targets Prmt5 to gene regulatory sequences, regardless of whether it is functioning in an 
activating or repressing capacity.  
 In contrast, Carm1/Prmt4 binding to late gene loci correlates with the time of late 
gene activation.  In both developing embryonic skeletal muscle tissue and MyoD 
differentiated fibroblasts, the time of late gene activation is marked by coincident binding 
of myogenin, Mef2, and the SWI/SNF ATPase, Brg1 and changes in chromatin 
accessibility (157).  The addition of Carm1/Prmt4 to this complex of regulators that 
functions at the time of transcription initiation suggests that Carm1/Prmt4 acts as a co-
activator of myogenin and/or Mef2 proteins.  Transient transfection studies imply 
cooperativity between Carm1/Prmt4 and Mef2, and Carm1/Prmt4 interacts with the 
Mef2C isoform in in vitro interaction assays (35).  The demonstration by re-ChIP 
analysis that Carm1/Prmt4 is co-localized with myogenin, but not MyoD, at late gene 
regulatory sequences  (Fig. 4D) also supports this hypothesis.  The additional 
demonstration that Carm1/Prmt4 can directly interact with the Mef2D1b isoform and 
with the myogenin protein in vitro (Fig. 7A), but only weakly interacts (Fig. 7A) or does 
not interact (35) with MyoD in vitro suggests that targeting of Carm1/Prmt4 occurs via 
myogenin and/or Mef2 proteins. 
 Both Prmt5 and Carm1/Prmt4 were shown to co-immunoprecipitate and co-purify 
with Brg1 (165, 237) and coordinated activity between Brg1 and Prmt5 (46, 164, 165) 
and between Brg1 and Carm1/Prmt4 (237) has previously been demonstrated.  
Collectively the data presented here and in previous reports (19, 46, 54) support a model 
(Fig. 9) where MyoD initially binds indirectly to the myogenin promoter via interaction 
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with Pbx1 and also binds to sites at late myogenic gene regulatory sequences, thereby 
facilitating and recruitment of Prmt5 to both classes of genes.  The recruitment of Prmt5 
at the myogenin gene mediates dimethylation of H3R8 and is necessary for the 
subsequent recruitment of Brg1 based SWI/SNF chromatin remodeling enzymes, leading 
to chromatin remodeling and expression of the myogenin gene.  Upon accumulation of 
myogenin protein, myogenin and Mef2 proteins bind to cognate binding sites at late gene 
regulatory sequences, displacing MyoD and the HDAC, as shown previously (157) and 
recruiting Carm1/Prmt4.  Carm1/Prmt4 recruitment mediates dimethylation of H3R17 
and facilitates the recruitment of Brg1 based SWI/SNF chromatin remodeling enzymes, 
leading to chromatin remodeling and expression of the late myogenic genes, terminal 
differentiation, and the formation of mature skeletal muscle tissue. 
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Figure 3-9. 
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Figure 3-9.  A schematic model illustrating Prmt function at the myogenin and at 
representative late gene regulatory sequences.  Prmt5 mediates dimethylation of H3R8 
and facilitates Brg1 based SWI/SNF chromatin remodeling enzyme interaction and 
function at the myogenin promoter at early times of myogenic differentiation while 
Carm1/Prmt4 mediates dimethylation of H3R17 and facilitates Brg1 based SWI/SNF 
chromatin remodeling enzyme interaction and function at myogenic late genes. 
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MATERIALS AND METHODS 
 
Cell Culture 
NIH3T3 cells, Prmt5 antisense-expressing cell lines (164), and immortalized MEFs from 
wild type or knockout Carm1 embryos (240) were cultured in Dulbecco’s Modified Eagle 
Media supplemented with 10% calf serum.  Prmt5 antisense cell lines were maintained in 
2.5ug/mL puromycin.  Cells were grown to ~50% confluence then transdifferentiated into 
the skeletal muscle lineage by ectopic expression of MyoD or myogenin in combination 
with Mef2D1b, using the pBABE retroviral vector system (149, 150), as previously 
described (53, 56, 157, 190) .  The viral inoculum was applied to the subconfluent cells 
for 24 hours, during which time the cells became confluent.  Cells were then 
differentiated using DMEM supplemented with 2% horse serum + 10ug/mL insulin.  
Mock infected cells were also treated with DMEM + 2% horse serum, and all samples 
were maintained in the differentiation media for up to 24 hours.  Samples were harvested 
at indicated times for RNA, protein, and ChIP analysis. 
   
RNA Isolation and RT-PCR 
RNA was isolated using Trizol (Invitrogen) according to the manufacturer’s instructions.  
Reverse transcriptase reactions performed to generate cDNA used 1 ug of RNA as 
previously described (46, 54, 157) .  Amplification of transcripts was quantified by Q-
PCR using the Opticon Engine (MJ Research) and primers previously described (46, 54, 
157).        
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Chromatin Immunoprecipitation 
Chromatin immunoprecipitation was performed and quantified as described previously 
using primers that were also previously described (46, 54, 157, 158).  Primers spanning 
the desmin and MCK promoters and enhancers were used with no significant differences 
between binding to enhancer or promoter sequences observed.  The immunoprecipitation 
step utilized rabbit polyclonal antisera raised against Brg1 (52), dimethylated H3R8 and 
Prmt5 (164, 165) and commercial antibodies raised against Prmt5 (Becton Dickinson - 
611539), Carm1/Prmt4 (Bethyl Labs – A300-421A, Upstate – 07-080), and dimethylated 
H3R17 (Upstate -07-214).  As an additional negative control, every sample was analyzed 
for the presence of the IgH enhancer sequences; no specific enrichment of IgH sequences 
was ever observed.  Re-ChIP analysis was performed as previously described (146) with 
antibodies against Prmt5, MyoD (12) and myogenin (Santa Cruz - sc576). 
 
Westerns 
Samples were harvested at the indicated time points by scraping into 1mL of PBS 
followed by brief centrifugation to obtain a cell pellet.  Carm1 westerns were performed 
by using cell lysates from immortalized MEFs using the ReliaBlot protocol (Bethyl Labs), 
while all other cell pellets were resuspended in NP-40 Lysis Buffer (50 mM Tris-HCl pH 
7.5, 150 mM NaCl, 0.5% NP-40, 20% glycerol, 1 mM dithiothreitol), with freshly added 
protease inhibitors (1 ug/mL of pepstatin A, 4 ug/mL of leupeptin, 1 mM 
phenylmethylsulfonyl fluoride), and lysed by brief sonication.   
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Following centrifugation at 10K for 10 minutes, cell debris was discarded and lysate 
concentrations were quantified by spectrophotometry.  50ug of protein were loaded and 
electrophoresed on an SDS gel, then transferred overnight onto nitrocellulose membranes.  
Membranes were blocked for 1 hour in 5% milk in 1X TBST, and incubated in primary 
antibody diluted in 5% milk in 1X TBST overnight.  Antibodies used included Brg1 
antisera (52), Prmt5 antisera (165), Carm1 (Bethyl Labs), and PI3K (Upstate).  
Membranes were then washed 3X for 5 minutes each in 1X TBST, incubated in 
secondary antibody diluted in 5% milk in 1X TBST, washed 3X for 5 minutes each and 
visualized by ECL (Amersham).   
 
Isolation of nuclei from liver and myofibers was performed as described previously (46, 
158).  Briefly, skeletal muscle tissue from the hindlimb of 4-6 week old BL6 mice was 
dissected and minced on ice into 1mm
Tissue Isolation and Nuclei Preparation 
3 pieces.  Minced samples were pooled and 
digested with 110U of collagenase supplemented with 1mM CaCl2 in PBS at 37º C for 1 
hour with agitation.  Separation of satellite cells and myotubes was achieved by use of a 
70uM filter (Becton Dickinson).  Separated populations of cells were resuspended in lysis 
buffer (10mM HEPES-KOH (pH7.3), 10mM KCl, 5mM MgCl2, 0.5mM DTT, 0.2mM 
PMSF, 3ug/mL cytochalasin B, 10ug/mL leupeptin) and nuclei were released by 
homogenization followed by dounce homogenization.  Integrity of nuclei was ascertained 
by light microscopy.  This nuclei mixture was overlayed onto a sucrose gradient and 
centrifuged as previously described (46, 157, 158).  Following centrifugation, nuclei were 
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crosslinked for ChIP and snap frozen using liquid nitrogen.  All samples were then stored 
at -80º C until use.   
 
Restriction Enzyme Accessibility Assay 
Restriction enzyme accessibility analysis was performed as described previously (54, 
157).  Briefly, nuclei were released from cells by dounce homogenization and DNA was 
quantified by spectrophotometry.  100ug of DNA was subjected to limited digestion with 
PvuII for 1 hour at 37º C.  Following digestion, DNA was ligated to a linker previously 
described (54, 157).  Ligation mediated PCR was used to quantify the amount of nuclease 
accessible DNA using primers corresponding to linker DNA and specific gene loci as 
previously described (54, 157).  Results were normalized to input genomic DNA using 
Q-PCR. 
 
pCDNA3.1-MyoD was constructed by isolating the EcoR1 fragment encoding the MyoD 
cDNA from pEMSV-MyoD (50) and cloning it into EcoR1 digested pCDNA3.1 
(Invitrogen).  
 
Plasmid Construction 
Competent BL21 E. Coli was transformed with pGEX-2TK, pGEX-Prmt5 (165), and 
pGEX-Carm1 (34).  Cells were grown to OD=0.8 and induced with 1.5mM IPTG 
(Invitrogen # 15529019) for 6 hours at 37ºC.  Cells were pelleted and resuspended in 
GST Pull-down Experiments 
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STE Buffer (20 mM Tris pH 7.6, 5 mM MgC12, 100 mM NaCl, 1 mM EDTA) 
containing 4mg/mL Lysozyme and incubated on ice for 15 minutes.  5 mM DTT, 0.5 mM 
PMSF and 1% (w/v) aprotinin were added sequentially and followed by brief vortexing.  
1.5% Sarkosyl was added to the cells followed by brief vortexing.  Lysis of bacterial cells 
was accomplished by sonication and the protein lysate was centrifuged at 14.5K for 15 
minutes at 4°C.  The sonicated lysate was incubated with a slurry of Glutathione beads 
resuspended in PBS for 30 mins at 4°C while rocking.  Beads were washed for 5 minutes 
5X with STE buffer and resuspended in a 50% slurry.  Beads were resuspended in sample 
buffer and subjected to SDS PAGE and followed by Coomassie staining to quantify 
immobilized GST or GST-fusion proteins. 
pCDNA3.1-MyoD, pCS2-Myogenin (a kind gift from Dr. S. Tapscott), and 
pCDNA1.1-MEF2D1b (a kind gift from Dr. E. Olson) were incubated with the TNT 
Quick Coupled Transcription/Translation System (Promega # 1171, 2081) to 
generate 35S-Methionine labeled proteins.  In order to preclear, radiolabeled proteins were 
resuspended in 500uL of NETN and incubated with 35uL of glutathione beads for 45 
minutes at 4°C while rocking.  Beads were discarded and glutathione-immobilized GST, 
GST-Prmt5 and GST-Carm1 fusion proteins were then incubated with 35S-radiolabelled 
full length MyoD, Myogenin and Mef2D1b for a minimum of 2 hrs at 4°C while rocking.  
Beads were washed for 5 minutes 5X with NETN Buffer, resuspended in sample buffer, 
boiled and subjected to SDS-PAGE.  Gels were dried and were visualized using a 
phosphoimager (Molecular Dynamics). 
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 We have demonstrated that Prmt5 is functionally required for transcriptional 
regulation of myogenic differentiation because it facilitates ATP-dependent chromatin 
remodeling at myogenin promoter sequences.  Binding of Prmt5 and dimethylation of 
histone substrates at the myogenin promoter are necessary for the targeting of Brg1, and 
remodeling of chromatin at this locus to enable binding of transcription factors such as 
MyoD.  Prmt5 has been described primarily as a repressor though few groups have 
described its role as an activator.  One report indicated that dose-dependent reduction of 
Prmt5 results in reduced NFAT and IL-2-dependent gene expression (186).  A purified 
multi-protein complex containing Prmt5 and p44 has been shown to mediate androgen 
receptor-dependent gene expression though Prmt5-dependent transcription activation did 
not require methyltransferase activity.  Collectively these findings indicate that the 
mechanism by which Prmt5 influences transcription activation is quite complex.               
 Prmt5 has been purified in a multi-protein repressor complex containing Brg1 
mSin3A and HDAC2, and this complex serves to regulate the expression of c-Myc target 
genes such as carbamoyl-phosphate synthase-aspartate carbamoyltransferase-
dihydroorotase (cad) and nucleolin (nuc)(165).  This complex also regulates the genes  
nonmetastatic 23 (NM23) and suppressor of tumorigenicity 7 (ST7)(164).  Prmt5-
mediated methylation of Spt5, a component of the transcription elongation complex that 
CHAPTER IV 
General Discussion 
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is associated with the active hyperphosphorylated form of the polymerase, reduced its 
affinity for the complex and thus inhibited transcription elongation (117).   
 By virtue of the fact that Prmt5 is able to associate with a variety of protein 
complexes, it is likely that these interactions dictate its role as a repressor or, in our hands, 
an activator.  It is possible that many unidentified coregulators of Prmt5 exist, and these 
factors direct Prmt5 activity to specific subsets of genes or augment its interaction with 
multi-protein transcription regulatory complexes.  Recent reports have revealed that such 
a coregulator exists and it is aptly termed cooperator of Prmt5 (COPR5).  This factor 
bound tightly and specifically to Prmt5, permitting preferential binding to histone H4 at a 
subset of Prmt5 target genes (118).   
 Since we have established that Prmt5 is necessary for the activation of early 
myogenic targets, it was of interest that binding of Prmt5 and methylation of histone 
substrates did not require the function of Brg1, and were needed to facilitate Brg1 
binding, suggesting that Prmt5 binds before Brg1.  It is possible that methylated histone 
substrates are better substrates for Brg1-dependent chromatin remodeling.  In fact, 
acetylated histones precede and assist Brg1 targeting to the myogenin promoter prior to 
gene activation (54).  It is not unreasonable to suggest that different histone modification 
events may be cooperating at the myogenin promoter to facilitate loading of Brg1.  For 
example, hyperacetylated histones have been shown to provide higher affinity substrates 
for methyltransferases.  At the estrogen-inducible pS2 promoter, the HAT CBP is bound 
to and acetylates histone H3 at the promoter providing a better substrate context for 
Carm1-mediatead histone H3 methylation (48).  Alternatively, the function of 
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methyltransferases may be necessary for subsequent histone modifications.  siRNA-
mediated knockdown of PRMT1 resulted in near complete ablation of methylated histone 
H4 arginine 3 (H4R3) at the ß-globin locus.  Furthermore, domain wide loss of histone 
H3 acetylation, accompanied by increased H3 methylation, was observed, indicating that 
histone methylation may be required for subsequent histone modifications such as 
acetylation (100).   
 Alternatively, the association of Prmt5 and dimethylation of histones substrates at 
myogenic regulatory regions may be required at early time points, prior to the onset of 
early muscle genes in order to facilitate the recruitment of HATs and acetylation of 
histones.  Prior studies (54) have indicated that histone acetyltransferases occupy the 
myogenin promoter, acetylate histones and MyoD in order to facilitate binding of 
SWI/SNF complex.  Binding of these chromatin remodeling factors occurs hours before 
the onset of myogenin gene expression.  Our preliminary data suggests that Prmt5 is 
present at the myogenin promoter prior to the onset of differentiation and stable MyoD 
binding (data not shown).  Prior to the onset of differentiation, Prmt5 is bound to the 
myogenin promoter prior to the association of HATs or SWI/SNF, and is accompanied by 
increases in H3R8 and H4R3 dimethylation.  When Prmt5 is downregulated in the 
antisense-expressing cells, its requisite histone methylation marks disappear and 
acetylation of histones H3 and H4 is severely diminished.  Furthermore, as histone 
acetylation is required to allow binding of SWI/SNF complex, binding of Brg1 is also 
compromised when Prmt5 is knocked down.  Prmt5 is likely bound to the myogenin 
promoter via its interaction with the Pbx-bound MyoD protein.  These results indicate 
 
 
135 
that an early role for Prmt5 exists.  Specifically, Prmt5 and/or dimethylated H3R8 and/or 
H4R3 are required to facilitate the binding of HATs, acetylation of histones and 
ultimately the binding of the SWI/SNF complex, which is required to remodel chromatin 
and permit stable binding of myogenic transcription factors such MyoD.       
 These results however, do not clarify if Prmt5 itself or its enzymatic activity are 
required for subsequent events at the regulatory regions of the muscle gene myogenin.  
ChIPs performed in cells expressing a mutant version of Prmt5, which contains a 
mutation or deletion of its enzymatic SAM domain, rendering it functionally inert, would 
be useful in determining if dimethylation of histones is essential for the recruitment of 
HATs and SWI/SNF or if the protein itself functions as a scaffold protein that binds both 
HATs and SWI/SNF complex.  Coimmunoprecipitations using either wt or mutant Prmt5 
would reveal if an associations with HATs and Brg1 exist, or if these interactions are 
dependent on methyltransferase activity.   
 We have established that the regulation of early and late myogenic target genes is 
mediated by two distinct PRMTs.  These Prmts function independently during various 
stages of differentiation but are ultimately required to facilitate binding of Brg1 and 
consequently, to elicit ATP-dependent chromatin remodeling.  It is puzzling why two 
different PRMTs are needed for essentially one function.  Our previous studies have 
shown that an interaction between Prmt5, Brg1 and MyoD exists.  MyoD has also been 
observed at the regulatory sequences of myogenin prior to the onset of gene expression 
via its interaction with the constitutively bound heterodimer Pbx1/Meis.  This interaction 
appears to specifically “mark” the myogenin locus for activation as HAT binding, histone 
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acetylation and ATP-dependent chromatin remodeling closely follow the initial non-
consensus binding of MyoD to Pbx1/Meis (54).   
 In comparison, it has been reported that MyoD associated with late muscle gene 
promoters in a Brg1 independent manner and was responsible for recruiting HDAC 
activity, prior to the onset of late activation (157).  Late gene activation occurs at 
approximately 8 hours and coincides with the disappearance of both MyoD and HDAC2.  
As expected, gene activation is concurrent with binding of Carm1, myogenin and its 
cofactor Mef2d1b, and recruitment of Brg1.  In the case of late muscle gene regulatory 
elements, MyoD is not sufficient to elicit binding of Brg1.  MyoD is required to facilitate 
the activation of myogenin and Mef2d, both of which appear to be essential for 
recruitment of Brg1.  Genes induced during skeletal myogenesis are classified into two 
groups, early and late.  The former do not require any additional rounds of protein 
synthesis and are dependent upon factors such as MyoD and/or Myf5.  Myogenin and 
MRF4, products of MyoD-mediated transcriptional activation, are subsequently required 
for the activation of late muscle genes such as desmin and muscle creatine kinase.   
 MyoD appears to have a distinct role at early and late myogenic gene regions.  
While MyoD is required at early genes in order to facilitate recruitment of Brg1, it acts in 
a repressive capacity at the regulatory sequences of late muscle genes.  MyoD 
recruitment to late gene promoter elements and its association with HDAC activity 
indicate that it may be responsible for maintaining late muscle targets in a repressed state 
until myogenin and Mef2d1b are present and able to recruit Brg1.  Ectopic 
overexpression of myogenin and Mef2d1b are sufficient to induce significant and 
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precocious late muscle gene activation, hours earlier than when cells are differentiation of 
MyoD (157).  Though Prmt5 is present and regulates dimethylation of histones at late 
muscle gene promoters, precocious gene activation does not occur because myogenin and 
Mef2d1b are required to recruit Brg1 and initiate gene activation.  As an interaction 
exists between Prmt5 and MyoD, its role at late muscle gene sequences may also be 
somewhat altered in comparison with its requirement as an activator at early gene 
promoters.  According to the ChIP data that we present, Prmt5 is not required for the 
recruitment of Brg1 at the promoter regions of late genes.  
  Our results have shown that throughout a time course of differentiation, Prmt5 is 
bound to and dimethylates histones at the regulatory regions of late muscle genes.  Prmt5 
association with these promoters was observed at t = 0h, prior to the onset of gene 
activation at t = 8h.  It is apparent that Prmt5 is bound to these gene sequences via its 
interaction with MyoD, which we know to be associated with HDAC activity and 
possessing similar kinetics to Prmt5.  In vitro binding experiments using GST and GST-
Prmt5 fusion proteins and S-35 radio-labeled MyoD, myogenin and Mef2D, revealed that 
Prmt5 was able to interact directly with all three proteins.   
 Though coimmunoprecipitations of Prmt5 and endogenous muscle regulatory 
proteins have not been performed in primary myoblasts, Prmt5 recruitment to the 
promoter sequences of late muscle genes occurs via its interaction with MyoD.  At the 
onset of gene activation, MyoD and HDAC2 disappear and are replaced by the binding of 
myogenin, Mef2D1b and Brg1.  Though MyoD is no longer present at these regulatory 
sequences, Prmt5 is able to remain bound to late muscle promoters via its interaction with 
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myogenin and Mef2D.  It is unclear what the sustained association of Prmt5 with late 
muscle gene sequences is indicative of, though we have ascertained that Prmt5 binding 
occurs via its interaction with either myogenin or Mef2D.        
 In order to eliminate the possibility that Prmt5 or its methyltransferase activity 
could be necessary for subsequent recruitment of Carm1, ChIPs were performed in Prmt5 
antisense-expressing cells and revealed that though Prmt5 proteins levels were knocked 
down, Carm1 binding and dimethylation of histones was intact.  Furthermore, the binding 
and methyltransferase activity of Carm1 were not required for Prmt5 binding and activity.   
 The role of Prmt5 at the regulatory sequences of late muscle genes is complex.  Its 
association with MyoD and HDAC activity prior to the onset of gene activation implies it 
behaves in a repressive capacity.  However, sustained binding of Prmt5 and its 
accompanying modification mark throughout the time course of differentiation suggests 
that while it is not essential for late gene activation, it is involved in the induction process 
and its constitutive binding may be to combat the activity of arginine demethylase 
activity.  In order  to determine if this is the case, additional ChIPs may be performed to 
determine the status of methylated histones at the regulatory sequences of late muscle 
targets when Prmt5 protein is knocked down.  Additionally, ChIPs could be performed to 
determine if JMJD6, a recently identified protein arginine demethylase, exhibited 
increased occupancy at late myogenic promoter regions when Prmt5 protein levels were 
reduced.  Though Prmt5 is not absolutely required to facilitate Carm1 binding or 
recruitment of Brg1 to these late muscle gene sequences, it is decidedly important for 
priming these promoter regions for key activation events.      
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 Evidence (data now shown) indicates that in the adipogenic differentiation 
program, Prmt5 appears to have a dual role as both repressor and activator.  Prior to 
adipocyte marker activation, Prmt5 is required to suppress lipogenic transcripts since a 
knockdown of Prmt5 protein levels results in precocious lipid accumulation and lipid 
biosynthetic gene induction.  Association of Prmt5 at lipogenic gene regulatory 
sequences was observed in concert with dimethylated histones.  In contrast, during the 
differentiation process, Prmt5 binds to and is responsible for dimethylating histones at 
adipogenic promoter regions.  Reductions in Prmt5 and dimethylated histones are 
followed by diminished Brg1 binding at these promoters and ultimately elicit a 
significant decrease in adipocyte gene transcription, indicating that Prmt5 is also an 
activator.   
 Further, evidence indicates that MyoD and myogenin have distinct roles at 
specific promoters, such that MyoD is required for robust activation of early transcripts 
while myogenin is necessary for enhancement of late gene expression.  Thus the 
interaction between Prmt5 and MyoD may dictate which subset of promoter sequences 
are directly regulated by Prmt5, specifically that Prmt5 is recruited by MyoD and is 
functionally required for early gene transcription events but is involved in repressing 
precocious activation of late muscle transcripts.   
 We have shown that Carm1 at late myogenic targets occurs concomitantly with 
the onset of gene expression.  Others have demonstrated that transcription of late muscle-
specific targets is accompanied by concurrent binding of myogenin, Mef2d1b and Brg1 
(157).  A specific interaction has been shown to exist between Carm1 and Mef2 family 
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members but not MyoD or myogenin (35), though in our hands Carm1 is able to interact 
with Mef2D and myogenin.  The muscle-specific isoform Mef2d1b has been shown to 
synergistically activate late myogenic gene expression in combination with Brg1 and 
myogenin as ChIP analysis places these proteins at late muscle-specific promoter 
sequences concurrently with gene activation (157).  The nucleosomal methylosome 
activator complex (NUMAC) is a multi-protein complex which contains Carm1 and Brg1, 
and is assembled at the regulatory regions of activated estrogen-dependent genes (237).  
These findings suggest that Mef2-mediated targeting of Carm1 influences the subset of 
genes that are regulated by this PRMT.  Furthermore, as we have shown that no 
interaction exists between Carm1 and MyoD, this is a key element in distinguishing the 
function of Carm1 at the regulatory sequences of muscle genes, from that of Prmt5, 
which depends greatly on MyoD for the specificity of its interactions with muscle 
specific cis-elements.  Therefore, we have shown that these Prmts posses unique 
interactions with MRFs, that themselves have distinct transactivation functions during the 
different stages of muscle differentiation.  The binding of Prmt5 or Carm1 with their 
respective partners and any associated complexes will define their functional status at 
early and late stages of muscle differentiation.   
 Our results show that late myogenic gene activation is ablated in cells where 
Carm1 is absent.  Strangely, the knock out mouse model does not present with any overt 
skeletal muscle phenotypes though there do appear to be defects in adipocyte gene 
expression (239).  Histological analysis of wild type and null Carm1 MEFs reveal no 
major structural defects though reduced muscle fiber density was observed in conjunction 
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with reduced individual myotube size and skeletal muscle presented with centrally 
localized nuclei indicating newly synthesized or repaired fibers reminiscent of 
regenerating muscle.   
 Muscle regeneration is characterized by 2 phases: degenerative and regenerative.  
The initial degenerative phase is accompanied by activation of mononucleated cells, 
principally inflammatory cells and myogenic cells (182, 218).  It has been postulated that 
factors released by injured muscle cells activate resident inflammatory cells causing them 
to signal circulatory inflammatory cells which subsequently activate myogenic cells (71, 
162).  Muscle degeneration is then followed by activation of muscle repair processes 
characterized by increased cellular proliferation (180, 223, 226).  Activated myogenic 
cells serve as sources of new myonuclei which fuse to new or existing myofibers during 
the repair process (31, 85).  Newly formed myofibers can be identified morphologically 
by their small caliper and centrally localized nuclei, similar to what was observed by 
histology.  These findings suggest that there some defect exists during terminal 
differentiation or fusion of newly regenerated myofibers, but does not affect whole tissue 
function in the animal.   
 Though others have shown defects in muscle-specific gene expression when 
Carm1 was reduced the mouse model dictates that Carm1 is dispensable for this process. 
It is apparent that some compensatory mechanism exists in vivo to complement the 
absence of Carm1.  It is possible that other PRMTs may be functionally redundant.  
Studies knocking down both Prmt5 and Carm1 specifically in skeletal muscle tissue,  
would be useful in determining if functional overlap exists between these proteins, 
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though there is no precedence to implicate Prmt5 functionally compensates for the lack of 
Carm1.     
 Our findings have demonstrated that PRMT function is required to facilitate ATP-
dependent chromatin remodeling during myogenic differentiation.  Another caveat is 
promoter specificity is conferred by association of these Prmts with distinct MRFs and 
these interactions will ultimately determine the functional status of these Prmts in the 
context of gene activation.  We have focused on molecular events necessary to elicit 
transcription activation during differentiation.  As we have seen binding of Prmt5 and 
Carm1 in vivo, it would be intriguing to examine if either PRMT was involved in the 
activation and self-renewal process of satellite or possibly the repair and regeneration 
dynamics of myofibers.  It would also be of interest to determine the role of PRMTs 
during higher order chromatin reorganization events in response to differentiation signals 
as the role of histone modifying proteins remains largely unexplored.  It is apparent that 
much more remains to be elucidated concerning the role of arginine methylation during 
cellular differentiation events. 
 
 
 
 
 
143 
 Exquisite temporal regulation of transcription activation is a hallmark of cell 
differentiation processes.  Many reports have demonstrated that lineage specific 
transcription factors cooperate with chromatin remodeling enzymes, specifically ATP-
dependent nucleosome remodelers and histone-modifying enzymes, to initiate gene 
induction.  Using a cell line capable of tetracycline-inducible expression of dominant 
negative Brg1, the catalytic subunit of the Swi/Snf enzyme, we examine the role of ATP-
dependent chromatin remodeling enzymes during activation of neuromuscular junction 
target genes such as acetylcholine receptor (AChR) • , ß, • , and muscle specific kinase 
(MuSK).  Subsets of myogenic targets can be activated by distinct muscle regulatory 
factors (MRFs) and recent work has shown that the combination of myogenin & 
Mef2d1b is sufficient to activate late stage muscle-specific genes as well as NMJ 
transcripts.  Chromatin immunoprecipitation (ChIP) conducted using Brg1 antisera 
indicate that Brg1 is indeed present at the regulatory sequences of these loci.  Expression 
of dominant-negative Brg1 impedes the ability of Swi/Snf to bind at these promoter 
regions, and corresponds to a failure to activate NMJ gene transcription.  Analysis of 
chromatin structure by restriction accessibility assay in the absence of Swi/Snf confirmed 
that chromatin at NMJ gene loci was not remodeled and remained in an inaccessible and 
therefore repressive state.  To elucidate the relationship between Brg1 and MRFs during 
NMJ gene regulation in vivo, ChIPs were performed using samples isolated from skeletal 
Appendix A 
Brg1 is Required for Transcription Regulation of Neuromuscular 
Junction Gene Activation 
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muscle adult mice to analyze the binding patterns of these proteins.  Interestingly, MyoD 
was enriched at NMJ regulatory sequences in satellite cells but not in mature myofibers.  
In contrast, myogenin, which has been shown to be sufficient to activate late myogenic 
gene targets and NMJ transcripts, was robustly localized to NMJ promoter regions in 
myofibers but not in satellite cells.  Brg1 was present at NMJ loci in both satellite cells 
and myofibers.  As NMJ target genes are only induced following terminal differentiation 
of the myofiber, these results suggest that myogenin specifically targets the activity of 
Swi/Snf during the later stages of myogenic differentiation, specifically to regulate genes 
required for neuromuscular junction formation.    
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Figure A1. 
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Figure A1. 
Skeletal muscle differentiation was induced in cells by the exogenous expression of 
myogenic regulatory factors (MRFs); specifically, NIH 3T3 fibroblasts were infected 
with retrovirus encoding MyoD, myogenin or the muscle specific isoform Mef2d1b.  
Cells were mock differentiated with the empty retroviral vector as a negative control.  
Robust transcription activation of neuromuscular junction (NMJ) gene targets, such as 
acetylcholine receptor (AChR) • , ß, •  or  muscle-specific kinase (MuSK), was observed 
in cells that were differentiated with MyoD & Mef2d1b or Myogenin & Mef2d1b.  NMJ 
transcripts were undetectable in cells differentiated using MyoD or myogenin alone, 
indicating the activity of the MRF myogenin, in combination with the muscle specific 
coactivators Mef2d1b, is sufficient to induce NMJ gene activation.  As expected, levels 
of NMJ transcripts were undetectable in mock-differentiated samples. 
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Figure A2. 
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Figure A2.   
 Cellular differentiation was achieved by the exogenous expression of MyoD, 
myogenin, Mef2d1b, and combinations of MyoD & Mef2d1b, or myogenin & Mef2d1b.  
Mock-differentiated cells were used as a negative control.  Samples were crosslinked and 
chromatin immunoprecipitation was performed as described previously.  Brg1-antisera 
was used to immunoprecipitate Brg1-containing complexes present at the gene regulatory 
regions of NMJ targets acetylcholine receptor (AChR) • , ß, •  and  muscle-specific kinase 
(MuSK).  Binding of Brg1 was significantly enriched at the regulatory regions of all NMJ 
target genes analyzed in cells differentiated using MyoD & Mef2d1b or myogenin & 
Mef2d1b, indicating that the binding of Brg1 occurs in a myogenin & Mef2d1b-
dependent fashion and coincides with transcription activation.   
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Figure A3. 
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Figure A3.   
 As described previously, modified NIH 3T3 fibroblasts were maintained in the 
presence of tetracycline to prevent the expression of dominant negative Brg1, while the 
removal of tetracycline permits the expression of dominant negative Brg1.  
Differentiation was accomplished by retroviral infection with vectors encoding MyoD or 
myogenin & Mef2d1b.  Cells were also mock-differentiated using empty retroviral vector.  
Samples were harvested for ChIP and gene expression analysis via quantitative PCR (Q-
PCR).  Brg1-antisera was used to immunoprecipitate Brg1-containing complexes present 
at the promoter sequences of NMJ loci AChR •  and MuSK.  Significant enrichment of 
Brg1 binding was observed at these regulatory regions in cells differentiated using the 
combination of myogenin & Mef2d1b.  Notably, association of Brg1 with NMJ 
promoters was reduced in cells expressing dominant negative Brg1.  However, no 
appreciable binding was seen in MyoD-differentiated samples.  As expected, no 
significant binding was seen in mock-differentiated cells.  Analysis of gene expression 
indicates that transcription activation of NMJ targets is heavily reduced in cells 
expressing dominant-negative Brg1, indicating that the binding and ATP-ase activity of 
Brg1 are required to elicit gene activation of NMJ genes.   
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Figure A4. 
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Figure A4.   
 The state of chromatin at NMJ loci was assessed using restriction enzyme 
accessibility assay (REAA) in differentiated cells in the presence and absence of 
tetracycline.  Chromatin was highly accessible in cells differentiated using myogenin & 
Mef2d1b.  However, nuclease accessibility was diminished in cells expressing dominant 
negative Brg1.  No detectable increase in chromatin accessibility was observed in MyoD-
differentiated or mock-differentiated cells.  The ATP-ase activity of Brg1 is required for 
the alteration of chromatin structure at NMJ loci in order to promote transcription 
activation.  The values represent data from 3 independent experiments.   
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Figure A5. 
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Figure A5.   
Skeletal muscle tissue isolated from mice was used to purify a population of satellite cells 
and myofibers, which were then prepared for ChIP analysis.  Liver was isolated and used 
for negative control.  Antibodies recognizing myogenin, MyoD and Brg1 were used to 
immunoprecipitate DNA sequences bound by these proteins.  MyoD-binding was 
increased at the regulatory regions of NMJ genes in satellite cells but not in myofibers or 
liver.  However, myogenin binding was robustly induced at promoter sequences of NMJ 
loci in myofibers but not in satellite cells or liver.  Brg1 was present at these promoter 
regions in both satellite cells and myofibers but not in liver.  The distinct binding pattern 
of MyoD and myogenin indicates that both MRFs contribute to the regulation of NMJ 
target genes but myogenin is the primary transcription factor responsible for directing 
transcription activation in a Brg1 dependent manner.          
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Appendix B 
Comparative in silico analysis identifies bona fide MyoD binding sites 
within the Myocyte Stress 1 gene promoter 
 
 The molecular mechanisms governing the regulation of skeletal muscle specific 
expression of Myocyte stress I (MSI), a striated muscle actin binding protein required for 
the activity of the myocardin related transcription factor (MRTF)/serum response factor 
(SRF), are largely unknown.  Analysis of the regulatory sequences of MS1 was 
conducted in C2C12 myoblasts and using in silico comparative techniques.  Our 
contributions included a time course of myoblasts and differentiated C2C12 cells that 
were used to show that MS1 gene expression was upregulated in a differentiation-specific 
manner in C2C12 muscle cells.  In silico analysis of the promoter sequences within the 
1.5kbp residing 5’ upstream of the start site revealed two conserved myogenic regulatory 
domains.  Cotransfection of C2C12 muscle cells with plasmids over-expressing MRFs 
and ms1 promoter driven luciferase reporter indicated that MS1 was transactivated by 
MyoD.  Mutagenesis and EMSA demonstrated that MyoD binding occurred at two 
distinct E-boxes, E1 and E2.  We also demonstrated, through chromatin 
immunoprecipitation analysis, binding of MyoD at these respective E-boxes 
corresponded with the onset of gene expression.  Thus tissue specific and differentiation 
dependent induction of ms1 mRNA is mediated by temporal binding of MyoD at distinct 
evolutionary conserved E-boxes within 1.5kbp 5’ upstream of the start site. 
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Abstract
Background: Myocyte stress 1 (MS1) is a striated muscle actin binding protein required for the
muscle specific activity of the evolutionary ancient myocardin related transcription factor (MRTF)/
serum response factor (SRF) transcriptional pathway. To date, little is known about the molecular
mechanisms that govern skeletal muscle specific expression of MS1. Such mechanisms are likely to
play a major role in modulating SRF activity and therefore muscle determination, differentiation and
regeneration. In this study we employed a comparative in silico analysis coupled with an
experimental promoter characterisation to delineate these mechanisms.
Results: Analysis of MS1 expression in differentiating C2C12 muscle cells demonstrated a
temporal differentiation dependent up-regulation in ms1 mRNA. An in silico comparative sequence
analysis identified two conserved putative myogenic regulatory domains within the proximal 1.5
kbp of 5' upstream sequence. Co-transfecting C2C12 myoblasts with ms1 promoter/luciferase
reporters and myogenic regulatory factor (MRF) over-expression plasmids revealed specific
sensitivity of the ms1 promoter to MyoD. Subsequent mutagenesis and EMSA analysis
demonstrated specific targeting of MyoD at two distinct E-Boxes (E1 and E2) within identified
evolutionary conserved regions (ECRs, α and β). Chromatin immunoprecipitation (ChIP) analysis
indicates that co-ordinated binding of MyoD at E-Boxes located within ECRs α and β correlates
with the temporal induction in ms1 mRNA.
Conclusion: These findings suggest that the tissue specific and differentiation dependent up-
regulation in ms1 mRNA is mediated by temporal binding of MyoD at distinct evolutionary
conserved E-Boxes within the ms1 5' upstream sequence. We believe, through its activation of ms1,
this is the first study to demonstrate a direct link between MyoD activity and SRF transcriptional
signalling, with clear implications for the understanding of muscle determination, differentiation and
regeneration.
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Background
During mammalian embryogenesis, the development of
skeletal muscle is mediated by a co-ordinated series of
events that begins with commitment of mesodermal pre-
cursor cells to the skeletal muscle lineage, followed by
myoblast fusion and the subsequent progression of a pro-
gramme of muscle specific gene expression [1-3]. A spe-
cialised group of transcription factors control this process
of myogenic specification and differentiation. These fac-
tors, designated the myogenic regulatory factors (MRFs),
include four basic helix-loop-helix (bHLH) E-Box binding
proteins: MyoD, Myf5, Myogenin and MRF4 [4]. During
development MyoD and Myf5 dictate myoblast specifica-
tion while Myogenin and MRF4 regulate terminal differ-
entiation [5,6]. In collaboration with the MRFs, the
MADS-box myocyte enhancer factor (MEF) family of pro-
teins contribute to the programme of muscle specific gene
expression [7,8].
Serum response factor (SRF), a MADS box transcription
factor related to the MEFs, also regulates skeletal muscle
gene expression through binding of a DNA sequence
known as the serum response element (SRE) or CArG box
[9-11]. In addition to binding and regulating numerous
muscle specific promoters [12,13], perturbation of SRF
activity severely impairs myoblast fusion and differentia-
tion [14-16]. Confirming an important role for myogenic
SRF activity, a conditional skeletal muscle specific knock-
out of SRF results in severe skeletal muscle myopathy that
results in perinatal lethality [17].
SRF activity is dependent on its interaction with a range of
cell-type specific and signal responsive co-factors [18].
Myocardin, the founding member of a family of extraor-
dinarily powerful myogenic SRF co-activators [19], has
been shown to be necessary and sufficient for cardiac and
smooth muscle specific gene expression [9,20,21]. Unlike
myocardin, the myocardin-related transcription factors
(MRTFs), MRTF-A (also known as MAL/MKL1/BASC) and
MRTF-B (MKL2), are expressed in skeletal muscle in addi-
tion to multiple other cell types [22-24].
A requisite role for the MRTFs in skeletal muscle develop-
ment has been inferred from experiments in cultured
muscle cells, in which RNAi mediated knock-down of
MRTF-A repressed SRF-dependent gene expression result-
ing in impaired myoblast fusion and subsequent forma-
tion of multinucleated myotubes [25]. Transgenic mice
expressing a dominant-negative form of MRTF-A dis-
played a phenotype reminiscent of the skeletal muscle SRF
knock out mice supporting an important role for the
MRTFs in the control of muscle fiber growth and matura-
tion [17]. In contrast to myocardin, which is constitutively
nuclear, the MRTFs shuttle between the cytoplasm and the
nucleus with nuclear accumulation required for SRF trans-
activation. Muscle specific mechanisms, which promote
MRTF nuclear accumulation, represent important regula-
tory pathways in the process of myogenic differentiation
via the MRTF/SRF signalling axis [9].
We, and others, have previously identified a novel striated
muscle specific actin binding protein, myocyte stress 1
(MS1, also known as STARS) [26,27] which has the ability
to synergistically activate SRF-dependent transcription
through a Rho-A dependent mechanism. Kuwahara and
colleagues subsequently demonstrated that STARS
(mouse homologue of MS1) activates SRF dependent
transcription by inducing the nuclear accumulation of
MRTF-A and -B through a Rho-A dependent mechanism
[28]. STARS perturbation via RNAi resulted in a significant
attenuation of muscle specific SRF activity suggesting that
endogenous STARS is an important component of the
muscle specific MRTF/SRF transcriptional pathway [28].
In support of this we have shown that ectopic MS1 expres-
sion results in an increased expression of characterised
MRTF/SRF target genes (Koekemoer AL and Chong NW,
unpublished) [29]. Interestingly, we have recently shown
that morpholino knockdown of zebrafish ms1 (zms1)
resulted in severe musculoskeletal deformities with curva-
ture and shortening of the longitudinal axis [30]. This data
supports the previous studies and demonstrates that MS1
is a central component of the evolutionary ancient muscle
specific MRTF/SRF signalling axis.
Despite the important role of MS1 in skeletal muscle for-
mation and function, little is known about the molecular
mechanisms governing its expression. The proximal 1.5
kbp 5'-flanking sequence has recently been shown to be
able to direct LacZ expression in adult cardiac and skeletal
muscle, with two MEF2 responsive motifs within the
proximal flanking sequence essential for the observed car-
diac specificity [31]. However, the factors, motifs and reg-
ulatory mechanisms governing the skeletal muscle
specific expression profile remain unknown. Understand-
ing such mechanisms will give us an exquisite insight into
how the MRTF/SRF signalling axis is regulated during
myogenesis in addition to expanding our knowledge of
the genetic circuits involved in mygenic differentiation.
In this study we investigated the transcriptional regulation
of the ms1 gene during myogenic differentiation using the
C2C12 myoblast cell line as an established model system.
We have shown that two myogenic E-Boxes, located
within evolutionary conserved regions in the ms1 pro-
moter, play distinct roles in recruiting MyoD and subse-
quently activating the ms1 promoter during myogenic
differentiation.
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Results
Ms1 transcript is differentially expressed during myogenic 
differentiation
Ms1 expression is restricted to striated muscle with early
developmental expression during myogenesis in both ver-
tebrate and invertebrate models [27,30]. In order to eval-
uate ms1 expression during myoblast differentiation in
vitro, cultured C2C12 cells, a myoblast cell line estab-
lished from the leg muscle of the C3H mouse [32], were
used. C2C12 is a myoblast cell line, which remains prolif-
erative in the presence of high concentrations of fetal
bovine serum. Upon serum depletion, these myoblasts
differentiate and fuse with each other into myotubes [33].
Quantitative RT-PCR was conducted using 1 µg of total
RNA obtained from subconfluent C2C12 myoblasts (MB)
and from C2C12 myotubes differentiated for 3 days (MT).
As shown in Figure 1A, there is a significant increase in
ms1 transcript in differentiated C2C12 cells compared to
confluent proliferating C2C12, suggesting a differentia-
tion dependent up-regulation of ms1 mRNA.
The temporal expression profile of specific genes
expressed during myogenic differentiation can give us an
exquisite insight into both the function of the gene and
the regulatory processes governing its expression [34,35].
We have therefore measured the temporal expression pro-
file of ms1 transcript during the controlled differentiation
of C2C12 myoblasts over a three-day period. RT-PCR
using RNA isolated on consecutive days during differenti-
ation shows that ms1 transcript is significantly induced
within the first day of the differentiation process with a
maintained increase in expression over the subsequent
three days (Figure 1B). Ms1 can thus be regarded as an
early wave myogenic transcript [36], with this temporal
profile having implications for its role and regulation dur-
ing myogenic differentiation.
Analysis of the ms1 5' upstream DNA sequence
The transcriptional up-regulation of ms1 during myogenic
differentiation suggests its expression might be targeted by
differentiation promoting transcription factors. During
myogenesis, differentiation is under the control of E-Box
binding myogenic basic helix-loop-helix (MyoD, Myo-
genin, Myf4 and Myf5) and MADS domain Mef2 proteins
[37], with all myogenic genes containing binding motifs
for these transcription factors in their promoters and asso-
ciated regulatory loci. We therefore, by means of compar-
ative sequence analysis, proceeded to analyse the rat ms1
5' upstream sequence for enrichment of myogenic tran-
scription factor binding motifs. Using the VISTA software
[38] we compared 5 kbp of 5' upstream sequence from rat,
with the orthologous locus in human. This compares
sequences that shared a common ancestor over 60 million
years ago and it has been shown empirically that con-
served non-coding sequences, also known as evolutionary
conserved regions (ECRs), identified between these spe-
Quantitative real-time PCR analysis of ms1 gene expression during the myogenic differentiation of C2C12 cellsFigure 1
Quantitative real-time PCR analysis of ms1 gene expression during the myogenic differentiation of C2C12 
cells. (A) Total RNA was isolated from C2C12 sub-confluent myoblasts (MB) and myotubes (MT: 3 days post differentiation). 
The RNA was subjected to reverse transcription followed by quantitative PCR with mouse ms1 and EF1α specific primers. (B) 
Total RNA was isolated from C2C12 cells during myogenic differentiation (day 0 to day 3) and subjected to quantitative PCR. 
Expression level at day 0 was arbitrarily set at 1. Values are represented as means ± SE of at least three different experiments. 
(*P < 0.05, **P < 0.05).
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cies represent ideal candidates as functional transcription
factor binding motifs and regulatory domains [39].
Our in silico analysis (identifying sequences with 80%
conservation over a minimum of 100 bp window, Figure
2A) identified two ECRs, α and β (represented in red),
within the flanking 5 kbp of 5' upstream sequence. ECR a
encompassed the proximal 400 bp upstream of the tran-
scription start site (TSS) and we propose represents the
proximal promoter. Within this proximal ECR a putative
TATA box (TATT) was found with optimal interspacing
from TSS [40], hence suggesting that this constitutes the
core promoter. Of particular interest, two E-Box sequences
(-253/-247 bp and -221/-215 bp) and a Mef2 motif (-135/
-125) were identified within this ECR. Further sequence
comparisons, aligning orthologous sequences obtained
from ENSEMBL, confirms full sequence conservation of
these identified myogenic motifs across multiple species
(Rattus norvegicus, Mus musculus, Bos taurus, Homo sapiens,
Pan troglodytes, Macaca mulatta), supporting a conserved
functional role for these motifs (Figure 2B).
In addition to the proximal ECR, a fully conserved E-Box
was also identified in the distal ECR β, located 1.5 kbp
upstream of the TSS (Figure 2A). This ECR may represent
a skeletal muscle enhancer, with such enhancer's com-
mon upstream of other myogenic genes including desmin
and muscle creatine kinase [41,42]. In summary our com-
in silico analysis of ms1 putative promoterFigure 2
in silico analysis of ms1 putative promoter. (A) Phylogenetic comparative analysis of ms1 5'-region from Homo sapiens and 
Rattus norvegicus (reference sequence), as obtained by VISTA, setting ECR at ≥ 100 bp and conservation at ≥ 80%. (B) Align-
ment of ECR α and β, containing several putative transcription factor-binding sites, in Rattus norvegicus, Mus musculus, Bos tau-
rus, Homo sapiens, Pan troglodytes and Macaca mulatta. Sequences were obtained from the ENSEMBL genome database and 
aligned using CLUSTAL W.
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parative analysis suggests that the cis hardwiring required
for myogenic specific expression is contained within the 2
kbp 5'-upstream sequence with myogenic motifs identi-
fied in ECRs α and β.
Cell specific activity of the ms1 promoter
On the basis of the comparative in silico analysis, a 1645
bp fragment of rat genomic DNA (-1585/+60) was
obtained by PCR. This DNA fragment, encompassing the
α and β ECRs, was sub-cloned into the promoterless pGL3
Basic reporter plasmid and the activity of the resulting P-
Analysis of ms1 promoter function in myogenic cell linesFigure 3
Analysis of ms1 promoter function in myogenic cell lines. (A) Subconfluent NIH3T3 fibroblasts and C2C12 myoblasts 
were transiently transfected with a ms1 promoter reporter construct spanning from -1585 relative to transcription start site 
and extending to nucleotide +60. Promoter fragment was cloned into the pGL3-Basic luciferase vector. Activity relative to 
pGL3-B alone was determined in each cell line 48 hours later, at which point the cells were still subconfluent. The relative 
activity of the promoter fragment (vs pGL3-B) in each cell line was then determined with relative activity in C2C12 assigned 
arbitrary value of one (B) Vectors (+:0.3 µg, ++:0.6 µg) expressing Mef2D, myogenin and MyoD were co-transfected in combi-
nation with the ms1 prompter reporter construct (P-1585/+60) into C2C12 myoblasts as described in (A). Luciferase activity 
in cells transfected with pcDNA and ms1 promoter reporter (P-1585/+60) was arbitrarily set at 1 fold activation. (C) Subcon-
fluent H9c2 myoblasts were transiently transfected with the MRF over-expression vectors (+:0.5 µg, ++:1 µg). 48 hours post 
transfection, at which point the cells were 80% confluent, total RNA was isolated, reverse transcribed and the expression lev-
els of TATA binding protein (TBP) and ms1 were determined by real time PCR. Ms1 expression in each sample was normalised 
to that of TBP. Statistically significant differences are indicated by *P < 0.05.
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1585/+60 construct was analysed in vitro. The P-1585/+60
wild type promoter reporter (Figure 3A) is approximately
four times more active in the C2C12 myoblasts than in
the NIH 3T3 mouse fibroblasts. This data suggests that
there is sufficient myogenic cis information encompassed
within the promoter reporter to drive cell-specific activity
in a myogenic cellular environment.
Myogenic factors can modulate the ms1 promoter
Since putative E-Box and Mef2 binding motifs are located
within ECR α and β, the sensitivity of these motifs to the
over-expression of their cognate binding proteins was
determined. The rat ms1 promoter (P-1585/+60) was
transfected into C2C12 myoblasts in the presence or
absence of the specific MRFs and Mef2D. In the presence
of MyoD, ms1 promoter activity was dose dependently
increased seven fold compared with control (empty
pcDNA3.1 vector). Myogenin alone or in combination
with Mef2D, shown to synergistically activate other myo-
genic promoters [43], did not significantly activate the
ms1 promoter (Figure 3B). Mef2D alone had no overall
activating effect on the ms1 promoter.
To determine whether these effects were observed at the
endogenous ms1 promoter, MRF and Mef2D proteins
were ectopically expressed in H9c2 cells, a rat myoblast
cell line which can enter the skeletal muscle differentia-
tion programme and expresses an array of skeletal muscle
specific contractile and calcium handling proteins [44].
The expression level of endogenous ms1 mRNA in both
control (empty vector alone) and MRF transfected H9c2
cells was determined by quantitative real-time PCR.
MyoD over-expression (1.0 µg) significantly increased
ms1 mRNA levels by two fold (Figure 3C). Myogenin and
Mef2D alone, or in combination, had no effect on endog-
enous levels of ms1 transcript, suggesting MyoD is the pri-
mary myogenic activator of the endogenous ms1
promoter in a myoblast cellular context. These results sug-
gest that MyoD can target the ms1 promoter to enhance its
activity, both in vitro and in vivo.
Site directed mutagenesis of the ms1 promoter
MyoD activates target promoters via heterodimerisation
with ubiquitous E2A proteins (E12, E47, E2-5, [45]),
which allows a stable DNA binding complex to bind the
E-Box sequence (consensus sequence, CANNTG). In order
to asses the contribution of the three conserved E-Boxes
(in ECR α and β) in mediating MyoD sensitivity, we exe-
cuted site directed mutagenesis of their binding sites
within the ms1 promoter reporter construct (Table 1, Fig-
ure 4A).
Reporter constructs containing mutated sequences for the
three E-Boxes, singular and in combination (Figure 4A),
were co-transfected with the MyoD over-expression plas-
mid into C2C12 myoblasts. Mutating E1 (P-1585/
+60∆E1) reduced promoter sensitivity to ectopic MyoD
expression by 50% (from 7- to 3.5-fold; Figure 4B), sug-
gesting this E-Box (located in ECR β) is important for pro-
moter sensitivity to MyoD. The additional mutation in E2
(P-1585/+60∆E1/∆E2) further attenuated promoter sensi-
tivity to 2.5 fold (~67% decrease) (Figure 4B). The com-
bined triple E-Box mutant (P-1585/+60∆E1/∆E2/∆E3)
did not result in a further decrease in promoter sensitivity
to MyoD compared to the double mutant (Figure 4B).
These results suggest that both E1 and E2, but not E3, are
required for MyoD activation of the rat ms1 promoter.
The putative TATA box (TATT) was also mutated exchang-
ing the adenine, at second position for a guanine (TATT to
TGTT). This resulted in a dramatic 95% decrease in pro-
moter activity (Figure 4C) in C2C12 myoblasts. Compara-
ble loss of activity was observed in H9c2 myoblasts and
NIH 3T3 fibroblasts (data not shown) suggesting loss of
activity is not cell type specific. This suggests that this
proximal TATT sequence represents a bona fide TATA box.
In vitro binding of MyoD at distal and proximal E-Box 
sequences
The present mutagenesis analysis suggests that E1 and E2,
but not E3, play an important role in mediating MyoD
sensitivity to the rat ms1 promoter. To further elucidate
the biological importance of the E1 and E2 sequences, we
synthesised specific oligonucleotides (Table 1) containing
the E-Box elements present in ECR α and β, E1, E2 and E3.
These digoxigenin (DIG)-labelled double-stranded oligo-
nucleotides were then incubated with a cold MyoD bind-
ing consensus E-Box sequence control in EMSA
experiments with whole cell extracts from C2C12 myob-
lasts. As shown in Figure 5, incubation of C2C12 whole
cell extracts with both MyoD consensus and E1, E2 and E3
sequences results in a specific DNA-Protein band shift.
The E1 and E2 shifted bands were successfully competed
with excess unlabelled MyoD consensus sequence, sug-
gesting these probes were bound by MyoD protein. In
contrast, E3 could not be competed with unlabelled
excess of MyoD consensus suggesting other E-Box binding
proteins are shifting E3 in vitro. All three E-Box shifted
bands were competed with unlabelled excess of self, con-
firming shifted bands were specific to each sequence (data
not shown).
In agreement with our mutagenesis analysis, our EMSA
data suggests that MyoD can target E1 and E2, but not E3.
Other E-Box binding proteins expressed in C2C12 myob-
lasts are able to bind E3. Future experiments are aimed at
determining their identity.
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Direct binding of MyoD to the endogenous ECRs within 
the ms1 promoter
Our results suggest that the E1 and E2 sites are essential
for ms1 reporter gene function. We then utilised chroma-
tin immunoprecipitation (ChIP) to determine whether
MyoD is physically recruited to the endogenous ECRs in
vivo, and determine the temporal dynamics of MyoD
recruitment during C2C12 differentiation.
An ECR-specific quantitative PCR (Figure 6A) was per-
formed on formaldehyde-crosslinked, sheared chromatin
isolated during C2C12 differentiation, which was immu-
noprecipitated with MyoD and IgG specific antibodies. As
shown in Figure 6B, MyoD appears to be constitutively
bound at the E2 domain during differentiation, thus
MyoD binding precedes the induction of ms1 transcript
(Figure 1B). Interestingly MyoD is not bound to E1 until
day 1 (Fig. 6C), which coincides with transcriptional
induction of ms1 during the differentiation process. A
five-fold enrichment in relative binding of MyoD is
present at day 1 compared to day 0, with this level of
enrichment maintained at E1 during the subsequent three
days. These data suggest that MyoD targets both the E1
and E2 domains in vivo during C2C12 differentiation.
However, temporal binding at E1 coincides with differen-
tiation dependent transcriptional induction. We speculate
that the ECR β represents a differentiation-dependent
skeletal muscle enhancer, with temporal binding required
for differentiation-dependent transcriptional induction of
the ms1 promoter.
Discussion
Understanding the mechanisms through which SRF activ-
ity is regulated during myogenesis is important if we want
to expand our knowledge of the gene regulatory pathways
and networks that drive skeletal muscle determination
Table 1: Oligonucleotide Sequences for PCR and EMSA*
Cloning PCR
P-1585-SacI 5'-TATTCAATGCTTAGTCCTGC-3'
P+60-HindIII 5'-CCAAGCTTCAGGCTACCTGTTTCTTCTC-3'
Site Directed Mutagenesis PCR
∆T ATA Fw 5'-CACCCTTTCACACCCTGCTTCTGTTTAAATCCCAGGCAACTC-3'
∆T ATA Rv 5 '-GAGTTGCCTGGGATTTAAACAGAAGCAGGGTGTGAAAGGGTG-3'
∆E1 Fw 5 '-CACTGAACAGGTGCTGTTTCTCTGTCGTTAAGACTTATCCTTTCAG TTCTCTTAAAA-3'
∆E1 Rv 5 '-TTTTAAGAGAACTGAAAGGATAAGTCTTAACGACAGAGAAACAGCA CCTGTTCAGTG-3'
∆E2 Fw 5'-CTTTCCACCCTGGCGCGGGGAGAAGAAAGGAG-3'
∆E2 Rv 5'-CTCCTTTCTTCTCCCCGCGCCAGGGTGGAAAG-3'
∆E3 Fw 5 '-CAAGGAAAACATAAAGCTAAGCGCGGGATTCAATCTAGTACTTC-3'
∆E3 Rv 5 '-GAAGTACTAGATTGAATCCCGCGCTTAGCTTTATGTTTTCCTTG-3'
Quantitative PCR
MS1 Fw 5'-GTGACAGCATAGACACAGAGGAC-3'
MS1 Rv 5'-CACTGCTGCCCACCTGCCTT-3'
EF1-α Fw 5'-AGCTTCTCTGACTACCCTCCACTT-3'
EF1-α Rv 5'-GACCGTTCTTCCACCACTGATT-3'
ChIP Quantitative PCR
E1-1526 5'-CACATTTTTATCTGGTCTAATACACTG-3'
E1-1482 5'-ATTTTTAATAGAACTGAAAAGAGAAGTCA-3'
E2-281 5'-TAAGGTCAAGGAAAACATAAAGCTA-3'
E2-190 5'-ACGGATATGTTCCCTCCTCTCTC-3'
EMSA
E-Consensus 5'-CCCTTGGAACATCTGTCGATGCTG-3'
E1-MS1 5'-TTCTCTGTCCACATGACTTATCCT-3'
E2-MS1 5'-ACCCTGGCACTTGGAGAAGAA-3'
E3-MS1 5'-AGCTAAGCACATGATTCAATC-3'
*Mutated oligonucleotides are indicated in bold and underlined.
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Ms1 promoter sensitivity to exogenous MyoD with targeted mutations of putative MyoD binding E-Box sequencesFigure 4
Ms1 promoter sensitivity to exogenous MyoD with targeted mutations of putative MyoD binding E-Box 
sequences. (A) Schematic representation of the reporter gene constructs used in luciferase assays. Wild type and mutant E-
Box sequences are represented in white and black ovals respectively. (B) The E-Box sequences 1,2 and 3 (E1, E2 and E3) con-
tained within the wild type P-1585/+60 construct were subjected to site directed mutagenesis. The subsequent single, double 
and triple E-Box mutant constructs were transiently co-transfected with MyoD into subconfluent C2C12 myoblasts for luci-
ferase assays that were harvested 48 hours later, when the cells were 80% confluent, Luciferase activity, representing pro-
moter sensitivity to ectopic MyoD expression (fold activation vs pcDNA), was inhibited by approximately 50% in the single E1 
mutant with the double E1/E2 mutant resulting in a 67% reduction in activity with respect to wild type promoter sensitivity. 
Triple E1/E2/E3 mutant maintained the same level of MyoD sensitivity compared to the double E1/E2 mutant. (C) The putative 
TATA box sequence was subjected to site directed mutagenesis and transiently expressed in C2C12 myoblasts as described 
above and assayed for luciferase activity. TATA mutation resulted in a 95% reduction in luciferase activity with respect to wild 
type P-1585/+60 construct. The results are expressed as mean ± SE of at least three different experiments, in triplicate for 
each construct. Statistically significant differences compared to the appropriate WT construct are indicated by *P < 0.05 and 
**P < 0.05.
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and differentiation. Targeting and activation of muscle
specific genes by SRF is dependent on specific association
with the powerful co-activators, MRFT-A and -B, and Rho-
A signalling. We, and others, have recently shown the
actin binding protein, MS1 (STARS), to be both required
and sufficient for muscle specific activation of the RhoA/
MRTF/SRF signalling axis. Therefore, understanding the
transcriptional regulatory mechanisms governing ms1
expression will give us a key insight into how the MRTF/
SRF axis is regulated during myogenic differentiation.
As a first step towards understanding the transcriptional
mechanisms governing ms1 expression in muscle differen-
tiation, we analysed ms1 expression in differentiating
C2C12 cells. A robust induction in ms1 expression was
observed during the first day of differentiation suggesting
ms1 is an early 'wave' myogenic transcript [34]. Fernandez
and colleagues [48] have reported that C2.7 myoblast
fusion and differentiation is dependent on SRF, as a con-
sequence of its role in regulating MyoD expression. In
addition, MyoD and SRF have been shown to physically
interact and syngerstically activate target promoters, with
consensus SREs enriched in bona fide MyoD target pro-
moters [35]. Considering this, one would expect SRF
activity to coincide with MyoD during early myogenic dif-
ferentiation. We propose this early expression of ms1
drives muscle specific activation of the MRTF/SRF axis,
coupling this pathway with MyoD expression and activity.
An in silico comparative sequence analysis suggested that
the proximal 1.5 kbp 5'-upstream sequence would be
capable of driving muscle specific transcription. Within
this region, two evolutionary conserved regions were
identified, both of which were enriched with ultra con-
served binding motifs for key myogenic regulatory factors.
The proximal ECR also contained a conserved TATA box
located at the correct distance from transcription start site
suggesting it constitutes the core promoter. This 1.5 kbp
promoter fragment was significantly more active in a mus-
cle versus a non-muscle cell type (Figure 3A) supporting
the in silico derived hypothesis. It is of interest that in a
recent study the proximal 1.5 kbp 5'-upstream region of
the mouse STARS gene was able to direct transgenic lacZ
expression in adult skeletal muscle in vivo, thus support-
ing our in vitro data [31].
We speculated that the ultra conserved myogenic regula-
tory motifs encompassed within this promoter fragment
would be important for muscle specific activity. A signifi-
cant increase in promoter reporter activity was observed
with the ectopic expression of the MRF, MyoD. However
myogenin and Mef2D were not able to activate the ms1
promoter reporter in this myoblast cellular environment.
This pattern of sensitivity was also the same at the level of
endogenous ms1 transcription.
The observed specific sensitivity to MyoD complements
the endogenous ms1 expression profile during C2C12 dif-
ferentiation. MyoD is responsible for myogenic gene acti-
vation during early stages of differentiation [2,35], the
time at which ms1 transcription is induced. Myogenin and
Mef2 proteins are themselves subsequently induced by
MyoD, and in a combinatorial manner drive expression of
late myogenic genes as well as consolidating and main-
taining expression of early myogenic genes [43,49]. In
addition this specific sensitivity may suggest that only
MyoD and not myogenin can target the myogenic E-Boxes
within the ms1 promoter in a myoblast cellular environ-
ment. This is not uncommon, for example, MyoD targets
myogenic E-Boxes within the chicken MLC-1 promoter,
which cannot be bound by myogenin [50].
It is of interest that Mef2C binding to the Mef2 consensus
sequence identified in our comparative analysis (ECR α)
has been shown to mediate basal and stress inducible car-
diac specific promoter activity both in in vitro and in vivo
(Kuwahara et al, 2007). In addition, skeletal muscle spe-
cific deletion of the Mef2C isoform at early, but not late
times of embryogenesis, results in mice with disorganised
myofibers that are perinatal lethal (Potthoff et al, 2007).
Our data (Fig. 3) suggest that this Mef2 motif in the ms1
promoter is not required for the initial MyoD mediated
induciton of ms1. However, our data do not preclude the
possibility that Mef2D may contribute to ms1 expression
EMSA analysis of E1, E2 and E3 in the ms1 promoterFigure 5
EMSA analysis of E1, E2 and E3 in the ms1 promoter. 
DIG-labelled oligonucleotide probes for the MyoD E-Box 
binding consensus, E1, E2 and E3 binding sites were incu-
bated with whole cell protein extracts made from subconflu-
ent C2C12 myoblasts. Competition experiments were 
performed using a 200-fold excess of unlabeled MyoD E-Box 
consensus probe. Arrow indicates the resulting bandshifts.
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Chromatin immunoprecipitation assay performed on differentiating C2C12 cells to evaluate in vivo MyoD binding at the ms1 promoterFigure 6
Chromatin immunoprecipitation assay performed on differentiating C2C12 cells to evaluate in vivo MyoD 
binding at the ms1 promoter. (A) A schematic map of the amplified DNA fragments (product size) and the primer locations 
encompassing E1, E2 and E3. TSS position is also illustrated. Proteins were cross-linked to the DNA (in C2C12 cells during 
myogenic differentiation) with formaldehyde, DNA was sheared by sonication, and Abs directed against IgG or MyoD were 
added to precipitate any protein-DNA complexes. The precipitated complexes were pre-cleared with protein A beads. Sam-
ples analyzed included proliferating, subconfluent myoblasts (M), confluent myoblasts harvested prior to the induction of differ-
entiation (D0), myoblasts subjected to differentiation conditions for 24 hours (D1), and differentiating myotubes at 48 hours 
(D2) or 72 hours (D3) post-differentiation. Quantitative real time PCR were performed on isolated DNA using primers 
encompassing the proximal (B) and distal (C) E-Box sequences (E2/E3 and E1 respectively). Amplification was quantified and 
normalised to the input of each sample. The results are expressed as mean ± SE of at least three different ChIPs. Statistically 
significant differences in fold enrichment are indicated by *P < 0.05. Representative PCR reactions were stopped in the linear 
amplification range and run on agarose gel for visualisation.
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later in myogenesis or that other isoforms of Mef2 may
contribute to ms1 activation.
We hypothesised that the observed MyoD sensitivity was
via specific targeting of MyoD to the ultra conserved E-
Box's, E1, E2 and E3, located within the two evolutionary
conserved regions. Indeed, via site directed mutagenesis
and electromobility shift assays, we demonstrated that E1
and E2, but not E3 appear to be targeted by MyoD. Sur-
prisingly a significant level of MyoD sensitivity was
retained in the triple E-Box mutant. This may suggest the
presence of other non-conserved E-Boxes targeted by
MyoD within the promoter reporter or alternatively be a
result of the up-regulation of other myogenic transcrip-
tion factors by MyoD, which subsequently target and acti-
vate the ms1 promoter at other motifs. It is of interest to
note the presence of a conserved SRE within the proximal
ECR, which can be bound by SRF in cardiomyocytes in
vivo (Ounzain S, unpublished). MyoD upregulation is
predicted to increase the activity of SRF [48], so it is possi-
ble for SRF to target and increase activity of ms1 promoter
independent of MyoD binding at E1 and E2. It is also
interesting to consider the up-regulation of the muscle
specific isoform of Mef2D (Mef2D1b), which we suspect
may target the ms1 promoter in late stages of differentia-
tion.
Many muscle specific genes are activated at different times
during the myogenic differentiation process. Numerous
studies suggest that this differential expression of each tar-
get gene is a product of specific temporal binding of
MyoD at distinct E-Boxes within the cis regulatory
domains of the gene, which itself is coupled to chro-
matain modification and remodelling [3]. We therefore
used ChIP to measure in vivo binding of MyoD at the ms1
E1 and E2 domains during C2C12 differentiation. Our
analysis shows that MyoD is constitutively bound at the
proximal E2 domain during differentiation, with binding
preceding the induction of ms1 transcript at day 1 (Figure
6B). MyoD is capable of binding target sequences prior to
gene activation, acting in a repressive manner via the spe-
cific recruitment of repressive chromatin remodelling
complexes. Interestingly, ms1 transcriptional induction at
day 1 (Figure 1B) coincides with MyoD binding at E1,
located within the ECRβ (Figure 6C). This suggests MyoD
targeting at E1 is required for transcriptional activation of
ms1 and we therefore propose that ECRβ could represent
a differentiation-dependent skeletal muscle enhancer.
Prior to activating transcription, MyoD associated with
HDACs serves to mark myogenic genes for subsequent dif-
ferentiation cues and thus activation [51]. It is conceivable
that MyoD binding at the ms1 promoter prior to differen-
tiation primes the promoter in a 'poised' myogenic state.
The recruitment of HDACs by MyoD causes the local chro-
matin environment to be compacted and will prevent the
association of MyoD and other activating factors with spe-
cific cognate binding sites. However appropriate differen-
tiation signals can stimulate MyoD to toggle between
HDAC and HAT recruitment in addition to association
with differentiation-specific myogenic factors [3]. This
facilitates binding of MyoD with other E-Boxes (E1) and
allows the formation of activating transcriptional com-
plexes.
MyoD acetylation has recently been implicated as a cen-
tral mediator of the temporal activation of muscle specific
gene expression during myogenesis [47]. We therefore
cannot rule out the possibility that during C2C12 differ-
entiation an acetylated MyoD form with increased DNA
binding efficiency [52] is capable of binding the E1
domain, resulting in the temporal activation of ms1 tran-
scription. It is of interest that preliminary data indicate
that trichostatin A, a HDAC inhibitor, is able to increase
ms1 transcript abundance in H9c2 myoblasts (Ounzain S,
unpublished).
Taking the present data together, we propose a model
whereby MyoD binding at the ms1 proximal ECR in
myoblasts represses ms1 transcription via the recruitment
of HDACs. This proximal binding is essentially priming
the ms1 promoter, placing it in a poised state for sensing
appropriate differentiation cues. Upon differentiation
MyoD associates with HATs and SWI/SNF, which subse-
quently causes remodelling of the local chromatin envi-
ronment, allowing MyoD to bind E1 within the distal ECR
or alternatively, temporally acetylated MyoD binds the E1
domain. Further targeting of HATs and specifically SWI/
SNF complexes (at E1) can facilitate binding of TBP and
other factors involved in polymerase II pre-initiation com-
plex formation and promote transcriptional elongation
[53-58]. We thus speculate that temporal targeting of
MyoD at E1 is required to establish the optimum environ-
ment for Pol II action and robust transcription.
In summary our data suggests that MS1 is a key compo-
nent of a MyoD generated feed-forward regulatory circuit,
where factors induced by MyoD (like ms1) feed-forward to
regulate late MyoD activity (via SRF) at subsequent target
genes, therefore acting to temporally pattern the timing of
gene expression during skeletal myogenesis. This MyoD-
MS1-SRF feed-forward network would serve to consoli-
date and amplify the myogenic cascade. Indeed SRF itself
acts in combination with MyoD to activate many down-
stream genes, thus, through the specific regulation of ms1,
MyoD is able to synchronize SRF activity with its own and
thus collaborate to mediate the temporal activation of
downstream genes.
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We believe this is the first study to demonstrate a direct
link between MyoD activity and SRF transcriptional sig-
nalling, with ms1 serving as the nodal point to integrate
these two central myogenic regulatory networks. It is of
interest that in cardiomyocytes MS1 serves a similar func-
tion in that it integrates the Mef2 and SRF signalling net-
works, providing a link for crosstalk between them [31].
This is thus a conserved emerging paradigm for MS1 func-
tion both in cardiac and skeletal muscle. In addition we
have data to suggest that MS1 is capable of integrating the
GATA4 cardiogenic network with SRF activity [59].
This study also has implications for myogenic disease
phenoptypes. IGF-1 and IL-4, both central mediators of
post-natal skeletal muscle regeneration are regulated by
SRF in response to stress [60]. Therefore understanding
the molecular mechanisms regulating ms1 expression may
allow us to identify and develop therapeutic strategies for
the up-regulation of ms1 gene expression in a disease phe-
notype, which would facilitate regeneration via stimula-
tion of SRF activity and resulting up-regulation of IL-4 and
IGF-1.
Conclusion
Identification of direct transcriptional targets of MyoD
and de-convolution of the transcriptional regulatory net-
works that operate in muscle cells represent an essential
target if we are to understand not only how muscle differ-
entiates but also how it responds to stress and damage,
therefore allowing regeneration. We have demonstrated
that via temporal binding of MyoD at distinct E-Boxes
within the ms1 promoter, ms1 potentially serves to inte-
grate the MyoD and SRF myogenic regulatory circuits,
thus driving a feed-forward auto-regulatory circuit that
consolidates and amplifies the myogenic phenotype. We
believe this is the first study to describe a direct link
between MyoD activity and SRF signalling, with ms1
allowing cross talk to occur between these two independ-
ent myogenic networks. This implicates MS1 as a key fac-
tor involved in myogenic differentiation and potentially
regeneration.
Methods
Cell cultures
The H9c2 rat myoblast and NIH3T3 mouse fibroblast cell
lines were grown in a humidified atmosphere containing
5% CO2 at 37°C in DMEM supplemented with 10% FCS,
2 mM glutamine, streptomycin and penicillin (each at 10
g/liter). C2C12 mouse skeletal myoblasts were cultured in
DMEM supplemented with 20% FBS, 100 units/ml peni-
cillin and 100 ug/ml streptomycin and maintained at
37°C in 5% CO2. The differentiation of C2C12 myoblasts
into myotubes was achieved by the addition of differenti-
ation medium (DMEM supplemented with 2% horse
serum) at confluence for up to 4 days with medium
change every 2 days.
Plasmid constructs
The rat MS1 gene sequence was obtained from GenBank
(NC_005106) and was used to design primers that would
amplify the 5' flanking region. Two oligonucleotides, P-
1585-SacI and P+60-HindIII (Table 1), were designed to
amplify a portion of DNA sequence starting -1585 bp
upstream of the transcription start site (+1), with primers
tailed with restriction sites for SacI and HindIII restriction
enzymes respectfully. In addition to template (rat
genomic DNA, WKY strain) and primers P-1585-SacI and
P+60-HindIII, the reaction contained 0.2 mM dNTPs,
Expand polymerase buffer and 5 units of Taq Expand high
fidelity polymerase (Roche). Reaction was subjected to 35
cycles of amplification (45 s at 94°C, 45 s at 59°C and 90
s at 72°C). The PCR product was cloned into the vector
pGEM-T Easy (Promega) and sequenced to ensure fidelity
of amplification. The verified plasmid was then cut with
SacI/HindIII and the released -1585 promoter fragment
was purified and cloned into the pGL3-Basic (Promega)
reporter vector, SacI/HindIII digested. The subsequent
construct was designated P-1585/+60WT. The MyoD and
Myogenin expression plasmids were provided by Dr
Andrew Lassar [62,63] and the Mef2D expression plasmid
was a gift from Dr Eric Olson (University of Texas, South
Western Medical centre) [64].
Site directed mutagenesis
The P-1585/+60WT construct was subjected to site
directed mutagenesis to mutate the TATA, E-Box1, 2 and 3
binding sites, using the Quik Change II site-directed
mutagenesis kit (Stratagene). The mutagenic primers used
to generate the TATA and E-Box mutations are reported in
Table 1. Site-directed mutagenesis was performed accord-
ing to the manufacturers instructions. Mutated fragments
were then re-cloned into the Sac I/Hind III sites of the cor-
responding pGL3-Basic vectors. Double (∆E1/∆E2) and
triple-site (∆E1/∆E2/∆E3) mutation constructs, were gen-
erated by consecutive rounds of mutagenesis. The result-
ing plasmids were confirmed by DNA sequencing.
Transient transfections and luciferase assays
C2C12 and NIH 3T3 cells were transfected using the cati-
onic transfection reagent, Jet Pei (QBiogene), according to
the manufacturers protocol. Cells were seeded in six well
plates. Twenty-four h post plating; the cells were co-trans-
fected with 0.5 µg of promoter-luciferase construct and
equimolar amounts for the other plasmids used (total of
0.6 µg). The total amount of DNA was kept constant using
empty vector (pcDNA3.1). To normalise for transfection
efficiency, the pRL-TK (Promega) expression plasmid con-
taining Renilla luciferase (20 ng per well) was co-trans-
fected. Firefly and Renilla luciferase activities were
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measured at 48 h post-transfection using the Dual-Glo™
Luciferase assay system (Promega) and a Lumat LB9507
luminometer (Berthold Technologies). All plasmids were
purified using Qiagen columns (Qiagen) and at least two
preparations per plasmid were tested. The transfection
efficiency was normalised using the Renilla luciferase
activity levels and each transfection was performed in trip-
licate and repeated in a minimum of three independent
experiments.
RNA isolation and quantitative real time RT-PCR
H9c2 cells seeded in six well plates were transfected with
up to 1.5 µg of expression plasmid using JetPei (as above).
Total amount of DNA was kept constant using empty vec-
tor (pcDNA3.1). Forty-eight h post transfection or 24 h
with TSA, total RNA was isolated from cells using the RNe-
asy Mini Kit (Qiagen) according to the manufacturer's
instructions. RNA (1 µg) was reverse transcribed to cDNA
using oligo (dT) and Superscript II Reverse Transcriptase
(Invitrogen). Rat ms1 mRNA expression was analysed
using quantitative PCR with fluorescent-labelled TaqMan
probes (Rat ms1 primers and probe, Cat No.
Rn00598518_m1, Applied Biosystems). TBP was used as
the internal control (Cat No. Mm00446973_m1, Applied
Biosystems). PCR amplifications were performed in
duplicate in 25 µl containing 2 µl cDNA template in 2×
PCR master mix (Applied Biosystems). Amplification con-
ditions as follows: 50°C, 2 min; 95°C, 10 min; 40 cycles
of 95°C for 15 s followed by 60°C for 1 min. Reactions
were performed and products detected using an ABI-Prism
HT 7900 sequence detector (Applied Biosystems). The
level of expression of ms1 mRNA was normalised to TBP
expression. For C2C12 myoblasts, cells were cultured and
harvested for RNA extraction according to the time course
of differentiation. Total RNA was isolated using Trizol rea-
gent (Invitrogen) according to the manufacturers instruc-
tions. Total RNA (2 µg) was reverse transcribed with
Superscript III (Invitrogen). Quantitative PCR was per-
formed with Qiagen HotStart Taq Master Mix and SYBR
Green I as described previously (Schmittgen and Zakra-
jsek, 2000) using primers for ms1 and EF1-α (Table 1).
Amplifications were performed in a DNA Engine Opticon
System (MJ Research) and quantified. Ms1 mRNA levels
were normalised to EF1-α mRNA levels.
Electromobility shift assays (EMSA)
Whole cell extracts were prepared from cultured C2C12
myoblasts using the CelLytic™-M cell lysis extraction rea-
gent (Sigma) according to the manufacturers instructions.
The protein concentrations were determined using the
Bradford assay (Bio Rad). Whole cell extracts were incu-
bated for 15 min with 0.5 pmol of the appropriate digox-
igenin (DIG)-labelled double-stranded oligonucleotide
probe (Table 1) in a 20 µl reaction containing binding
buffer (Roche), 1 µg poly (dI-dC) (Roche) and 0.1 µg poly
L-lysine (Roche). The probes were end-labelled with DIG-
11-ddUTP (Roche). The reaction was stopped by the addi-
tion of 5 µl loading dye (Roche). For competition experi-
ments, a 200-fold excess of unlabeled double-stranded
oligonucleotide (Table 1) was added to the reaction. The
samples were then run on a 4% non-denaturing polyacry-
lamide gel using 1× TGE buffer (50 mM Tris, 380 mM Gly-
cine and 2 mM EDTA), and transferred to a positively
charged nylon membrane (Amersham Biosciences). DIG-
labelled oligonucleotides were visualised by incubation
with alkaline phosphatase-labelled F(ab)2 anti-DIG Ab,
followed by chemiluminescence reaction with 100 µg/ml
CPSD substrate (Roche).
Chromatin immunoprecipitation assay (ChIP)
C2C12 ChIPs were performed using MyoD (de la Serna et
al 2005) and IgG (Santa Cruz) antibodies. The ChIP was
performed as described previously [57], except that
immune complexes were eluted with 0.1 M NaHCO3 and
1% SDS, and following reversal of cross-links, the eluate
was digested by proteinase K digestion and purified using
the Qiagen PCR Purification kit (28106). 4 µl of DNA
eluted from the column was used for PCR. Inputs con-
sisted of 1% chromatin before immunoprecipitation.
PCRs were performed with Qiagen HotStart Taq Master
Mix using primer sets reported in Table 1. Amplification
was quantified by a DNA Engine Opticon System (MJ
Research), then normalised to the input of each sample.
PCR reactions run on agarose gels were stopped in the lin-
ear range and visualised using SYBR Green I.
Comparative DNA analysis
Comparative sequence analysis of human and rat was per-
formed using web-based software available at the Law-
rence Berkley Laboratory genome website (VISTA).
Orthologous sequences from Mus musculus, Bos taurus,
Homo sapiens, Pan troglodytes and Macaca mulatta were
obtained from the ENSEMBL genome data base and
aligned using CLUSTAL W.
Data Analysis
Data are expressed as means ± SE (represented as error
bars). Comparisons were made using the Student's t test,
considering P < 0.05 statistically significant.
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MS1: myocyte stress 1; IGF-1: insulin growth factor 1; IL-
4: interleukin 4; DMEM: dulbecco's modified eagle
medium; FCS: fetal calf serum; TBP: TATA binding pro-
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tetraacetic acid; SDS: sodium dodecyl sulfate.
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Appendix C 
 
Myogenin and the SWI/SNF ATPase Brg1 Maintain Myogenic Gene 
Expression at Different Stages of Skeletal Myogenesis 
 
 Though transcriptional regulation during skeletal muscle specification is well 
understood, there is less information regarding the maintenance of the differentiated state.  
The MRF MyoD and the mammalian SWI/SNF ATP-dependent remodeling enzymes are 
required for the induction of myogenesis in cell culture systems and the developing 
embryo.  Myogenin, another member of the MRF family is necessary for activation of 
late myogenic transcripts that induce terminal differentiation.  Our results revealed that 
myogenin was able to bind to its own promoter during the late stages of embryonic 
muscle development.  Our contributions entailed the isolation of primary muscle satellite 
cells and mature myofibers from adult tissue for use during gene expression and ChIP 
analysis.  Interestingly, in primary adult muscle satellite cells, MyoD and Brg1 localize to 
the myogenin promoter.  In contrast, in mature myofiberes, myogenin and Brg1 were 
preferentially colocalized to the myogenin promoter, indicating that two distinct MRFs 
were required for coordinate myogenin expression.  Further, we demonstrate that in the 
absence of MyoD, myogenin was able to occupy its own promoter, targeted the Brg1 
ATPase to modify chromatin structure and thereby facilitated its own gene expression.  In 
vivo electroporation of dominant negative Brg1 into skeletal muscle of newborn mice 
revealed that myogenin expression was abrogated and continued production of myogenin 
protein was reliant on Brg1 activity.  Therefore, cooperation between myogenin and Brg1 
was required to maintain the skeletal muscle phenotype in vivo.    
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Many studies have examined transcriptional regulation dur-
ing the initiation of skeletal muscle differentiation; however,
there is less information regarding transcriptional control dur-
ing adult myogenesis and during the maintenance of the differ-
entiated state.MyoD and themammalian SWI/SNF chromatin-
remodeling enzymes containing the Brg1 ATPase are necessary
to induce myogenesis in cell culture models and in developing
embryonic tissue, whereas myogenin and Brg1 are critical for
the expression of the late genes that induce terminal muscle
differentiation. Here, we demonstrate that myogenin also binds
to its own promoter during the late stages of embryonic muscle
development. As is the case during embryonic myogenesis,
MyoD and Brg1 co-localize to the myogenin promoter in pri-
mary adultmuscle satellite cells. However, inmaturemyofibers,
myogenin and Brg1 are preferentially co-localized to the myo-
genin promoter. Thus, the myogenin promoter is occupied by
differentmyogenic factors at different times ofmyogenesis. The
relevance ofmyogenin in the continued expression from its own
promoter is demonstrated in culture, where we show that myo-
genin, in the absence ofMyoD, is capable ofmaintaining its own
expression by recruiting the Brg1 ATPase to modify promoter
chromatin structure and facilitate myogenin expression.
Finally, we utilized in vivo electroporation to demonstrate that
Brg1 is required for the continued production of the myogenin
protein in newborn skeletal muscle tissue. These findings
strongly suggest that the skeletal muscle phenotype is main-
tained by myogenin and the continuous activity of Brg1-based
SWI/SNF chromatin-remodeling enzymes.
During skeletal muscle differentiation, MyoD plays a critical
role in initiating the onset ofmuscle-specific gene expression in
cooperation with the Mef2 family of activators and with the
SWI/SNF chromatin-remodeling enzyme, Brg1, which alters
chromatin structure at myogenic loci in a manner that facili-
tates transcription (1, 2). An important target of MyoD is myo-
genin, a related basic helix-loop-helix myogenic regulatory fac-
tor (MRF)2 (3, 4). In addition toMyoD andmyogenin, there are
two additionalmembers of the basic helix-loop-helixMRF fam-
ily, Mrf4 andMyf5 (5, 6). Genetic analyses of mice deficient for
one or for different combinations of the MRFs have demon-
strated that complex relationships exist between members
of this family. In particular, there is significant redundancy of
function in numerous parameters relating to the initiation of
myogenesis (reviewed in Ref. 7). In contrast, gene knock-out
analyses indicate that terminal differentiation specifically
requires myogenin, as mice deficient for myogenin formed
myoblasts but did not develop mature skeletal muscle tissue
(8–10). Thus, myogenin is the only MRF that is absolutely
required for skeletal muscle differentiation during embryogen-
esis, and this requirement is manifested not for the initiation of
myogenesis but instead for events associated with tissue
formation.
Recently, we demonstrated that myogenin, in cooperation
withMef2D and Brg1, directed the expression of myogenic late
genes that specify the skeletal muscle phenotype in cell culture
and in embryonic tissue (11). We hypothesized that during the
time of terminal differentiation and in post-differentiated skel-
etal muscle, myogeninmight also bind to its own promoter and
cooperate with Brg1 to regulate its own expression. This idea is
further supported by prior cell culture experiments demon-
strating that ectopic expression of myogenin in 10T1/2 cells
could induce expression from the endogenous myogenin locus
by an undefinedmechanism (12, 13). Here we provide evidence
to support this hypothesis by examining the occupancy and
function of myogenin at its own promoter during embryonic
and adult skeletal muscle differentiation and in culture and by
functionally evaluating the requirement for Brg1 in myogenin
expression in differentiated tissue.
EXPERIMENTAL PROCEDURES
Preparation of Mouse Embryonic Tissue—Conditions were
identical to those published previously (11).
Nuclei Isolation from Mouse Skeletal Muscle Satellite Cells
and Myofibers—Unless noted, all procedures were performed
at 4 °C. Skeletal muscle from the upper hind limbs of 4- to
6-week-oldC57/BL6micewasminced to1mm3 and digested
with 110 units/ml collagenase type II (Invitrogen) in phos-
phate-buffered saline containing 1 mM CaCl2. Samples were
incubated at 37 °C for 1 h with agitation (14, 15) and filtered
* This work was supported by National Institutes of Health Grant GM56244
(to A. N. I.). The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordancewith 18U.S.C. Section 1734 solely to
indicate this fact.
1 To whom correspondence should be addressed: Dept. of Cell Biology, Uni-
versity of Massachusetts Medical School, 55 Lake Ave. North, Worcester,
MA 01655. Tel.: 508-856-1029; Fax: 508-856-5612; E-mail: anthony.
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2 The abbreviations used are:MRF,myogenic regulatory factor; ChIP, chroma-
tin immunoprecipitation; GFP, green fluorescent protein.
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using a 70-m cell strainer (352350; BD Biosciences) (16).
Flowthrough material was enriched for satellite cells, while
material that did not pass through the filter was enriched for
myofibers. Aliquots of the separated fractions were taken for
RNA isolation; the remainder was pelleted by centrifugation
and resuspended in 7 volumes of lysis buffer (10 mM HEPES-
KOH, pH 7.3, 10 mM KCl, 5 mM MgCl2, 0.5 mM dithiothreitol,
0.2 mM phenylmethylsulfonyl fluoride, 3 g/ml cytochalasin B,
10 g/ml leupeptin). Following a 30-min incubation at 4 °C,
nuclei were released by Dounce homogenization using the A
pestle. Nuclei release was checked by Hoechst 33258 staining,
and cell debris was removed by centrifugation. Nuclei were first
resuspended in 2.5 volumes of 10 STM buffer (5 mMMgCl2, 10
mM triethanolamine, pH 7.5, 5 mM MgCl2, 10% sucrose, 10
g/ml leupeptin) and then 2 volumes of 2.0 M sucrose/10 mM
Tris-HCl/5 mMMgCl2. The samples were overlaid onto 750 l
of 2.0 M sucrose/10 mM Tris-HCl/5 mM MgCl2 in a Beckman
ultracentrifuge tube (number 344057) and spun at 116,140 g
for 1 h at 4 °C. The pellet was resuspended in 500 l of lysis
buffer 0.1% Nonidet P-40. 1.0% formaldehyde at room tem-
perature was added for 5 min for cross-linking, and, following
centrifugation at 13,500 g, pellets were frozen in liquid nitro-
gen. Thawed samples were resuspended in lysis buffer and
sonicated.
Cell Culture—The B22 cell line inducibly expressing
ATPase-deficient, dominant negative Brg1 (17) and retroviral
infection (11, 18, 19) was previously described. Cells were cul-
tured for 4 days in the presence of tetracycline (dominant neg-
ative Brg1 repressed) or in the absence of tetracycline (domi-
nant negative Brg1 expressed) and were infected at 50%
confluence with the indicated retrovirus for 30 h. Low serum
differentiationmediumwas then added (time 0) to inducemyo-
genic differentiation (20). Control samples were mock infected
but still subjected to the differentiation protocol.
Quantitative Reverse Transcriptase Polymerase Chain Reac-
tion Analysis—Reverse transcriptase PCR and quantitative
PCR conditions were previously described (11). Primers for
MyoD, myogenin, desmin, MCK (21), and EF1- (11) were
described. Endogenousmyogenin (Fig. 3A) was amplified in the
3-non-coding region with 5-CAAGTGTGCACATCTGTT
CTA GTC TC-3, 5-GTA TCA TCA GCA CAG GAG ACC
TTGGT-3. Quantitative PCR reactions shown on agarose gels
were stopped in the linear range and visualized using SYBR
Green I (Molecular Probes).
Chromatin Immunoprecipitation Assay—Chromatin immu-
noprecipitation (ChIP) assays were performed as described (11,
22). ChIP PCRs were performed with Qiagen HotStart Taq
Master mix using the primer sets described for the myogenin
promoter and IgH enhancer (22). Antibodies used include
myogenin (sc-576; Santa Cruz) and affinity-purified polyclonal
rabbit antibodies raised against glutathione S-transferase fused
to full-length MyoD (22) and against glutathione S-transferase
fused to a unique portion of Brg1 (17). PCR amplification was
quantified using a DNA Engine Opticon system (MJ Research).
Restriction Enzyme Accessibility Assay (REAA)—REAA and
detection of restricted DNA by a modified version of ligation-
mediated PCR were described previously (11, 22).
In Vivo Electroporation—In vivo electroporation was per-
formed on CL57/BL6 mice at postnatal day 2 (P2) (23, 24).
Expression vectors encoding GFP (0.2 g/l) and dominant
negative Brg1(1.0 g/l) (25) were co-injected into the hind
limb and electroporated with a CUY21EDIT square wave elec-
troporator (Nepa Gene). Muscle tissue was analyzed 2 days
after electroporation.
Immunohistochemistry—The dissected mouse hind limb
muscle was fixed in 0.1 M phosphate buffer (PB) containing 4%
paraformaldehyde and 5% sucrose for 4 h at 4 °C. After fixation,
the sample was cryoprotected with 25% sucrose in 0.1 M PB and
embedded in OCT compound. Frontal sections (10 m thick)
were prepared. The following procedures were carried out at
room temperature. The sections were pretreated with blocking
solution (5% normal goat serum, 0.2% bovine serum albumin,
0.1% Triton X-100, 5 mM NaN3, 0.1 M phosphate-buffered
saline) for 1 h, incubated with rabbit polyclonal anti-myogenin
antibody (1:100; Santa Cruz) for 16 h, and incubated with the
Alexa Fluor 546 secondary antibody (1:500; Molecular Probes)
in blocking solution. Fluorescence images were obtained using
an IX-71 fluorescent microscope (Olympus) and processed
with Adobe Photoshop software.
RESULTS
Our previous results indicated that at the time of expression
in developing embryos, myogenic late genes that specify the
skeletal muscle phenotype are predominantly bound by myo-
genin and Mef2D and that these factors cooperate with the
Brg1 chromatin-remodeling enzyme to alter promoter chro-
matin structure and facilitate late gene expression (11). Though
multiple studies have examined the initiation of myogenin
expression by MyoD, we recently demonstrated that both
MyoD and myogenin could bind to the myogenin promoter in
MyoD-differentiated fibroblasts 24 h post-differentiation (22).
Therefore, we asked whether myogenin was present at its own
promoter in the developing embryo after the point at which
MyoD had initiated gene expression.
ChIP analysis of tissue samples at embryonic (E) 10.5 (body
with head and internal organs removed), E12.5 (limb buds), and
E14.5 (limb muscle) revealed that myogenin binding to the
myogenin promoter could be observed at E12.5, with increased
binding at E14.5 (Fig. 1). The kinetics of myogenin binding to
FIGURE 1. Myogenin and Brg1 bind to the myogenin promoter during
embryogenesis. ChIP assays for myogenin (left) and Brg1 (right) were per-
formed at the indicated stages of embryonic development. Relative recruit-
ment was defined as the ratio of amplification of the PCR product relative to
1%of input genomic DNA. Values obtained frombrain tissuewere defined as
1. Quantification represents the average of two independent experiments.
Variation between experiments did not exceed 20% for any sample. The IgH
enhancer region, which contains an E box that does not bind MyoD, was
amplified as control for ChIP specificity.
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the myogenin promoter precisely matched those of myogenin
binding to late genes (11), suggesting that at the timemyogenin
binds to genomic sequences in developing tissue, it does not
discriminate between the previ-
ously inactive late gene loci and the
transcriptionally active myogenin
locus. Tissue culture studies indi-
cate that Brg1 is essential for the ini-
tiation of myogenin transcription
(20, 22, 26); as expected, Brg1 was
present on the myogenin promoter
at each of the embryonic stages
examined (Fig. 1).We conclude that
myogenin and Brg1 are present on
the myogenin promoter at times
when skeletal muscle tissue specifi-
cation is occurring.
Mature skeletal muscle tissue is
comprised of differentiated myofi-
bers, which are the functional com-
ponent of the tissue, and satellite
cells, which associate with individ-
ual myofibers and are capable of
dividing and either fusing with
existing myofibers or creating new
myofibers. The satellite cell popula-
tion mediates the formation and
repair of skeletal muscle tissue fol-
lowing the completion of develop-
ment (reviewed in Refs. 27, 28). We
separated satellite cells and mature
myofibers from mouse hind limb
muscles of 4- to 6-week-old mice
and then isolated nuclei from the
respective cell populations for
molecular analyses of factor binding
and chromatin accessibility. Nuclei
were immediately utilized to isolate
total RNA or were treated with
cross-linking agents for ChIP analy-
sis (Fig. 2A). Examination of marker
gene expression permitted evalua-
tion of the separation protocol. Pro-
teins such as Pax3 and Pax7 are
markers of satellite cells (29, 30),
whereas the myogenic late gene
products MCK and desmin are
markers of differentiated skeletal
muscle. The expression of these
genes was enriched in the expected
cell preparations (Fig. 2B). The satel-
lite cell population is a pool contain-
ing both quiescent cells that are not
expressing MyoD or muscle-spe-
cific markers and activated cells
that express MyoD and have initi-
ated differentiation but have not
undergone cell fusion. Thus, both
the satellite cells and the myofibers express mRNAs encod-
ing the MyoD and myogenin transcriptional regulators
(Fig. 2B).
FIGURE 2. Changes in recruitment of MRFs at themyogenin promoter in muscle satellite cells andmyo-
fibers. A, flow chart of the separation and purification of nuclei from satellite cells andmyofibers. B, transcript
levels ofmuscle satellite cell andmyofibermarkerswere analyzedby reverse transcriptase PCR.C, ChIP analysis
using nuclei obtained frommuscle satellite cells and myofibers. Binding of MyoD, myogenin, and Brg1 to the
myogenin promoter in these tissueswas quantified by quantitative PCR. The data reflect themean S.D. from
three independent experiments.
FIGURE 3. Myogenin can activate expression from the endogenous myogenin locus. A, ChIP analyses show
changes in MRF binding to the endogenous myogenin locus during MyoD-mediated differentiation of B22 fibro-
blasts, which express dominant negative Brg1 in the absence of tetracycline (Tet). ChIPs were performed with
antibodiesagainst the indicatedproteinsorwithnonspecific IgGonmock(M)orMyoD-differentiatedsamplesatthe
indicated times. The IgH enhancerwas amplified as a negative control. B, coexpression ofmyogenin andMef2D1b
inducesendogenousmyogeninexpression.B22cellsexpressing(Tet)ornotexpressing(Tet)dominantnegative
Brg1were infectedwith the indicatedretrovirusesandallowedtodifferentiate for30h.mRNAlevelswereexamined
byquantitative PCR.Myogenin levels present in theMyoD-infectedTet samplewere set at 100%.C, coexpression
of myogenin and Mef2D1b recruits Brg1 to myogenic loci. ChIP assays were performed on B22 cells as described
above.D, recruitmentof functionalBrg1results inchanges in restrictionenzymeaccessibilityat themyogenin locus.
Nucleiwereharvested fromB22cellsgrown in thepresenceorabsenceof tetracyclineandexpressing the indicated
factors were digested with PvuII. Cleavage at a PvuII recognition sequence at370 relative to the start site of
transcriptionwasmeasured by amodified ligation-mediated-PCR protocol.
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Prior work revealed thatMyoD targets Brg1 to themyogenin
promoter during the initiation of myogenesis in tissue culture
models for skeletal muscle differentiation (22, 26). ChIP analy-
sis of the myogenin promoter showed that MyoD, not myoge-
nin, bound along with Brg1 in satellite cells, suggesting that
these two factors cooperate in the initiation of myogenin
expression during adultmyogenesis (Fig. 2C). In contrast, myo-
genin was preferentially associated with its own promoter in
mature myofibers (Fig. 2C). These data indicate that myogenin
binds to its own promoter in differentiated tissue, consistent
with its appearance at times during embryogenesis when termi-
nal differentiation is occurring or has already occurred (Fig. 1).
Brg1 was also present on the myogenin promoter in myofibers,
consistent with its presence on the promoter during the later
stages of embryogenic myogenesis.
The data suggest the possibility that activation of themyoge-
nin gene is mediated by MyoD whereas maintenance of myo-
genin expression may be mediated by myogenin itself. To
mechanistically address this possibility, we utilized MyoD-dif-
ferentiated B22 cells, which are NIH3T3-derived cells that
express an ATPase-deficient, dominant negative Brg1 protein
in a tetracycline-suppressiblemanner (17). Previouswork using
this system demonstrated that MyoD-driven differentiation
faithfully recapitulated the events that occur during the activa-
tion of myogenic late genes during embryogenesis (11). We
previously reported that MyoD binding to the myogenin pro-
moter correlated with the changes in nuclease accessibility at
the myogenin locus and activation of myogenin transcription
(22).We also noted that bothMyoD andmyogenin could inter-
act with the myogenin promoter in a Brg1-dependent manner
24 h after the initiation of differentiation (22). ChIP experi-
ments over a time course of MyoD-mediated differentiation
confirmed our earlier results and further revealed that as differ-
entiation progressed beyond 24 h, MyoD binding to the pro-
moter diminished whereas myogenin binding was enhanced
(Fig. 3A). This apparent transition from MyoD binding to the
promoter at the onset of myogenin expression to myogenin
binding as the cells completed the differentiation process is
similar to the observations made regarding MyoD and myoge-
nin binding to the myogenin promoter in satellite cells and
myofibers.
The ChIP data support the idea that myogenin, in combina-
tion with Mef2 and Brg1, is activating its own transcription at
times subsequent to the initial activation of gene expression by
MyoD and Brg1. To directly test this hypothesis, we ectopically
expressedMyoD,myogenin, andMef2D1b, themuscle-specific
isoform of the Mef2D protein that is highly induced during
myogenesis in vivo (11, 31), alone or in combination, in B22
cells to determine whether the endogenous myogenin gene
could be activated. As expected, MyoD stimulated myogenin
expression in a Brg1-dependent manner (Fig. 3B). Neither
myogenin nor Mef2D1b alone could activate the myogenin
gene; however, the combination of myogenin and Mef2D1b, in
the presence of functional Brg1, could activate endogenous
FIGURE 4.SWI/SNF chromatin-remodeling activity is required formyoge-
nin expression in differentiated skeletal muscle. A, expression vectors
encoding dominant negative Brg1 and GFP were introduced directly into
mousehind limbmuscleof P2miceby in vivoelectroporation. Thin sectionsof
hind limb skeletal muscle were examined in bright field, were immuno-
stained with anti-myogenin antibody, and were monitored for GFP fluores-
cence 48 h later. B, control experiments showco-localization of GFP andmyo-
genin in the absence of dominant negative Brg1 (dnBrg1). Nuclei were
visualized by 4,6-diamidino-2-phenylindole. Tissue sections were perme-
able to 4,6-diamidino-2-phenylindole, so all nuclei in the field are visible.
Permeability issues limit the myogenin staining to nuclei at or near the sur-
face of the section.C, quantificationof the inhibitionofmyogenin expression.
The number of myogenin-positive nuclei present in GFP fluorescent myofi-
berswere counted in the control electroporation (GFP alonewithout dnBrg1)
and in samples from dnBrg1-electroporated tissue. A total of 400 myogenin-
stainednuclei from16different sections fromboth theGFPandGFPdnBrg1
samples were counted for quantification.
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myogenin expression.Our previous data demonstrated that the
combination of myogenin and Mef2D1b did not activate the
endogenous MyoD, Myf5, or Mrf4 loci in NIH3T3-based cell
lines (Refs. 11, 19 and data not shown). Thus, expression from
the endogenous myogenin locus is due solely to the activation
potential of myogenin and Mef2D1b. ChIP experiments
showed that the mechanism by which myogenin andMef2D1b
mediate myogenin expression is via recruitment of Brg1 to the
myogenin promoter (Fig. 3C). The presence of Brg1 thenmedi-
ated changes in chromatin structure at the myogenin locus,
which are reflected as increases in restriction enzyme accessi-
bility at a PvuII site upstream of the myogenin mRNA start site
(Fig. 3D). Both MyoD and the combination of myogenin and
Mef2D1b could recruit both the functional and ATPase-defi-
cient, dominant negative forms of Brg1 to the promoter, but
chromatin accessibility required functional Brg1. Thus,
whereas myogenin is not believed to initiate its own expression
in vivo, the data indicate that themyogenin protein, in conjunc-
tion with Mef2D1b, has the intrinsic ability to activate expres-
sion from the endogenous myogenin locus in the absence of
MyoD. These data and the differential binding of MyoD and
myogenin to the myogenin promoter in satellite cells andmyo-
fibers support the conclusion that myogenin and Mef2D1b are
responsible for maintaining the expression of myogenin after
the onset of myogenesis.
We further note that though the data indicate a role formyo-
genin in maintaining its own expression, a prior report has
shown that the loss of myogenin in postnatal mice does not
impact skeletal muscle formation (9). Thus, myogenin is not
required tomaintain expression from themyogenin locus nor is
it required for any skeletal muscle-specific function. These data
strongly suggest that there are redundant factors that can com-
pensate for the loss of myogenin during adult myogenesis.
The involvement of the Brg1
SWI/SNF ATPase in the initiation
of myogenesis in culture and during
embryogenesis is well established
(11, 19, 20, 22, 26). The data pre-
sented here suggest that Brg1 func-
tion is also required in differentiated
tissue, but detailed information
about the in vivo relevance of Brg1
function in myogenesis in the
mouse has been difficult to obtain
because knock out of the Brg1 locus
results in early embryonic lethality
(32). To circumvent this problem,
we adapted an in vivo electropora-
tion protocol (24) to directly deliver
plasmidDNAs encoding green fluo-
rescent protein (GFP) and a Brg1
allele containing a mutated ATP
binding site to differentiatedmuscle
tissue in the hind limb of a postnatal
day 2 (P2) mouse. This ATPase-de-
ficient protein has been character-
ized extensively and acts as a domi-
nant negative by interfering with
normal Brg1-dependent functions (17, 25). Tissue isolated 48 h
post-electroporation revealed that nuclei showingGFP fluores-
cence (Fig. 4A, white arrow) did not express myogenin protein.
Conversely, nuclei that did not take up plasmid DNA showed
no GFP fluorescence but immunostained for myogenin (yellow
arrow). Control experiments where GFP alone was electropo-
rated showed that cells expressing GFP also expressed myoge-
nin (Fig. 4B). Quantification of these results revealed that intro-
duction of dominant negative Brg1 inhibited myogenin
expression in 90% of electroporated nuclei (Fig. 4C). The
results demonstrate that functional Brg1 is required for expres-
sion of myogenin in fully differentiated skeletal muscle tissue.
Thus, Brg1 is required for both the initiation and maintenance
of myogenin gene expression in vivo.
DISCUSSION
Our earlier work demonstrated that although MyoD was
present on myogenic late gene regulatory sequences during
embryogenesis prior to activation of these genes, the predomi-
nant factors present at the time of late gene expression in the
developing tissue were myogenin and Mef2D, along with the
chromatin-remodeling enzyme Brg1 (11). We reasoned that if
myogenin were being utilized to activate late gene expression
during the time of terminal differentiation, it might also acti-
vate its own expression both at this time and following the com-
pletion of differentiation. Although there have been prior
molecular studies examining the regulation of myogenin, we
believe this is the first report to explore the relationship
between specific MRF occupancy of promoters and the timing
of differentiation in primary embryonic and adult tissue.
The data support our hypothesis. ChIP analysis in embryonic
tissue shows that myogenin binds themyogenin promoter with
the same kinetics it binds to late gene promoters. Further sup-
FIGURE 5. Schematic representation of factor interactions at the myogenin promoter during myogen-
esis.Genomic DNA is depicted as being nucleosomal. Initiation ofmyogenin transcription is dependent upon
MyoD, the Pbx homeodomain factor, and SWI/SNF chromatin-remodeling enzymes (left panel) (reviewed in
Ref. 2). Upon the expression of myogenin, myogenin, Mef2D, and Brg1 localize to the myogenin promoter
(right, top panel) tomaintainmyogenin expression. At the same time,myogenin, Mef2D, and Brg1 also localize
to and activate late gene loci, displacing the MyoD and HDAC2 present at these loci prior to late gene expres-
sion (11). The schematic representation of these molecules is for illustrative purposes; the relative size of each
molecule is not to scale.
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port was derived from ChIP studies of adult satellite cells and
myofibers, where themyogenin promoter in differentiating sat-
ellite cells was occupied by MyoD and the promoter in differ-
entiated myofibers was predominantly bound by myogenin.
This implies that when myogenin becomes competent to acti-
vate gene expression in the developing embryo or in differenti-
ating adult tissue, there are no structural features associated
with the myogenin promoter that distinguish it from the late
gene loci.
Based on these and earlier data, we propose that there is a
transition in MRF binding during the terminal differentiation
stages of embryonic and adultmyogenesis.MyoD initially binds
to both early and late myogenic genes, but activation of late
genes is repressed due to the simultaneous presence of histone
deacetylases and possibly other repressive chromatin-modify-
ing enzymes at these loci (11). Following the induction of myo-
genin and Mef2 family members by MyoD, these factors medi-
ate the transcriptional activation of late genes that specify
muscle formation and the continued transcription of early
myogenic genes such as myogenin. This model is presented
schematically in Fig. 5. Such a model is both similar to and
different from the conclusions of previous studies. Prior work
comparing the activation domains of MyoD and myogenin in
culture led to a model of sequential functions at some genes by
MyoD and then myogenin (33). However, genome-wide factor
binding studies, where analyzed regulatory sequences were
identified as targets of MyoD, myogenin, or both (34, 35), were
more recently used to conclude that the myogenic genes iden-
tified as targets of both MyoD and myogenin are cooperatively
regulated by these MRFs. Although the concept of cooperative
regulation could encompass either sequential or simultaneous
binding by MyoD and myogenin, we note that the cell culture
data shown here and previously (11) demonstrate that myoge-
nin, in the presence ofMef2D, is capable of initiating andmain-
taining its own transcription and that of the rest of the myo-
genic genes without cooperative effects by MyoD or any other
MRF. Further support for sequential functionwas recently pro-
vided by studies of the E box binding factor HEB, which can
heterodimerize withMRFs. That study demonstrated that HEB
acted synergistically withMyoD to activate transcription in cell
culture at the onset of differentiation but synergized with myo-
genin following differentiation (36).
Although the data support the idea that myogenin is the rel-
evant factor in maintaining its own expression, it is clearly not
required for this function. Early studies demonstrated that a
myogenin-lacZ transgene was expressed normally inmyogenin
null mice (37), and recent analysis of a conditional myogenin
knock-out mouse indicated that loss of myogenin after myo-
genesis affected body size but no skeletal muscle deficiencies
were observed (9). Thus, unlike during embryonic myogenesis,
functional redundancy by other factors, presumablyMRFs, can
compensate for the lack of myogenin in adult tissues.
In contrast, the SWI/SNF chromatin-remodeling enzyme is
required for continued expression of myogenin in differenti-
ated tissue. Multiple reports show the requirement for SWI/
SNF chromatin-remodeling function in culture, and the pres-
ence of SWI/SNF subunits on gene regulatory sequences in
cultured cells and primary tissue (11, 19, 20, 22, 26) and genetic
analysis of a non-enzymatic subunit, Baf60c, revealed a require-
ment for embryonic myogenesis (38). Here we provide the first
in vivo evidence that the SWI/SNF enzymes are required for
myogenic gene expression in differentiated muscle tissue. In
combination with earlier cell culture studies, we suggest that
Brg1 and SWI/SNF enzymes are required continuously
throughout every stage of adult and embryonic myogenesis.
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Appendix D 
 
MyoD Targets Chromatin Remodeling Complexes to the Myogenin 
Locus Prior to Forming a Stable DNA-Bound Complex 
  
 Transcription activation of muscle-specific genes requires the cooperation of 
muscle regulatory factors and chromatin remodeling enzymes.  Gene expression analysis 
using microarray indicated that 30% of MyoD-induced genes required the function of 
SWI/SNF enzymes.  Our contributions included the generation of mock and MyoD-
differentiated samples and confirmation of targets identified in the microarray study.  
ChIPs were performed to analyze the molecular events occurring at the myogenin 
promoter and revealed that hyperacetylation of histone H4 preceded the binding of Brg1 
in a MyoD-dependent manner.  Binding of MyoD occurred before histone H4 
modification and association of Brg1 with the promoter.  Coimmunoprecipitations 
revealed that MyoD was able to interact with the constitutively bound homedomain factor 
Pbx1, prior to all chromatin remodeling events.  This initial non-consensus binding 
permitted subsequent targeting of HATs and SWI/SNF.  We performed 
coimmunoprecipitation in mock and MyoD-differentiated smaples and determined that 
Brg1 interacts with MyoD and Mef2.  Thus a two-step mechanism exists where MyoD 
binds to constitutively bound Pbx1-Meis allowing binding of HAT and SWI/SNF, which 
facilitates chromatin remodeling at the myogenin locus, and ultimately permits direct 
binding by MyoD and other coactivators to initiate transcription.    
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The activation of muscle-specific gene expression requires the coordinated action of muscle regulatory
proteins and chromatin-remodeling enzymes. Microarray analysis performed in the presence or absence of a
dominant-negative BRG1 ATPase demonstrated that approximately one-third of MyoD-induced genes were
highly dependent on SWI/SNF enzymes. To understand the mechanism of activation, we performed chromatin
immunoprecipitations analyzing the myogenin promoter. We found that H4 hyperacetylation preceded Brg1
binding in a MyoD-dependent manner but that MyoD binding occurred subsequent to H4 modification and
Brg1 interaction. In the absence of functional SWI/SNF enzymes, muscle regulatory proteins did not bind to
the myogenin promoter, thereby providing evidence for SWI/SNF-dependent activator binding. We observed
that the homeodomain factor Pbx1, which cooperates with MyoD to stimulate myogenin expression, is consti-
tutively bound to the myogenin promoter in a SWI/SNF-independent manner, suggesting a two-step mechanism
in which MyoD initially interacts indirectly with the myogenin promoter and attracts chromatin-remodeling
enzymes, which then facilitate direct binding by MyoD and other regulatory proteins.
In eukaryotes, activation of gene expression involves the
ordered assembly of transcriptional regulators, chromatin-
modifying enzymes, RNA polymerase II, and associated gen-
eral transcription factors onto cis-acting elements that are em-
bedded in chromatin. Chromatin-remodeling enzymes play an
integral role in gene activation by perturbing chromatin struc-
ture and making specific loci permissive for transcription. Mo-
lecular analysis of multiple gene activation events suggests that
the temporal recruitment of transcription factors and chroma-
tin-remodeling enzymes is gene specific and dictated by the
interplay between specific activators and local chromatin struc-
ture (1, 52, 55).
Two classes of enzymes have been shown to remodel chro-
matinstructureeitherbycatalyzingcovalentmodificationsofhis-
tones or by hydrolyzing ATP to mobilize nucleosomes. Among
the latter class of enzymes are the SWI/SNF chromatin-remod-
eling complexes. A distinguishing feature of this family is the
presence of a bromodomain in the ATPase subunit, which
promotes interaction with acetylated histones and links the
activities of the two classes of chromatin remodelers in the
regulation of gene expression (22). SWI/SNF enzymes physi-
cally interact with histone acetyltransferases (HATs), histone
deacetylases (HDACs), and methyltransferases, showing the
potential for coordination of chromatin-remodeling activities
(reviewed in reference 53).
Mammalian SWI/SNF chromatin-remodeling enzymes are
multisubunit complexes that contain either the Brg1 or Brm
ATPase subunits and can activate or repress expression of a
subset of genes (39, 53). They function in cell cycle control, and
some of the subunits are tumor suppressors (49). Diverse SWI/
SNF complexes exist that are distinguished by the particular
ATPase, the presence of unique subunits, and tissue-specific
isoforms of common subunits (60, 61). The Brg1- and Brm-
containing complexes are similar biochemically but display dif-
ferent physiological characteristics. In mice, disruption of Brg1
is early embryonic lethal while disruption of Brm has a mild
effect on proliferation (6, 48). Moreover, the two ATPase sub-
units can be associated with different promoters (25, 38).
Mammalian SWI/SNF enzymes have been shown to facili-
tate the binding of TBP and other factors involved in polymer-
ase II (Pol II) preinitiation complex formation and to promote
transcriptional elongation both in vitro and in vivo (5, 11, 24,
33, 52, 55). Multiple models to explain targeting of SWI/SNF
enzymes to specific regulatory sequences exist: interactions
with RNA polymerase II holoenzyme (62), binding of bromo-
domains to acetylated histones (22), and recruitment by se-
quence-specific transcriptional activators (12). In yeast, inter-
action with activators is critical for SWI/SNF function (47), and
in mammalian cells, SWI/SNF components interact with nu-
merous activators, at least some of which likely target SWI/
SNF to specific promoters (8, 11, 18, 26, 30, 32, 35, 46).
During the differentiation of skeletal muscle, the myogenic
basic helix-loop-helix family of regulatory factors (MRFs) het-
erodimerize with ubiquitously present E proteins and bind to
6-bp elements called E boxes. MRFs interact with members of
the myocyte enhancer family (MEF2) of proteins, which bind a
conserved A/T-rich sequence in the regulatory regions of mus-
cle-specific genes, to synergistically activate downstream mus-
cle gene expression (42). Although each MRF can bind to the
* Corresponding author. Mailing address: University of Massachu-
setts Medical School, Department of Cell Biology, 55 Lake Avenue
North, Worcester, MA 01655. Phone: (508) 856-1029. Fax: (508) 856-
5612. E-mail: anthony.imbalzano@umassmed.edu.
† Supplemental material for this article may be found at http://mcb
.asm.org/.
‡ Equal contributors.
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E box with similar affinities, myogenin promotes myogenesis
less efficiently than Myf5 in mouse embryos and is less effective
than MyoD in activating endogenous muscle-specific genes
when introduced into fibroblasts (3, 19). MyoD-mediated gene
activation is associated with chromatin remodeling in the reg-
ulatory regions of muscle-specific genes and depends on a
cysteine-histidine-rich region and a carboxy-terminal region
(16, 19). The carboxy-terminal alpha-helical region of MyoD
that is distinct from that of myogenin specifies the ability to
initiate muscle-specific gene expression (3).
During embryogenesis and skeletal muscle regeneration, it is
the induction of MyoD and/or other MRF proteins that is
critical for commitment to the skeletal muscle lineage, such as
occurs in primary cell cultures and in activated satellite cells
(44, 58). To model events controlling myogenic differentiation
via the induction of MyoD, we have utilized the well-estab-
lished model of MyoD-induced transdifferentiation of fibro-
blast cells, first used to identify MyoD as the regulator of
myogenic differentiation (14).
We previously used this system to establish a role for SWI/
SNF chromatin-remodeling enzymes in MyoD-mediated acti-
vation of two muscle-specific genes and correlated activation of
myogenin transcription with changes in myogenin promoter
chromatin structure (16). We later extended our results to
show that several muscle-specific genes were also inhibited by
dominant-negative SWI/SNF enzymes but that cell cycle con-
trol and expression of key cell cycle regulators, such as p21,
cyclin D3, and Rb, were unaffected during muscle differentia-
tion induced by the different MRFs (17, 50).
To more specifically describe the role that SWI/SNF chro-
matin-remodeling enzymes play in muscle differentiation, we
performed a microarray analysis of cells differentiated by
MyoD in the presence or absence of dominant-negative BRG1
and found that a subset of genes activated by MyoD require
SWI/SNF enzymes. We demonstrate that MyoD induces his-
tone H4 acetylation and localization of Brg1 at the myogenin
promoter; however, stable MyoD binding to the promoter oc-
curs only after chromatin modifications. Expression of domi-
nant-negative BRG1 interferes with MyoD binding to its cog-
nate E box on the myogenin promoter but does not affect
acetylation of histone H4. This raises a paradox: interaction of
SWI/SNF and acetylation of histones at the myogenin pro-
moter require MyoD, but MyoD does not stably bind to the
promoter in the absence of functional SWI/SNF enzyme. To
address this, we demonstrate that the Pbx-1 homeodomain
factor, which cooperates with MyoD to stimulate myogenin
transcription, is constitutively bound to the myogenin pro-
moter in a SWI/SNF-independent manner. This suggests a
novel mechanism by which MyoD interacts with the promoter
indirectly via Pbx-1 and recruits chromatin-remodeling en-
zymes, which then facilitate the binding of MyoD and other
regulators. Demonstration of physical interactions between
Brg1 and MyoD and Brg1 and Pbx support this conclusion.
Models describing the role of SWI/SNF enzymes in the acti-
vation of the myogenin locus that address these and other
recently published data (54) are discussed.
MATERIALS AND METHODS
Cell culture. The B22 cell line inducibly expressing dominant-negative BRG1
(15) was infected with retrovirus expressing MyoD- or MyoD-related regulators
as previously described (14, 16, 17, 50). Briefly, this protocol involves culturing
cells for 3 days in the presence of tetracycline (dominant-negative BRG1 re-
pressed) or in the absence of tetracycline (dominant-negative BRG1 expressed)
and passaging the cells so that 24 h later the cells are at about 50% confluence.
The cells were infected with the retrovirus and incubated for 30 h. A low-serum
differentiation medium was then added to induce myogenic differentiation. The
time at which the differentiation medium was added is referred to as time zero.
Samples were collected at the times indicated (hours) for analysis. Control
samples were mock infected but still subjected to the differentiation protocol and
are labeled “M” or “mock” for mock differentiated. Since the dominant-negative
allele was derived from the human gene (28), capital letters are used throughout
this report when describing the protein produced from this allele. Endogenous
Brg1 in mouse-derived cell lines and the total amount of protein in mouse cells
expressing the dominant-negative human allele are referred to as “Brg1.”
Microarray analysis. For microarray analysis, RNA was prepared with the
RNeasy kit from QIAGEN, and cDNA was generated as described previously
(2). MyoD target genes were identified by comparing cells infected with MyoD-
producing retrovirus (n  3) to control cells (n  3). Data points identified as
unreliable by the scanner software were discarded. Data were normalized using
the Lowess algorithm in the GeneSpring 6.0 analysis package (Silicon Genetics,
Redwood City, CA). Normalized data were then transformed into log2 space. A
heterocedastic t test was performed on each gene. The false discovery rate was
estimated using Storey’s q value (57). The resulting q values were used in
conjunction with the magnitude severalfold change to identify significant genes at
the thresholds described in the text. Brg1-dependent genes were identified in a
similar fashion by comparing cells expressing a dominant-negative BRG1 (n 3)
to control cells (n  3). Estimation of false-discovery rate (q value) for the Brg1
analysis was limited to the 94 genes identified as upregulated by MyoD.
RNA analysis. For reverse transcription (RT)-PCR, RNA was isolated and
reverse transcribed as previously described (17). The cDNA was amplified with
AmpliTaq Gold (Applied Biosystems) with 200 M deoxynucleoside triphos-
phates, 1.5 mM MgCl2, and 0.1 g of each primer as described previously (17).
MyoD and myogenin were amplified for 20 cycles with previously described
primers (59). Hprt was amplified for 20 cycles with previously described primers
(17). Amplification of p21 was for 20 cycles with (5-ACACACAGAGAGAGG
GCTAGG-3) and (5-AGATCCACAGCGATATCCAGAC-3). Flag-BRG1
was amplified for 23 cycles with a primer to the BRG1 coding region (5-GTA
CAAGGACAGCAGCAGTGGA-3) and primer to the Flag coding region (5-
TTTGTCATCGTCGTCCTTGTAGTC-3). [32P]dATP incorporation was de-
tected with PhosphorImager (Molecular Dynamics), and quantification was per-
formed using ImageQuant software.
Antibodies, protein extracts, Western analysis, and immunoprecipitations
(IP). Commercial antibodies utilized were phosphatidylinositol 3-kinase (PI 3-ki-
nase) (06-496; Upstate), Pbx1 (sc-889; Santa Cruz), Mef2 (sc-313; recognizes the
Mef2A, -C, and -D isoforms; Santa Cruz), and MyoD (sc-304; Santa Cruz).
MyoD chromatin immunoprecipitation (ChIP) experiments were confirmed us-
ing an affinity-purified rabbit antibody generated against a fusion protein be-
tween glutathione S-transferase (GST) and full-length MyoD. Polyclonal rabbit
antisera raised against GST fused to a unique portion of BRG1 (15) was used for
all experiments except for the coimmunoprecipitation studies in Fig. 8D and 9A,
which utilized affinity-purified antibody isolated from rat antisera that was gen-
erated against the same GST-BRG1 fusion protein. Flag-tagged proteins were
detected using rabbit antisera against a peptide encoding the Flag epitope or M2
Flag antibody (Sigma).
Isolation of protein and Western analyses were previously described (15). For
coimmunoprecipitations in Fig. 9B, and C, cells were washed three times with
phosphate-buffered saline and lysed with hypotonic buffer (10 mM Tris-HCl, pH
7.5, 10 mM KCl, 3 mM MgCl2, 10 mM NaF, 2 mM sodium orthovanadate,
0.5 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 3 g/ml cytocha-
lasin B, 5 g/ml leupeptin, 2 g/ml pepstatin, and 2 g/ml aprotonin). Cell lysates
were incubated at 4°C for 30 min, homogenized, and centrifuged at 3,000  g for
10 min. Nuclei were then lysed with IP buffer (50 mM Tris-HCl, pH 7.5, 5 mM
MgCl2, 200 mM KCl, 0.5 mM EDTA, 1 mM dithiothreitol, 50 mM NaF, 2 mM
sodium orthovanadate, 1 mM -glycerophosphate, 0.5% NP-40, 1 mM phenyl-
methylsulfonyl fluoride, 2 g/ml pepstatin, and 2 g/ml aprotonin). Nuclear
extracts were incubated with 200 g/ml DNase I and 10 g/ml RNase A for
30 min at 26°C and then centrifuged at 15,000  g for 15 min. The supernatant
(250 l) was rocked with 2 g of antibody for 12 h at 4°C, followed by the
addition of protein A Sepharose (Amersham) and an additional incubation for
6 h. The beads were washed three times in lysis buffer and eluted with 2% sodium
dodecyl sulfate (SDS) sample buffer. The coimmunoprecipitation experiments in
Fig. 8D and 9A utilized a previously published protocol (43). The coimmuno-
3998 DE LA SERNA ET AL. MOL. CELL. BIOL.
precipitation of Flag and MyoD (data not shown) utilized a different previously
published protocol (15).
ChIPs. ChIPs were performed using the antibodies listed above as described
previously (52), except that immune complexes were eluted with 0.1 M NaHCO3
and 1% SDS, and following reversal of cross-links, the DNA was purified by
proteinase K digestion followed by phenol-chloroform extraction and ethanol
precipitation. The purified DNA was dissolved in 50 l Tris-EDTA, and 2 l was
used for PCR. For acetylated H4 ChIPs, the dissolved DNA was diluted 20-fold
before PCR. Inputs were 0.5% to 1% of chromatin before immunoprecipitation.
PCRs were performed with QIAGEN HotStart Taq master mix with 2 Ci
[-32P]dATP for 32 cycles. PCR products were run on polyacrylamide gels and
exposed to a PhosphorImager. Band intensities were quantified using the Im-
ageQuant program. Primers to the myogenin regulatory region (34), the immu-
noglobulin H (IgH) enhancer (2), and the -actin promoter (52) were described.
Primers to the p21 promoter region were 5-GTTGGTCTCCATCGGAATA
G-3 and 5-GCCACATACATCTATGAACA-3.
Restriction enzyme accessibility assay. Restriction enzyme accessibility exper-
iments were performed as described previously (16) through purification of the
digested genomic DNA. To visualize the cleaved DNA via PCR, a modified
ligation-mediated PCR protocol was used. One microgram of digested DNA was
ligated to 1 l of 100 mM adaptor as described in reference 7 using Ligation kit
version 2 (Takara). PCR amplification was performed with QIAGEN HotStart
Taq master mix under the following conditions: 94°C for 15 min, followed by 26
cycles of 94°C for 30 s and then 65°C for 60 s, followed by 72°C for 60 s. PCR
products were resolved in a 1.2% Tris-acetate-EDTA-agarose gel and stained
with Sybr Green I. Primers used were the sense primer LM-PCR1, as described
in reference 7, and the antisense primer used for myogenin ChIP (34). Quanti-
fication was performed by densitometry using NIH image 1.62 software.
RESULTS
A subset of MyoD-regulated genes are highly dependent on
the activity of the SWI/SNF complex. Our previous studies
demonstrated that SWI/SNF enzymes are necessary for MyoD
to activate muscle gene transcription but not for MyoD to
stimulate the expression of several cell cycle-regulated genes.
To broadly assess the requirement of SWI/SNF enzymes for
MyoD-mediated gene expression, we used spotted cDNA ex-
pression arrays with approximately 5,400 tiled features repre-
senting 4698 UniGene clusters (UniGene build no. 128, Sep-
tember 2003). We used NIH 3T3 murine fibroblasts that
possess a tetracycline-suppressible, dominant-negative BRG1
allele (15, 28) and compared cells transduced with MyoD to
control cells. Following 24 h in differentiation medium, MyoD
increased the expression of 94 genes and decreased that of 70
genes (q  0.10; change in expression greater than twofold)
(Tables 1 and 2; see also Table S1 in the supplemental mate-
rial). These 94 genes (represented by 96 array features) were
analyzed for their dependence on a functional Brg1-based
SWI/SNF complex. In the presence of dominant-negative
BRG1, 29 genes did not achieve full activation by MyoD, as
determined by statistical criteria (q  0.05) and a twofold or
more decrease in expression level (Table 1; see also Table S1
in the supplemental material). Some of the genes regulated by
MyoD that were not dependent on SWI/SNF activity, such as
pRb, cyclin D3, and p21 (17) (Table 2), are expressed prior to
MyoD induction, whereas others, such as the beta and gamma
subunits of the nicotinic acetylcholine receptor, are not ex-
pressed in fibroblasts and are induced by MyoD even in the
presence of dominant-negative BRG1 (Table 2). We had pre-
viously documented that MyoD could activate cell cycle-regu-
lated genes in the absence of functional SWI/SNF enzymes;
however, the ability of MyoD to induce the expression of some
previously silent loci in the absence of SWI/SNF function was
not previously recognized. Of the 70 genes repressed by MyoD,
only five were derepressed more than twofold in the presence
TABLE 1. Selected MyoD-induced genes affected twofold or more by dominant-negative BRG1
GenBank no. UniGene no. Name of gene product
Fold change
MyoD/BRG1a Dom. Neg. BRG1b
NM_009394 Mm.1716 Troponin C2, fast 307.3 	10.1
NM_011620 Mm.14546 Troponin T3, skeletal, fast 225.7 	8.4
NM_011619 Mm.247470 Troponin T2, cardiac 219.3 	2.4
NM_016754 Mm.14526 Myosin light chain, phosphorylatable, fast skeletal muscle 209.9 	5.8
X15784 Mm.16528 Myogenin 186.3 	10.7
M38129 Mm.340090 Myosin, heavy polypeptide 3, skeletal muscle, embryonic 90.7 	19.1
X15784 Mm.16528 Myogenin 83.4 	7.3
NM_009405 Mm.39469 Troponin 1, skeletal, fast 2 71.2 	7.4
AL385643 Mm.269621 Myosin binding protein H 19.8 	10.4
Al324268 Mm.2375 Creatine kinase, muscle 16.6 	8.3
M19436 Mm.247636 Myosin, light polypeptide 4, alkali; atrial, embryonic 12.9 	4.1
Al324023 Mm.1000 Myosin, light polypeptide 1, alkali; atrial, embryonic 9.6 	3.6
NM_010518 Mm.309617 Insulin-like growth factor binding protein 5 9.1 	2.0
Al324248 Mm.35134 ATPase, Ca2 transporting, cardiac muscle, fast twitch 1 8.6 	4.1
Al414541 Mm.24059 Schwannomin-interacting protein 1 6 	2.2
Al661474 Mm.7342 PDZ and LIM domain 3 4.3 	2.2
Al325234 Mm.251322 Enolase 3, beta muscle 7.4 	2.5
NM_009668 Mm.4383 Bridging integrator 1 3.8 	2.3
Al604795 Mm.220982 Dysferlin 3.3 	2.1
Al326773 Mm.39968 Histidine-rich calcium binding protein 2.9 	2.5
Al447277 Mm.295105 (PTPRF), interacting protein (liprin), alpha 4 2.9 	2.1
M12866 Mm.214950 Actin, alpha 1, skeletal muscle 2.9 	2.2
Al430815 Mm.29475 CK2-interacting protein 1 2.8 	2
Al325457 Mm.22513 Kinesin family member C3 2.8 	2.3
Al385590 Mm.275654 Glycogen synthase 3, brain 2.3 	2.8
Al326236 Mm.31646 Actin-like 6 	2.2 	2.1
a Induction of gene expression after 24 h of differentiation with MyoD in the absence of dominant-negative BRG1.
b Fold change in induction after 24 h of differentiation with MyoD when dominant-negative BRG1 is expressed.
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of dominant-negative BRG1, suggesting that SWI/SNF en-
zymes play a limited role in MyoD-mediated gene repression
(see Table S1 in the supplemental material).
Despite the fact that only a subset of MyoD-regulated genes
are highly dependent on SWI/SNF enzymes based on a sever-
alfold change and statistical criteria, the expression of most of
the MyoD-regulated genes was reduced in the absence of an
active SWI/SNF complex. Graphing the log of the ratio of gene
expression in the presence or absence of dominant-negative
BRG1 revealed a distribution centered on zero for all the
genes in the array (median ratio in log2 space is 	0.02) (Fig.
1A), indicating that SWI/SNF activity does not globally alter
gene expression. In contrast, limiting the analysis to the 94
genes regulated by MyoD shifted the center of the distribution
below zero (median ratio in log2 space is 	0.56), indicat-
ing that MyoD-regulated genes require SWI/SNF activity to
achieve their full level of expression more than the typical gene
spotted on the array (Fig. 1B). This is not solely due to the
contribution of the highly SWI/SNF-dependent MyoD targets,
because limiting the analysis to the MyoD target genes that
were not identified as Brg1 dependent by the statistical criteria
also provides a skewed histogram, with a median ratio of
	0.23, as opposed to the median near 0 for all genes (Fig. 1B,
double-headed arrow). The subset of genes that is highly de-
pendent on SWI/SNF for MyoD activation is represented in
the asymmetric tail of genes with negative ratios (29 genes
demonstrate more than a twofold decrease in expression in the
presence of dominant-negative BRG1; see Fig. 1B, unfilled
bars). Therefore, the array data reveal a modest global depen-
dence of MyoD-regulated genes on SWI/SNF enzymes and a
more profound dependence for approximately one-third of the
MyoD-regulated genes tested.
To better document the role of SWI/SNF enzymes during
the induction of the subset of muscle marker genes that are
highly dependent on these chromatin remodelers for MyoD-
mediated gene activation, we elected to focus on the myogenin
gene. Previously, we demonstrated that myogenin activation by
MyoD or other members of the MyoD family of muscle regu-
TABLE 2. Selected MyoD-induced genes affected twofold or less by dominant-negative BRG1
GenBank no. UniGene no. Name of gene product
Fold change
MyoD/BRG1a Dom. Neg. BRG1b
NM_010866 Mm.1526 Myogenic differentiation 1c 42.7 1.1
M30514 Mm.2810 Cholinergic receptor, nicotinic, gamma polypeptide 19.6 	1
Al427434 Mm.256342 Kinesin family member 5C 12.3 1.8
Al385656 Mm.4583 Cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) 10 	1.9
M14537 Mm.86425 Cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) 8.6 	1.2
NM_013597.2 Mm.132788 Myocyte enhancer factor 2A 7.5 	1.7
Al323806 Mm.195663 Cyclin-dependent kinase inhibitor 1A (p21) 7.2 	1.5
Al894122 Mm.4261 Kangai 1 (suppression of tumorigenicity 6, prostate) 7.1 	1.2
Al326893 Mm.280029 Hairy and enhancer of split 6 (Drosophila) 5.5 1.0
Al323835 Mm.273862 Purinergic receptor (family A, group 5) 4.9 	1.0
NM_009029 Mm.273862 Purinergic receptor (family A, group 5) 4.8 	1.2
Al324186 Mm.297976 Glypican 1 4.7 	1.4
NM_011817 Mm.281298 Growth arrest and DNA-damage-inducible 45 gamma 4.2 1.1
Al451932 Mm.4081 Runt-related transcription factor 1 4.0 	1.8
Al450263 Mm.333762 Lectin, galactose binding, soluble 4 3.8 1.3
Al415710 Mm.25559 Serine/threonine kinase 17b (apoptosis-inducing) 3.5 	1.9
Al426448 Mm.28683 Transferrin receptor 3.4 	1.5
Al528676 Mm.347398 B-cell leukemia/lymphoma 6 3.1 	1.8
NM_011484 Mm.273174 Signal transducing adaptor molecule (SH3 domain and ITAM motif) 2.9 	1.2
Al428484 Mm.30841 Calcium channel, voltage-dependent, alpha2/delta subunit 1 2.9 	1.2
NM_007483 Mm.687 ras homolog gene family, member B 2.9 	1.6
NM_010722 Mm.7362 Lamin B2 2.8 1.2
Al326964 Mm.3862 Insulin-like growth factor 2 2.8 	1.9
Al450264 Mm.180750 Prion protein dublet 2.8 	1.7
AB025099 Mm.30262 Kruppel-like factor 5 2.8 	1.5
Al326148 Mm.289832 Proteasome (prosome, macropain) 26S subunit, ATPase 3 2.7 	1.3
Al429452 Mm.280805 Huntingtin-interacting protein 1 2.6 1.1
Al451071 Mm.25594 Protein kinase, cAMP dependent regulatory, type II beta 2.5 1.3
Al425917 Mm.29495 CUG triplet repeat, RNA binding protein 1 2.5 	1.0
Al326978 Mm.280103 ATPase, Na/K transporting, alpha 1 polypeptide 2.5 	1.2
Al573376 Mm.22673 Fc receptor, IgE, high-effinity I, gamma polypeptide 2.5 	1.3
Al414367 Mm.65906 Pre-B-cell leukemia transcription factor-interacting protein 1 2.5 1.2
Al447937 Mm.12863 Heparan sulfate 2-O-sulfotransferase 1 2.5 	1.2
Al324262 Mm.294083 Annexin A11 2.5 	1.4
Al449015 Mm.206218 Histone deacetylase 11 2.4 1.0
Al324952 Mm.289131 3-Hydroxy-3-methylglutaryl-coenzyme A synthase 2 2.4 	1.1
Al323871 Mm.246520 Cyclin D3 2.3 	1.1
Al894225 Mm.19016 Drebrin 1 2.3 	1.1
Al449069 Mm.6529 Dystrophia myotonica kinase, B15 2.3 	1.3
U22445 Mm.177194 Thymoma viral proto-oncogene 2 2.2 	1.5
Al428800 Mm.206779 Cytoplasmic polyadenylation element binding protein 3 2.2 	1.3
Al325922 Mm.276826 Cofilin 2, muscle 2.2 1.3
a Induction of gene expression after 24 h of differentiation with MyoD in the absence of dominant-negative BRG1.
b Fold change in induction after 24 h of differentiation with MyoD when dominant-negative BRG1 is expressed.
c Exogenously expressed from retroviral vector.
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latory proteins failed in the presence of dominant-negative
SWI/SNF enzymes and showed that SWI/SNF-dependent myo-
genin activation correlated with a SWI/SNF-dependent in-
crease in promoter accessibility at the endogenous myogenin
locus (16, 17, 50). We therefore sought to build on this base of
knowledge by temporally examining the interplay of SWI/SNF
enzymes and myogenic transcription factors during myogenin
activation.
Kinetics of myogenin activation during MyoD-mediated dif-
ferentiation. We first performed a temporal analysis of gene
expression. We infected cells with a MyoD-expressing retrovi-
rus for 30 h, induced differentiation by adding a low-serum
differentiation medium at time zero, and took samples for
analysis at the indicated time points. RT-PCR analysis showed
that MyoD was expressed 8 h before the addition of differen-
tiation medium and remained constant throughout differenti-
ation in the presence and absence of tetracycline (Fig. 2A). A
slight increase in the amount of myogenin mRNA was appar-
ent in the hours following addition of the differentiation me-
dium, with a significant increase in mRNA levels after 8 h of
differentiation. Myogenin expression was inhibited by domi-
nant-negative BRG1 at all time points (Fig. 2A and B). Induc-
tion of p21 cyclin-dependent kinase inhibitor occurred 4 h after
differentiation and continued to increase but was less than two-
fold affected by dominant-negative BRG1, in agreement with
previous work (17, 50) and with the microarray results (Table 2).
The levels of Brg1 and Brm as well as the levels of Flag-
tagged dominant-negative BRG1 remained constant during
MyoD-mediated differentiation (Fig. 2C). Interestingly, overall
expression of Brg1 did not change when dominant-negative
BRG1 was present, demonstrating that induction of dominant-
negative BRG1 did not result in overexpression of total Brg1.
FIG. 1. (A) Histogram of the expression ratio in cells expressing
dominant-negative BRG1 (BRG1	) to nonexpressing cells (BRG1)
for the 4,282 array features that reported reliable data. The median
value in log2 space is 	0.02. (B) Histogram of the BRG1	/BRG1
expression ratio for the 94 genes upregulated by MyoD. Hollow boxes
indicate the 29 genes identified as strongly BRG1 dependent at the
twofold change (q  0.05) threshold. The single-headed arrow indi-
cates the median ratio for all 94 MyoD-dependent genes (	0.56). The
double-headed arrow indicates the median for the 65 genes not iden-
tified as strongly BRG1 dependent (	0.23).
FIG. 2. (A) Time course of myogenin, p21, and ectopic MyoD
expression during differentiation. Cells expressing or not expressing
dominant-negative flag-tagged BRG1 were infected with retrovirus
containing MyoD. Thirty hours later, differentiation was initiated by
replacement of the medium with a low-serum differentiation medium
(time zero). mRNA levels of each gene were examined at the indicated
time points by RT-PCR. The 	8 time point is 8 h prior to addition of
differentiation medium. A titration of twofold dilutions of cDNA
shows the linearity of the PCRs. The 36-h time point, plus-tetracycline
(Tet) sample, was used for all titrations except for Flag-tagged domi-
nant-negative BRG1, which was amplified with the 36-h, minus-tetra-
cycline sample. (B) Quantification of mRNA levels observed in panel
A. Fold induction was defined as the ratio of myogenin or p21 levels in
a given sample relative to the levels of Hprt in the same sample and
standardized to the 	8-h time point. (C) Time course of dominant-
negative BRG1, total Brg1, and Brm protein levels during differenti-
ation. A Western blot was performed with protein extracts isolated at
the indicated time points. “Mock” refers to the samples that were not
infected with the MyoD-encoding retrovirus but were instead mock
infected, subjected to the same differentiation protocol, and harvested
24 h after the addition of differentiation medium.
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This effectively eliminates the possibility that expression of
dominant-negative BRG1 results in nonspecific effects on tran-
scription and promoter localization due to overexpression. It
also suggests that a compensating mechanism exists for regu-
lating Brg1 levels in cells. Tight regulation and compensation
for levels of the SWI/SNF enzyme subunits Brm, Baf57, and
Ini1 have previously been demonstrated (9, 20, 48).
We then examined changes in nuclease accessibility at the
endogenous myogenin promoter. Previously, we reported a dif-
ferentiation-dependent increase in restriction enzyme accessi-
bility at a PvuII site 370 bp upstream of the transcription ini-
tiation site and showed that the change in accessibility required
SWI/SNF chromatin remodeling activity (16). We monitored
the change in accessibility at this site as a function of time of dif-
ferentiation, using a modified protocol in which a linker DNA
was ligated to the purified, digested genomic DNA fragments
followed by PCR amplification to permit visualization of the
cleaved DNA (see Materials and Methods). We observed a
small but noticeable increase in accessibility at 4 h postdiffer-
entiation and a continued increase in accessibility as differen-
tiation proceeded (Fig. 3). Thus, the change in promoter acces-
sibility precedes the onset of myogenin mRNA accumulation.
Histone acetylation and recruitment of SWI/SNF to muscle-
specific promoters occurs in response to MyoD-mediated dif-
ferentiation. We previously showed that chromatin remodeling
is inhibited by dominant-negative BRG1 in MyoD-differenti-
ated cells (16). Upon differentiation, hyperacetylation of his-
tones surrounding the MyoD and Mef2 binding sites of several
muscle-specific genes has been reported (34, 37). To determine
whether dominant-negative BRG1 inhibits acetylation of his-
tone H4, we differentiated cells with MyoD in the presence or
absence of tetracycline, cultured the cells in differentiation
media for 36 h, and then performed ChIP analysis. Figure 4
shows that muscle differentiation resulted in histone H4 hy-
peracetylation at the myogenin promoter and that H4 hyper-
acetylation was not inhibited by dominant-negative BRG1 in
cells differentiated in the absence of tetracycline. This indicates
that hyperacetylation of histone H4 occurs independently of
SWI/SNF chromatin remodeling. We also looked at the acet-
ylation status of the p21 promoter, because p21 expression is
up-regulated during muscle differentiation but is not depen-
dent on functional SWI/SNF chromatin-remodeling enzymes
(17). We found a high level of histone acetylation at the p21
promoter in both mock-differentiated and differentiated cells
compared to results with the silent IgH enhancer (Fig. 4B and
C). This substantiates our previous conjecture that in fibro-
blasts, the promoters of genes that are constitutively expressed
at low levels or that are regulated in a cell cycle-dependent
manner may not require extensive chromatin remodeling.
To show that Brg1 is directly acting at these regulatory re-
gions, we performed ChIP analysis with a BRG1 antibody and
an antibody to the Flag epitope to detect epitope-tagged dom-
inant-negative BRG1. We found that Brg1 was recruited to the
myogenin promoter upon differentiation in the presence and
absence of tetracycline and that Flag-tagged dominant-nega-
tive BRG1 could also be localized to these regions in differ-
entiated cells (Fig. 4B and C). Surprisingly, although p21 up-
regulation during muscle differentiation is not appreciably
affected by dominant-negative BRG1 (17, 50) (Fig. 2A and B
and Table 2), Brg1 was localized to the promoter region both
in mock-differentiated and differentiated cells (Fig. 4B). SWI/
SNF enzymes have been reported to play a direct role in the
regulation of p21 transcription in other cell types that are
actively proliferating; therefore, the requirement for SWI/SNF
enzymes may be cell type or cell cycle stage specific (23, 27). In
fibroblasts, the local chromatin structure on the p21 promoter
may not require extensive chromatin remodeling by SWI/SNF
enzymes during muscle differentiation and/or there may be
redundant mechanisms for achieving remodeling. Thus, SWI/
SNF enzymes likely contribute to p21 expression but are not
required as they are for many of the muscle-specific genes.
MRF and Mef2 association with muscle-specific promoters
at an endpoint of muscle differentiation is inhibited by domi-
nant-negative BRG1. It is generally thought that transcrip-
FIG. 3. Restriction enzyme accessibility increases at the endoge-
nous myogenin promoter as a function of MyoD-induced differentia-
tion and requires functional Brg1 based-SWI/SNF enzymes. Nuclei
were isolated from cells that were differentiated in the presence or
absence of tetracycline at the indicated time points or from cells that
were mock differentiated (M) in the presence or absence of tetracy-
cline. The mock-differentiated cells were not infected with the MyoD-
encoding retrovirus but were subjected to the differentiation protocol
for 32 h. (A) A modified LM-PCR protocol (see Materials and Meth-
ods) was utilized to visualize cleaved genomic DNA isolated from
nuclei digested with PvuII, which cleaves the myogenin promoter at
	370 relative to the start site of transcription. The PCR product was
visualized by Sybr Green I staining, and an inverse image is shown. To
monitor the input DNA, 10% of the amount of purified, cleaved DNA
that was used for ligation-mediated PCR was used to amplify the
sequences between 	143 and 	5 of the myogenin promoter, which
contain no PvuII site. (B) Quantification of the change in nuclease
accessibility at the myogenin promoter. The relative values for each
time point were normalized to input and graphed relative to the value
obtained for cleavage in the mock-differentiated, plus-tetracycline
[Tet()] sample, which was arbitrarily set at 1.0. Each value is the
mean 
 standard deviation from three independent experiments.
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tional regulators play a critical role in targeting of chromatin-
remodeling complexes to specific promoters. Both MyoD and
Mef2 have been shown to interact with HATs and/or HDACs
(41). We therefore conducted ChIP analysis of cells following
differentiation in the presence or absence of dominant-nega-
tive BRG1 using antibodies to MyoD, myogenin, and Mef2 to
localize these proteins on the myogenin promoter. Figure 5A
and B shows that MyoD, myogenin, and Mef2 were associated
with the myogenin promoter in differentiated cells with wild-
type Brg1 activity; however, there was marked inhibition of
binding by all three proteins when dominant-negative BRG1
was expressed. No binding of MyoD, myogenin, or Mef2 was
observed on the -actin promoter or the inactive IgH en-
hancer, which contains a consensus E box. Since MyoD and
myogenin are structurally similar, we infected separate NIH
3T3 cell cultures with retroviruses encoding one of each of the
MyoD family of myogenic regulators (50) to demonstrate that
the MyoD and myogenin antibodies do not cross-react (Fig.
5C). This indicates that both MyoD and myogenin can occupy
the myogenin promoter.
We have previously shown that ectopic expression of MyoD
is not affected by dominant-negative BRG1 (16) (Fig. 1; see
also Fig. 8A), while endogenous myogenin induction is pro-
foundly inhibited and Mef2 induction is inhibited to a lesser
extent (16, 17) (Fig. 2A and B; see also Fig. 9). Thus, the ob-
served inhibition of myogenin and Mef2 binding in the pres-
ence of dominant-negative BRG1 is at least in part due to
reduced levels of these proteins. However, this is not the case
FIG. 4. Brg1 and hyperacetylated H4 are associated with the myo-
genin promoter. (A) A schematic diagram indicating the regions of the
myogenin and p21 promoters and the IgH enhancer that were ampli-
fied. Arrows indicate the location and direction of primers used for
amplification. The approximate locations of transcription factor bind-
ing sites are indicated. (B) Chromatin immunoprecipitations were per-
formed with antisera against BRG1, Flag, or tetra-acetylated histone
H4 (AcH4) or with no antibody (No Ab) on mock-differentiated (	) or
MyoD-differentiated () samples that had been cultured in the pres-
ence or absence of tetracycline (tet) and that were harvested for
analysis 36 h after the onset of differentiation. PCR amplification of
1% of the input DNA is shown on the left. A twofold titration of input
DNA using the undifferentiated, plus-tetracycline sample was per-
formed (far right) to show that the PCR was in the linear range. (C and
D) Quantification of the levels of hyperacetylated H4, Brg1, and Flag-
tagged dominant-negative BRG1 present on the myogenin and p21
promoters by ChIP analysis. Band intensities in each lane were nor-
malized to input. Induction relative to the plus-tetracycline, mock-
differentiated sample is shown for hyperacetylated H4 and Brg1. In-
duction relative to the minus-tetracycline, mock-differentiated sample
is shown for Flag-tagged dominant-negative BRG1. The data reflect
the means 
 standard deviations from three to four independent
experiments, except for the levels of Brg1 and Flag-tagged dominant-
negative Brg1 on the p21 promoter, which reflect the average values
from two independent experiments.
FIG. 5. Binding of muscle regulatory proteins to the myogenin
promoter is inhibited by dominant-negative BRG1. (A) Chromatin
immunoprecipitations were performed with antisera against MyoD,
myogenin, or Mef2 or with no antibody (No Ab) on MyoD-differen-
tiated samples that had been cultured in the presence or absence of
tetracycline (tet) and that were harvested for analysis 36 h after the
onset of differentiation. PCR amplification of 0.5% of the input DNA
is shown on the left. A twofold titration of input DNA using the
undifferentiated, plus-tetracycline sample was performed (far right) to
show that the PCR was in the linear range. (B) Quantification of the
level of MyoD, myogenin, or Mef2 present on the myogenin promoter
by ChIP analysis. Band intensities in each lane were normalized to
input. The decrease in promoter association due to the expression of
dominant-negative BRG1 is expressed relative to the differentiated,
plus-tetracycline sample, which was set at 1.0. The data reflect the
mean 
 standard deviation from three independent experiments.
(C) MyoD and myogenin antisera do not cross-react. Protein extracts
from C2C12 myotubes or NIH 3T3 cells infected with MyoD, myoge-
nin-, MRF4-, or Myf5-containing retrovirus or the empty retroviral
vector (pBABE) were run on an SDS-polyacrylamide gel, blotted, and
probed with either anti-MyoD or antimyogenin antiserum.
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for the inhibition of MyoD binding caused by dominant-neg-
ative BRG1. The inhibition of MyoD association with the myo-
genin promoter suggests that SWI/SNF enzyme function is
required to form a stable DNA binding complex within chro-
matin and does not support the idea that MyoD stably bound
to chromatin directly targets Brg1-containing SWI/SNF en-
zymes to muscle-specific promoters.
Activation of p21 expression is critical for muscle differen-
tiation and is promoted by MyoD (21, 45, 63). Although there
are potential E boxes in the upstream region of p21, we did not
detect significant levels of MyoD, myogenin, or Mef2 binding
on the endogenous p21 upstream region at the end of the
differentiation protocol by ChIP analysis (Fig. 5A), suggesting
that MyoD activates p21 expression by an indirect mechanism
and/or that our ChIP experiments do not detect an indirect
association of MyoD with the p21 promoter through protein-
protein interactions as previously was demonstrated for MyoD
and CREB on the Rb promoter (36).
Kinetics of myogenin promoter interactions during MyoD-
mediated differentiation. To determine how promoter interac-
tions might influence the timing of myogenin expression, we
performed ChIPs over the time course of differentiation (Fig.
6A). We found that Brg1 was recruited to the promoter 6 h
before addition of differentiation medium and remained pres-
ent throughout differentiation. Dominant-negative BRG1 was
also present on the myogenin promoter, as seen by the ChIPs
of Flag-tagged dominant-negative BRG1. Likewise, histone
H4 on the myogenin promoter was hyperacetylated by 6 h prior
to differentiation and was unaffected by dominant-negative
BRG1. This indicates that chromatin-remodeling enzymes are
associated with the myogenin promoter prior to significant
gene expression and suggests that additional chromatin mod-
ifications may occur before activation of transcription. On the
p21 promoter, recruitment of Brg1 and acetylation of histone
H4 did not change significantly as a function of muscle differ-
entiation, and neither was affected by expression of dominant-
FIG. 6. Brg1 and acetylated H4 associate with the myogenin promoter prior to stable binding of MyoD and Mef2. Shown is a time course of
histone H4 acetylation, total Brg1, dominant-negative BRG1, MyoD, and Mef2 association with (A) the myogenin promoter, (B) the p21 promoter,
and (C) the IgH enhancer as measured by ChIP during a time course of differentiation induced by MyoD in the presence or absence of tetracycline
(tet). M indicates samples that were mock differentiated for 24 h. “No Ab” indicates ChIP reactions performed in the absence of antibody. Linearity
of the PCRs was demonstrated by twofold titrations of input DNA using the mock-differentiated, plus-tetracycline sample. PCR amplification of
1% of the input DNA is shown. (D and E) Quantification of the levels of acetylated H4, Brg1, MyoD, or Mef2 present on the myogenin promoter
(D) or on the p21 promoter (E) by ChIP analysis. Band intensities in each lane were normalized to input. Induction relative to the plus-tetracycline,
mock-differentiated sample is shown. The data reflect the average value from two independent experiments.
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negative BRG1 (Fig. 6B). Neither Brg1 nor hyperacetylated
H4 was present on the inactive IgH enhancer (Fig. 6C).
ChIPs with the MyoD antibody showed that MyoD was
bound at 8, 12, and 24 h after the addition of differentiation
medium but not if the cells were differentiated in the presence
of dominant-negative BRG1. Stable association of MyoD with
the myogenin promoter was dependent on functional SWI/
SNF enzymes and occurred just prior to the significant increase
in myogenin gene expression after 8 h postdifferentiation (Fig.
2A and B and 6A). These results were confirmed with a dif-
ferent antibody against MyoD (data not shown). ChIP exper-
iments to detect Mef2 binding on the promoter generated
similar results (Fig. 6A). In contrast, amplification of the p21
promoter or IgH enhancer showed no or minimal interaction
of MyoD with these sequences (Fig. 6B and C).
These results indicate that histone hyperacetylation and re-
cruitment of Brg1 occur early during the differentiation pro-
cess and well prior to stable binding of MyoD to the myogenin
promoter. Bromodomains of chromatin-remodeling enzymes
display high affinity for acetylated histones, and histone acet-
ylation can facilitate the recruitment of SWI/SNF enzymes
(22). To determine whether histone acetylation occurs prior to
the recruitment of Brg1 to the myogenin promoter, we con-
ducted ChIPs at earlier time points. Figure 7A shows that
histone H4 hyperacetylation could first be detected 12 h after
infection with the MyoD retrovirus or 18 h before addition of
the differentiation medium at time zero, whereas recruitment
of Brg1 occurred 19 h after retroviral infection or 11 h before
addition of differentiation media. These results demonstrate
that histone H4 acetylation coincides with the appearance of
detectable levels of MyoD protein (Fig. 7B and C) and pre-
cedes the recruitment of Brg1, suggesting that histone acety-
lation facilitates the interaction of SWI/SNF complexes with
the myogenin promoter. Thus, during MyoD-directed differ-
entiation, the myogenin promoter becomes hyperacetylated on
H4 prior to Brg1 recruitment. Although these initial events
depend on MyoD, they precede stable binding of MyoD to the
promoter in a SWI/SNF-dependent manner, raising the ques-
tion of how the chromatin-remodeling enzymes become spe-
cifically localized to the promoter.
Pbx1 is constitutively associated with the myogenin pro-
moter and participates in the recruitment of chromatin-re-
modeling complexes. Recent studies suggest that MyoD is re-
cruited to the myogenin promoter through interaction of its
cysteine/histidine and helix 3 regions with a homeodomain
protein complex containing Pbx and Meis that is constitutively
bound to the myogenin promoter (4). If targeting of chroma-
tin-remodeling enzymes occurs via the Pbx-Meis site, one
would predict that factor binding to this site would be inde-
pendent of chromatin-remodeling activities. To address this
question, we performed ChIPs with an antibody against Pbx1
during a time course of differentiation in the presence or ab-
sence of dominant-negative BRG1. Western analyses showed
that Pbx1 levels did not change during MyoD-mediated muscle
differentiation and were not affected by dominant-negative
BRG1 (Fig. 8A). Figure 8B and C shows that, as previously
reported, Pbx1 was constitutively associated with the myogenin
promoter (4). Significantly, association of Pbx1 was not affect-
ed by dominant-negative BRG1; thus, Pbx1 potentially plays a
role in the recruitment of Brg1 and other chromatin-remodel-
ing activities to the myogenin promoter, perhaps via a direct
interaction or via indirect recruitment through MyoD bound to
the Pbx/Meis complex.
The previously published studies indicate that MyoD and
Pbx1 interact at the myogenin promoter both in vivo and in
vitro (4, 29). We therefore tested whether endogenous Brg1
and endogenous Pbx1 can physically interact before the onset
of stable MyoD binding and the initiation of myogenin tran-
scription. Figure 8D demonstrates that Brg1 from nuclear ex-
tracts prepared from differentiated cells coimmunoprecipi-
tated with Pbx1 at the onset of differentiation and at 4 h
postdifferentiation. The interaction was not observed in mock-
differentiated cells and was not appreciably affected by the
expression of dominant-negative BRG1 in the cells, indicating
that the mutant BRG1 molecule also likely interacts with Pbx1.
The results reveal that a specific Brg1-Pbx1 interaction occurs
in the presence of MyoD, thereby supporting the idea that
SWI/SNF enzymes are targeted by a MyoD-Pbx1 complex that
is present on the promoter prior to the stable interaction of
MyoD with the chromatin.
FIG. 7. (A) Histone H4 hyperacetylation precedes the binding of
Brg1 at the myogenin promoter. Shown is a time course of histone H4
hyperacetylation and Brg1 association with the myogenin promoter.
Cells were grown in the presence or absence of tetracycline (Tet),
infected or not with MyoD-encoding retrovirus, and harvested for
ChIP at the indicated times prior to the addition of differentiation
medium. Time points are also indicated as hours following retroviral
infection. Association with the IgH enhancer is presented as a control.
One percent of the input is shown. (B) Western analysis of MyoD and
Mef2 protein present at the indicated times prior to addition of dif-
ferentiation medium. Anti-Flag antiserum was used to document the
presence of the Flag-tagged dominant-negative BRG1. PI 3-kinase
(PI3K) is shown as a loading control. (C) Quantification of the levels
of acetylated H4 and Brg1 present on the myogenin promoter by ChIP
analysis. Band intensities in each lane were normalized to input. In-
duction of levels of association is presented relative to the plus-tetra-
cycline, mock-differentiated sample. The data reflect the average value
from two independent experiments.
VOL. 25, 2005 SWI/SNF ENZYMES FACILITATE MyoD BINDING 4005
Brg1 interacts with MyoD and Mef2 in differentiated cells.
To further examine mechanisms for recruitment of SWI/SNF
enzymes to the myogenin promoter, we investigated whether
endogenous Brg1 could stably associate with MyoD and/or
Mef2 in differentiating cells. Pulldown of Brg1 from differen-
tiated cell nuclear extracts demonstrated that MyoD and Brg1
could be coimmunoprecipitated at the onset of differentiated
as well as at later times and that MyoD was capable of inter-
acting with the dominant-negative Brg1 protein as well (Fig.
9A). As an independent confirmation of this interaction, an
antibody against the Flag epitope that marks the dominant-
negative BRG1 was used for immunoprecipitation to show that
the mutant BRG1 interacted with MyoD (data not shown).
Others have also demonstrated that MyoD and Brg1 can be co-
immunoprecipitated from extracts of differentiating cells (54).
Finally, we demonstrate that an antibody against BRG1 can
coimmunoprecipitate Mef2 from MyoD-differentiated cells
(Fig. 9B), while the converse experiment showed that an anti-
body against Mef2 could coimmunoprecipitate Brg1 (Fig. 9C).
An interaction between Mef2 and Brg1 was also detected in
the absence of tetracycline when dominant-negative BRG1 was
expressed. The lighter band likely results from the inhibitory
effect that dominant-negative BRG1 has on Mef2 expression
(see input in Mef2 Western, Fig. 9B). Previously, we reported
that expression of dominant-negative SWI/SNF complexes in-
hibited the expression of Mef2C RNA (17). These results dem-
onstrate that endogenous SWI/SNF enzymes can associate
with endogenous Mef2 in MyoD-differentiated cells.
Taken together, the results indicate that endogenous Brg1
interacts with both Pbx1 and MyoD at the onset of differenti-
ation and with MyoD and Mef2 later during differentiation.
The physical interactions between Brg1 and Pbx1 and between
Brg1 and MyoD support the idea that MyoD is initially tar-
geted to the myogenin promoter via the constitutively bound
Pbx1. Because MyoD and Mef2 have been shown to physically
and functionally interact (42), these data also suggest that
FIG. 8. Pbx1 mediates targeting of Brg1 to the myogenin promoter.
(A) Pbx1 protein levels are unaffected by differentiation (Diff.) or by
the expression of dominant-negative BRG1. Protein extracts from
mock-differentiated cells (	) or cells differentiated with MyoD () in
the presence or absence of tetracycline were run on an SDS-polyacryl-
amide gel and probed with Pbx1, MyoD, or PI 3-kinase antibodies. (B)
Pbx1 association with the myogenin promoter, the p21 promoter, and
the IgH enhancer as measured by ChIP during a time course of dif-
ferentiation induced by MyoD. M indicates samples that were mock
differentiated for 24 h. The linearity of the PCRs was demonstrated by
a twofold titration of input DNAs using the mock-differentiated, plus-
tetracycline (tet) sample. PCR amplification of 1% of the input DNA
is shown. (C) Quantification of Pbx1 association with the myogenin
promoter. Band intensities in each lane were normalized to input.
Induction relative to the plus-tetracycline, mock-differentiated sample
is shown. The data reflect the average of values from two independent
experiments. (D) Endogenous Pbx1 and Brg1 coimmunoprecipitate
from MyoD-differentiated but not mock-differentiated cells. Nuclear
extracts from mock (	) or MyoD-differentiated () cells were immu-
noprecipitated with Brg1 antibody or purified IgG as indicated, and the
immunoprecipitated material was run on an SDS-polyacrylamide gel,
transferred to a membrane, and probed for the presence of Pbx1 and
Brg1. The levels of Pbx1 and Brg1 present in 10% of the input for each
sample are shown.
FIG. 9. Brg1 interacts with MyoD and Mef2 in differentiating cells.
Extracts were prepared from mock-differentiated cells or cells differ-
entiated with MyoD in the presence or absence of tetracycline. (A) Im-
munoprecipitation from nuclear extracts from cells that were mock
differentiated (M) or MyoD differentiated was performed using puri-
fied IgG or antibody against Brg1 at the times indicated. Samples were
run on an SDS-polyacrylamide gel and transferred to a membrane for
Western blotting with MyoD and Brg1 antibodies. Ten percent of the
input for each sample is shown. The samples shown in Fig. 8D and 9A
were from the same time course; the Brg1 input and Brg1 IP bands for
the mock and 0-h time point are the same data that were presented in
Fig. 8D. (B and C) Nuclear extracts were immunoprecipitated from
cells mock (	) or MyoD () differentiated in the presence or absence
of tetracycline for 36 h using purified IgG or antibody against Brg1 or
Mef2 and probed for the presence of Mef2 or Brg1. Confirmation of
Mef2 immunoprecipitation by the Mef2 antibody could not be ob-
tained because the Mef2 band was obscured by the antibody heavy
chains.
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Brg1-based SWI/SNF enzymes may be part of a higher-order
complex containing both MyoD and Mef2 during the activa-
tion of muscle-specific genes. The data suggest that Brg1-based
SWI/SNF enzymes are associated with the myogenin promoter
throughout the differentiation process via protein-protein in-
teractions with several regulatory factors.
DISCUSSION
Stable recruitment of MyoD and Mef2 transcriptional acti-
vators requires functional SWI/SNF enzymes. We found that
Brg1 was localized to the myogenin promoter during differen-
tiation. Stable association of muscle-specific activators with
the myogenin promoter was inhibited by dominant-negative
BRG1, indicating that functional SWI/SNF enzymes are nec-
essary for activator binding. Although in vitro studies using
reconstituted templates and purified factors long ago demon-
strated that SWI/SNF enzymes have the potential to facilitate
activator binding to chromatin (13, 31, 60), there is only one
other direct example of this occurring in mammalian cells. Ma
et al. recently demonstrated that ectopic expression of BRG1
in BRG1-deficient cells stimulated MMP2 transcription and
increased the binding of Sp1 and AP2 to the MMP2 promoter
(35). Temporal analysis of protein binding events at other
mammalian promoters and enhancers has revealed that the
order is gene specific and that SWI/SNF chromatin-remodel-
ing enzymes are generally recruited during the later stages of
the activation process (1, 40, 52, 55, 56). For example, induc-
tion of the beta interferon gene by viral infection results in
ordered binding of an enhancesome complex to a nucleosome-
free region, recruitment of the GCN5 histone acetyltrans-
ferase, association of the Pol II/CBP complex, and subsequent
recruitment of SWI/SNF enzymes. Chromatin remodeling by
SWI/SNF enzymes promotes association of TBP with the
TATA box and transcription initiation (1, 33). During entero-
cyte differentiation, activation of 1 antitrypsin transcription
starts with association of the activator, HNF-1, TBP, and
TFIIB with the promoter followed by Pol II, TFIID compo-
nents, TFIIH, and mediator and then by recruitment of the
activator, HNF-4, CBP/PCAF, and BRM containing SWI/
SNF enzymes (55). We recently demonstrated that during adi-
pocyte differentiation, activation of the PPAR nuclear hor-
mone receptor promoter involves recruitment of SWI/SNF
enzymes to the promoter after binding of the C/EBP activator
and that SWI/SNF-promoter interactions facilitated or stabi-
lized the binding of Pol II-associated general transcription
factors (52). In these and other cases, localization of SWI/SNF
enzymes and chromatin remodeling at the promoter occurred
after activator binding, implying in most of these cases that SWI/
SNF enzymes are needed to complete PIC formation and/or
function. Indeed, early in vitro experiments indicated that SWI/
SNF-mediated remodeling of nucleosomes could permit TBP/
TFIIA binding to nucleosome particles (24). SWI/SNF enzymes
are also required, both in vitro and in vivo, to promote tran-
scriptional elongation of the hsp70 gene (5, 11). Thus, our data
reveal an additional role for SWI/SNF chromatin-remodeling
enzymes in cells and show that SWI/SNF enzymes are needed
at different steps during activation of different genes.
Requirement for MyoD to initiate chromatin remodeling at
the myogenin promoter: a model for SWI/SNF recruitment to
the myogenin promoter. The simplest mechanism for recruit-
ment of chromatin-remodeling enzymes to muscle-specific pro-
moters is recruitment by DNA-bound MyoD. In our study,
there is an apparent paradox: expression of MyoD was neces-
sary for early histone acetylation and SWI/SNF recruitment,
yet ChIP assays showed that MyoD formed a stable, DNA-
bound complex only after these changes occurred. A model to
explain this apparent paradox is that MyoD initially associates
with the myogenin promoter indirectly via interactions with
Pbx1/Meis proteins at a Pbx binding site next to a noncanonical
E box previously identified at 	123/97 of the myogenin pro-
moter. The initiation of myogenin expression in differentiating
cells was recently shown to require the interaction of MyoD
with a DNA-bound complex containing the Pbx homeodomain
protein in the absence of a canonical MyoD binding site, and
protein interactions between MyoD and the Pbx complex were
shown to be necessary for the initial association of MyoD with
the myogenin promoter (4). The interaction of MyoD with
these factors might induce a conformational change in the
Pbx/Meis proteins that permits targeting of Brg1 in differenti-
ating cells. Alternatively, others have demonstrated that Pbx
proteins can interact with HDACs and act to repress transcrip-
tion, and then, upon specific cell signaling, Pbx can become
associated with HATs and promote transcription (51). A sim-
ilar switch potentially could occur upon muscle differentiation,
with the Pbx protein facilitating transcription via interaction
with HATs and/or SWI/SNF enzymes. Indeed, coimmunopre-
cipitation of endogenous Brg1 and endogenous Pbx1 (Fig. 8D)
provides support for models involving targeting of SWI/SNF
components by Pbx/Meis proteins in differentiating cells.
However, given the existing data indicating that both SWI/
SNF and HAT enzymes can also interact with MyoD, we pro-
pose that recruitment of chromatin-remodeling enzymes oc-
curs early during differentiation via interaction with MyoD
bound to the promoter indirectly through the Pbx/Meis pro-
teins. Because the interaction of MyoD is indirect in this sce-
nario, it would not be easily cross-linked at early time points in
our ChIP assays. MyoD is known to interact with p300 and
P/CAF (reviewed in reference 41); targeting these HATs to the
myogenin promoter would result in acetylation of histone tails,
which would help promote the association of SWI/SNF com-
plexes through interactions with the bromodomain present on
the ATPase subunit. The ability of MyoD and Brg1 to stably
associate (Fig. 9) (54), combined with the ability of Brg1 to
interact with Pbx (Fig. 8D), would further promote the asso-
ciation of Brg1-based SWI/SNF enzymes with the myogenin
promoter. Thus, SWI/SNF association with the promoter can be
facilitated by its interactions with acetylated chromatin, with
MyoD, and with Pbx. Subsequent chromatin remodeling by SWI/
SNF would then open the canonical E boxes and the Mef2 site for
factor binding, resulting in stably bound activator complex at
the myogenin promoter that can be detected by ChIP assay. A
schematized version of these events is presented in Fig. 10.
This model is generally consistent with the recent findings of
Simone et al. (54). Using differentiating C2C12 myoblasts, they
demonstrated that MyoD is recruited to the myogenin pro-
moter and induces histone acetylation. Chromatin remodeling
at the promoter required the subsequent recruitment and ac-
tivity of SWI/SNF enzymes, which were dependent on an active
p38 kinase. In that study, MyoD was cross-linked to the myo-
genin promoter prior to chromatin remodeling, which could
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suggest that MyoD is directly bound to the promoter but alter-
natively could indicate that a tighter association exists between
MyoD and the Pbx complex in C2C12 myoblasts than exists in the
MyoD–differentiated fibroblasts, thereby permitting MyoD to
be visualized at the promoter by ChIP at the beginning of the
differentiation process. Both possibilities support a model of
early recruitment of MyoD to the myogenin promoter prior to
acetylation and SWI/SNF recruitment, though the loss of MyoD
binding in the presence of dominant-negative BRG1 (Fig. 5
and 6) and the contribution of Pbx complexes during myogenin
activation in C2C12 cells (4) argue for the latter possibility.
Further experiments will be needed to evaluate the role of
each of the potential interactions occurring at the myogenin
promoter during the activation of gene expression.
MyoD-induced genes show differential requirements for
SWI/SNF enzymes. The expression of the vast majority of
genes measured by the expression array was not altered by the
inhibition of SWI/SNF activity, whereas most genes induced by
MyoD were modestly affected by SWI/SNF inhibition and a
subset of MyoD-regulated genes were highly dependent on
SWI/SNF (see Fig. 1). Our data demonstrate that chromatin
modification and SWI/SNF activity are necessary for MyoD to
form a stable interaction with DNA at the myogenin promoter,
suggesting that chromatin remodeling may be necessary for
MyoD binding at the subset of genes that are highly dependent
on SWI/SNF activity. We suggest that the interaction between
MyoD and Pbx is necessary to initially target MyoD to the
myogenin promoter. It is interesting that there is a significant
overlap between the MyoD-regulated genes that are highly
dependent on SWI/SNF and the subset of genes that require
the domains of MyoD that interact with Pbx for full activation
(unpublished data), suggesting that these domains of MyoD
might be necessary for targeting the protein to multiple differ-
ent promoters as an initial step in gene activation.
Summary. During the establishment of new cell lineages,
changes in chromatin structure become apparent as previously
silent genes are activated. How activators initially gain access
to their binding sites within condensed chromatin structure has
been a topic of intense investigation. In some cases, such as
during differentiation of liver cells, the HNF3 homeodomain
protein can bind to nucleosomal DNA and disrupt nucleo-
somal structure in the absence of ATP-dependent chroma-
tin-remodeling enzymes (10). In other cases, gene-specific
activators recruit chromatin-remodeling enzymes to specific
promoters (12). Our results suggest that during muscle differ-
entiation, muscle-specific activators may both recruit and re-
quire chromatin-remodeling activities for stable binding to the
regulatory regions of muscle-specific genes.
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